20140106†5:00PM UTC,Merck to Hold Fourth-Quarter 2013 Sales and Earnings Conference Call on February 5,http://www.reuters.com/article/2014/01/06/nj-merck-idUSnBw066743a+100+BSW20140106
20140107†8:01AM UTC,"Presentation Schedules, Stock Movements, Agreements, and New Appointments - Research Report on Celgene, Merck, Bristol-Myers, Valeant, and Mylan",http://www.reuters.com/article/2014/01/07/bc-analysts-corner-idUSnPn7zp0hn+80+PRN20140107
20140108†9:48PM UTC,Novartis in talks with Merck to exchange business units- Bloomberg,http://www.reuters.com/article/2014/01/09/novartis-merck-idUSL3N0KJ0XL20140109
20140108†8:30AM UTC,Merck Receives FDA Approval for ISENTRESS¬Æ (raltegravir) for Pediatric Oral Suspension,http://www.reuters.com/article/2014/01/08/nj-merck-idUSnBw085210a+100+BSW20140108
20140108†8:00AM UTC,"Health Care Sector Under the Lens: Pfizer, Merck & Co., AbbVie and Zogenix",http://www.reuters.com/article/2014/01/08/bc-aaa-research-reports-idUSnPn7JSwhn+98+PRN20140108
20140109†9:24AM UTC,Novartis and Merck discuss earnings-boosting asset swap,http://www.reuters.com/article/2014/01/09/us-novartis-merck-idUSBREA080RA20140109
20140109†9:20AM UTC,UPDATE 1-Novartis and Merck discuss earnings-boosting asset swap,http://www.reuters.com/article/2014/01/09/novartis-merck-idUSL3N0KJ3B520140109
20140109†9:16AM UTC,Dako to collaborate with Merck on development of companion diagnostics for cancer treatment,http://www.reuters.com/article/2014/01/09/idUSnGNX7584kz+1c0+GNW20140109
20140109†9:00AM UTC,Dako to collaborate with Merck on development of companion diagnostics for cancer treatment,http://www.reuters.com/article/2014/01/09/idUSnHUGdsxd+70+ONE20140109
20140109†1:30AM UTC,Eurofins Expands Presence in Discovery Pharmacology and Bioanalysis by Acquiring the Discovery and Development Solutions Business of Merck KGaA,http://www.reuters.com/article/2014/01/09/eurofins-scientific-idUSnBw086156a+100+BSW20140109
20140110†8:00AM UTC,"Healthcare Companies Report Stock Price Movement, Conference Call Schedules, Study Results, and Presentations - Research Report on Merck, Keryx Biopharma, Pacira, Ligand Pharma, and Dyax",http://www.reuters.com/article/2014/01/10/bc-analysts-corner-idUSnPn7ND6hn+98+PRN20140110
20140110†8:00AM UTC,Merck to Present at the 32nd Annual J.P. Morgan Healthcare Conference,http://www.reuters.com/article/2014/01/10/nj-merck-idUSnBw105032a+100+BSW20140110
20140110†4:56AM UTC,"Research and Markets: Sezary Syndrome Global Clinical Trials Review, H2 2013 - Features Players such as Merck & Co., Inc. and Shionogi & Co., Ltd.",http://www.reuters.com/article/2014/01/10/research-and-markets-idUSnBw105176a+100+BSW20140110
20140112†9:00PM UTC,Alnylam Acquires Investigational RNAi Therapeutic Assets from Merck,http://www.reuters.com/article/2014/01/13/ma-alnylam-pharmaceuticl-idUSnBw125032a+100+BSW20140113
20140113†2:01PM UTC,Merck shares jump on early filing for skin cancer drug,http://www.reuters.com/article/2014/01/13/us-merck-brief-idUSBREA0C13D20140113
20140113†1:54PM UTC,UPDATE 2-Merck shares jump on early filing for skin cancer drug,http://www.reuters.com/article/2014/01/13/merck-brief-idUSL3N0KN3QT20140113
20140113†11:53AM UTC,US STOCKS-Wall St down modestly on earnings caution; Merck gains,http://www.reuters.com/article/2014/01/13/markets-usa-stocks-idUSL2N0KN19K20140113
20140113†10:12AM UTC,US STOCKS-Wall St flat on earnings caution; Merck climbs,http://www.reuters.com/article/2014/01/13/markets-usa-stocks-idUSL2N0KN10O20140113
20140113†9:57AM UTC,Merck's anti-blood clot drug should be approved: FDA review,http://www.reuters.com/article/2014/01/13/us-merck-vorapaxar-idUSBREA0C0SZ20140113
20140113†9:55AM UTC,UPDATE 2-Merck's anti-blood clot drug should be approved -U.S. FDA review,http://www.reuters.com/article/2014/01/13/merck-vorapaxar-idUSL2N0KN0UN20140113
20140113†9:01AM UTC,Merck says consumer or animal health move possible in 2014,http://www.reuters.com/article/2014/01/13/merck-mergers-idUSL2N0KN0VT20140113
20140113†8:35AM UTC,Merck's anti-blood clot drug should be approved -U.S. FDA staff,http://www.reuters.com/article/2014/01/13/merck-vorapaxar-idUSL2N0KC0Y820140113
20140113†8:35AM UTC,Merck Provides Update on Accelerated Strategic Actions for Growth at 32nd Annual J.P. Morgan Healthcare Conference,http://www.reuters.com/article/2014/01/13/nj-merck-idUSnBw135960a+100+BSW20140113
20140113†8:30AM UTC,"Merck Initiates Rolling Submission of U.S. Biologics License Application for MK-3475, an Investigational Anti-PD-1 Immunotherapy, in Patients with Advanced Melanoma",http://www.reuters.com/article/2014/01/13/nj-merck-idUSnBw135937a+100+BSW20140113
20140114†11:46AM UTC,"Merck needs a dose of joie de vivre, research chief says",http://www.reuters.com/article/2014/01/14/us-merck-perlmutter-idUSBREA0D12C20140114
20140115†6:59PM UTC,"Merck Statement on FDA Advisory Committee for Vorapaxar, Merck‚Äôs Investigational Antiplatelet Medicine",http://www.reuters.com/article/2014/01/15/nj-merck-idUSnBw156454a+100+BSW20140115
20140115†5:31PM UTC,FDA advisory panel backs Merck's blood clot-preventing drug,http://www.reuters.com/article/2014/01/15/us-merck-vorapaxar-idUSBREA0E1KV20140115
20140115†5:31PM UTC,UPDATE 1-FDA advisory panel backs Merck's blood clot-preventing drug,http://www.reuters.com/article/2014/01/15/merck-vorapaxar-idUSL2N0KP20420140115
20140115†4:19PM UTC,FDA advisory panel backs Merck's blood clot-preventing drug,http://www.reuters.com/article/2014/01/15/merck-vorapaxar-idUSL2N0KP1VE20140115
20140116†9:30AM UTC,"The Zacks Analyst Blog Highlights:Merck, United Continental Holdings, Delta Airline, Boeing and American Airlines Group",http://www.reuters.com/article/2014/01/16/zackscom-idUSnPnCGkCNkT+16d+PRN20140116
20140117†6:34PM UTC,"John Daly, Previous Merck Exec., Offers Consulting Tips",http://www.reuters.com/article/2014/01/17/idUSnMKWYqwxca+1e0+MKW20140117
20140117†10:03AM UTC,Sanford Heisler Adds Four New Class Representatives To $250M Gender Discrimination Class Action Suit Against Pharma Giant Merck,http://www.reuters.com/article/2014/01/17/sanfordheisler-merck-idUSnPnNYkT9mh+168+PRN20140117
20140123†2:37AM UTC,BRIEF-Hi-tech material firm AZ says Merck's offer extended to Feb. 5,http://www.reuters.com/article/2014/01/23/azelectronicmaterials-brief-idUSWLB006TJ20140123
20140124†12:46PM UTC,No serious side effects with Merck allergy pill: FDA documents,http://www.reuters.com/article/2014/01/24/us-merck-allergy-idUSBREA0N1CQ20140124
20140124†12:38PM UTC,No serious side effects with Merck allergy pill -FDA documents,http://www.reuters.com/article/2014/01/24/merck-allergy-idUSL2N0KY15220140124
20140126†6:04PM UTC,UPDATE 1-Merck KGaA CFO returns to Lanxess to succeed former boss as CEO,http://www.reuters.com/article/2014/01/26/lanxess-ceo-idUSL5N0L00OM20140126
20140126†3:57PM UTC,"Lanxess says CEO to step down, Merck KGaA CFO to succeed",http://www.reuters.com/article/2014/01/26/lanxess-ceo-idUSWEB00H6N20140126
20140127†4:39AM UTC,Lanxess lures former finance chief back from Merck for top job,http://www.reuters.com/article/2014/01/27/merck-lanxess-management-idUSL5N0L10TO20140127
20140127†3:08AM UTC,BRIEF-Shares in Merck KGaA fall 11.3 percent after CFO resignation,http://www.reuters.com/article/2014/01/27/merckkgaa-brief-idUSWEB00H6V20140127
20140128†2:12PM UTC,"U.S. FDA panel: data support safety, efficacy of Merck allergy drug",http://www.reuters.com/article/2014/01/28/us-merck-ragwitek-idUSBREA0R1K020140128
20140128†2:11PM UTC,"UPDATE 1-U.S. FDA panel: data support safety, efficacy of Merck allergy drug",http://www.reuters.com/article/2014/01/28/merck-ragwitek-idUSL2N0L21FV20140128
20140128†1:57PM UTC,"U.S. FDA panel: data support safety, efficacy of Merck allergy drug",http://www.reuters.com/article/2014/01/28/merck-ragwitek-idUSL2N0L21DB20140128
20140131†2:06PM UTC,Merck gets buyout interest for consumer health unit: sources,http://www.reuters.com/article/2014/01/31/us-merck-unit-idUSBREA0U1L020140131
20140131†1:58PM UTC,Merck gets buyout interest for consumer health unit -sources,http://www.reuters.com/article/2014/01/31/merck-unit-idUSL2N0L50N520140131
20140203†8:30AM UTC,"Merck Announces Canadian Approval of GRASTEK¬Æ (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)",http://www.reuters.com/article/2014/02/03/nj-merck-idUSnBw035349a+100+BSW20140203
20140203†8:10AM UTC,"ALK's partner for North America, Merck, announces launch of GRASTEK(R) (GRAZAX(R)) in Canada",http://www.reuters.com/article/2014/02/03/idUSnGNX5qhppN+1c1+GNW20140203
20140203†7:32AM UTC,Ablynx agrees Merck cancer deal worth up to 1.7 billion euros,http://www.reuters.com/article/2014/02/03/us-ablynx-merck-idUSBREA1209K20140203
20140203†7:28AM UTC,UPDATE 1-Ablynx agrees Merck cancer deal worth up to 1.7 bln euros,http://www.reuters.com/article/2014/02/03/ablynx-merck-idUSL5N0L81E720140203
20140203†2:19AM UTC,Ablynx signs Merck deal worth up to 1.7 bln euros,http://www.reuters.com/article/2014/02/03/ablynx-merck-idUSL5N0L80HV20140203
20140203†1:28AM UTC,"BRIEF-Ablynx, Merck sign cancer immunotherapy collaboration, licensing agreement",http://www.reuters.com/article/2014/02/03/ablynx-results-idUSWEB00HJ520140203
20140206†6:10PM UTC,Merck to settle NuvaRing lawsuits for $100 mln -media report,http://www.reuters.com/article/2014/02/06/merck-settlement-idUSL2N0LB27M20140206
20140206†9:03AM UTC,AstraZeneca takes on Merck in Alzheimer's drug race,http://www.reuters.com/article/2014/02/06/astrazeneca-earnings-alzheimers-idUSL5N0LB31520140206
20140206†4:05AM UTC,Merck extends offer for AZ Electronic takeover to Feb. 18,http://www.reuters.com/article/2014/02/06/merck-az-extension-idUSWEB00HUU20140206
20140207†6:07PM UTC,"Merck, Utrecht University to research pig virus vaccine",http://www.reuters.com/article/2014/02/07/us-usa-hogs-virus-idUSBREA161ZD20140207
20140207†6:02PM UTC,"Merck, Utrecht University to research pig virus vaccine",http://www.reuters.com/article/2014/02/07/usa-hogs-virus-idUSL2N0LC20D20140207
20140207†11:53AM UTC,Merck to pay $100 million in NuvaRing contraceptive settlement,http://www.reuters.com/article/2014/02/07/us-merck-nuvaring-idUSBREA1615F20140207
20140207†11:52AM UTC,UPDATE 2-Merck to pay $100 mln in NuvaRing contraceptive settlement,http://www.reuters.com/article/2014/02/07/merck-nuvaring-idUSL2N0LC0WR20140207
20140207†10:05AM UTC,Merck to pay $100 mln in NuvaRing contraceptive settlement,http://www.reuters.com/article/2014/02/07/merck-nuvaring-idUSL2N0LC0WH20140207
20140207†9:51AM UTC,BRIEF-Merck says to pay $100 mln to resolve all U.S. NuvaRing product liability cases,http://www.reuters.com/article/2014/02/07/merck-brief-idUSWEN00CIA20140207
20140210†12:16PM UTC,Merck joins race to copy Sanofi's diabetes drug Lantus,http://www.reuters.com/article/2014/02/10/us-sanofi-merck-idUSBREA191FT20140210
20140210†11:41AM UTC,Merck joins race to copy Sanofi's diabetes drug Lantus,http://www.reuters.com/article/2014/02/10/sanofi-merck-idUSL5N0LF33J20140210
20140210†8:30AM UTC,Merck and Samsung Bioepis Enter Collaboration Agreement to Develop and Commercialize Insulin Glargine Candidate for Diabetes,http://www.reuters.com/article/2014/02/10/nj-merck-idUSnBw105376a+100+BSW20140210
20140214†1:55PM UTC,Merck KGaA extends offer period for AZ for third time,http://www.reuters.com/article/2014/02/14/us-merck-az-period-idUSBREA1D1HM20140214
20140214†1:48PM UTC,Merck KGaA extends offer period for AZ for third time,http://www.reuters.com/article/2014/02/14/merck-az-period-idUSWEB00IIR20140214
20140214†12:36PM UTC,BRIEF-Merck extends AZ offer date until February 28,http://www.reuters.com/article/2014/02/14/merckkgaa-brief-idUSWLB0077N20140214
20140217†1:35PM UTC,"John Daly, Worked With Merck, American Airlines, IBM and Is the White House Author of Advocacy",http://www.reuters.com/article/2014/02/17/idUSnMKWKSF1pa+1f8+MKW20140217
20140219†4:12PM UTC,"Exclusive: Bayer, Novartis, others eye Merck's consumer health unit - sources",http://www.reuters.com/article/2014/02/19/us-merck-bids-idUSBREA1I22T20140219
20140220†5:53PM UTC,Merck KGaA ready for more deals - CEO,http://www.reuters.com/article/2014/02/20/merckkgaa-deals-idUSL6N0LP57020140220
20140220†5:00PM UTC,Merck to Participate in the Citi 2014 Healthcare Conference,http://www.reuters.com/article/2014/02/20/nj-merck-idUSnBw206242a+100+BSW20140220
20140220†8:30AM UTC,"FDA Accepts for Review Merck‚Äôs Biologics License Application for V503, Investigational 9-valent Human Papillomavirus Vaccine",http://www.reuters.com/article/2014/02/20/nj-merck-idUSnBw205302a+100+BSW20140220
20140220†7:55AM UTC,Deloitte Corporate Finance LLC Advises Health Management Resources Corporation in its Collaboration with Merck,http://www.reuters.com/article/2014/02/20/nc-deloitte-corporate-idUSnPnNYtcbgw+160+PRN20140220
20140224†9:30AM UTC,"The Zacks Analyst Blog Highlights: AT&T;, Merck, Omega Healthcare Investors, Sabra Health Care and Healthcare Trust of America",http://www.reuters.com/article/2014/02/24/zacks-analyst-blog-idUSnPnCGv0HkT+165+PRN20140224
20140225†12:31PM UTC,Merck Announces Second-Quarter 2014 Dividend,http://www.reuters.com/article/2014/02/25/nj-merck-idUSnBw256700a+100+BSW20140225
20140226†10:13AM UTC,Boston Children's Hospital and Merck to Study Social Media Behavior to Characterize Insomnia,http://www.reuters.com/article/2014/02/26/boston-merck-study-idUSnPnDCvQ8mt+168+PRN20140226
20140226†9:00AM UTC,Study Results Show ACTIVYL¬Æ by Merck Animal Health Outperforms FRONTLINE¬Æ Plus,http://www.reuters.com/article/2014/02/26/nj-merck-activyl-idUSnPnAQvj0kj+160+PRN20140226
20140228†12:41PM UTC,Merck KGaA extends offer period for AZ for fourth time,http://www.reuters.com/article/2014/02/28/merck-az-period-idUSWEB00JI220140228
20140228†9:30AM UTC,"Where Food Comes From(R) (d.b.a. IMI Global, Inc.) Announces Acquisition of Merck Animal Health Verification Business",http://www.reuters.com/article/2014/02/28/idUSnMKW812yya+1c0+MKW20140228
20140228†8:30AM UTC,CHMP Issues Positive Opinion for Tablet Formulation of Merck‚Äôs NOXAFIL¬Æ (posaconazole),http://www.reuters.com/article/2014/02/28/nj-merck-idUSnBw285133a+100+BSW20140228
20140228†8:25AM UTC,Germany's Merck to raise dividend to 1.90 euros/share,http://www.reuters.com/article/2014/02/28/merck-dividend-idUSWEB00JHR20140228
20140304†5:45PM UTC,"ALK's partner in North America, Merck, presents data on investigational house dust mite sublingual allergy immunotherapy tablet",http://www.reuters.com/article/2014/03/04/idUSnGNXbtqkbM+1c1+GNW20140304
20140304†5:30PM UTC,"Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet",http://www.reuters.com/article/2014/03/04/nj-merck-idUSnBw046818a+100+BSW20140304
20140304†5:30PM UTC,Merck says dust mite allergy drug reduces symptoms in midstage study,http://www.reuters.com/article/2014/03/04/merck-allergy-idUSL1N0M11X520140304
20140305†5:56PM UTC,Merck hepatitis C drugs work in HIV co-infected patients -study,http://www.reuters.com/article/2014/03/05/merck-hepatitis-idUSL1N0M22FO20140305
20140305†4:15PM UTC,Merck‚Äôs Investigational Hepatitis C Treatment Regimen MK-5172/MK-8742 Shows Robust Anti-HCV Activity in HIV/HCV Co-Infected Patients with HCV Genotype 1 Infection,http://www.reuters.com/article/2014/03/05/ma-merck-idUSnBw056553a+100+BSW20140305
20140305†12:15PM UTC,"Merck‚Äôs Investigational HIV Therapy, Doravirine (MK-1439), Demonstrates Antiviral Activity in Phase 2B Study of Treatment-Na√Øve Adults",http://www.reuters.com/article/2014/03/05/ma-merck-idUSnBw056276a+100+BSW20140305
20140306†12:56PM UTC,"Research and Markets: Global Chromatography Systems Market 2014-2018 with Agilent, GE, Perkin Elmer, Merck & ThermoScientific Dominating",http://www.reuters.com/article/2014/03/06/research-and-markets-idUSnBw066079a+100+BSW20140306
20140306†8:00AM UTC,Alnylam Announces Closing of Previously Announced Acquisition of Merck‚Äôs Sirna Therapeutics Subsidiary,http://www.reuters.com/article/2014/03/06/ma-alnylam-pharma-idUSnBw065420a+100+BSW20140306
20140306†8:00AM UTC,Merck‚Äôs Consumer Health Division Breaks $1bn Barrier Through Transition of Neurobion and Floratil Brands from Merck Serono,http://www.reuters.com/article/2014/03/06/merck-idUSnBw065069a+100+BSW20140306
20140306†6:13AM UTC,Merck KGaA says confident AZ takeover to be wrapped up in H1,http://www.reuters.com/article/2014/03/06/us-merckkgaa-results-az-idUSBREA250PZ20140306
20140306†6:10AM UTC,Merck KGaA says confident AZ takeover to be wrapped up in H1,http://www.reuters.com/article/2014/03/06/merckkgaa-results-az-idUSL6N0M31TF20140306
20140306†2:30AM UTC,UPDATE 1-Merck KGaA's profit up as cutbacks cancel out forex pain,http://www.reuters.com/article/2014/03/06/merckkgaa-results-idUSL6N0M30EW20140306
20140306†1:10AM UTC,Merck KGaA quarterly adj EBITDA edges up on cost cuts,http://www.reuters.com/article/2014/03/06/merckkgaa-results-idUSF9E7IC01Y20140306
20140307†11:09AM UTC,Research and Markets: Adult and Adolescent Vaccines Market to 2018 - Pharmaceutical Giants GSK and Merck Are Fighting It Out,http://www.reuters.com/article/2014/03/07/research-and-markets-idUSnBw075569a+100+BSW20140307
20140311†2:45PM UTC,"Greater Boston Chapter of the Society of Physician Entrepreneurs (SoPE) to Host ‚ÄúHealthcare IT‚Äù Meeting on Tuesday, March 18, 2014, 5:30‚Äî8:30 P.M., at Merck Research Laboratories, 33 Avenue Louis Pasteur",http://www.reuters.com/article/2014/03/11/ma-ronald-trahan-assoc-idUSnBw116461a+100+BSW20140311
20140312†8:00AM UTC,"Collaborations, Treatment Approvals, New Solutions, Clinical Trial Results, and New Drug Applications - Analyst Notes on Biogen Idec, Johnson & Johnson, Express Scripts, Merck, and Forest Laboratories",http://www.reuters.com/article/2014/03/12/bc-analysts-review-idUSnPnqbXthn+88+PRN20140312
20140205†12:52PM UTC,"Merck results flag, but cancer-drug deals lift shares",http://www.reuters.com/article/2014/02/05/us-merck-results-idUSBREA140SI20140205
20140205†12:52PM UTC,"UPDATE 3-Merck results flag, but cancer-drug deals lift shares",http://www.reuters.com/article/2014/02/05/merck-results-idUSL2N0LA0GS20140205
20140205†9:18AM UTC,"BRIEF-Merck says still assessing whether to keep, divest non-pharmaceutical units",http://www.reuters.com/article/2014/02/05/merck-brief-idUSWEN00CGH20140205
20140205†7:13AM UTC,Merck 4th-quarter sales just miss Wall St estimate,http://www.reuters.com/article/2014/02/05/merck-results-idUSL2N0LA04A20140205
20140205†7:00AM UTC,Merck Announces Fourth-Quarter and Full-Year 2013 Financial Results,http://www.reuters.com/article/2014/02/05/nj-merck-idUSnBw055626a+100+BSW20140205
20140205†6:45AM UTC,Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies,http://www.reuters.com/article/2014/02/05/pfizer-idUSnBw055504a+100+BSW20140205
20140205†6:45AM UTC,Incyte Announces Clinical Trial Collaboration with Merck to Evaluate Combination of Two Novel Immunotherapies,http://www.reuters.com/article/2014/02/05/de-incyte-idUSnBw055238a+100+BSW20140205
20140205†6:40AM UTC,"Merck Enters Strategic Collaborations with Amgen, Incyte and Pfizer to Evaluate Novel Combination Anti-cancer Regimens with MK-3475",http://www.reuters.com/article/2014/02/05/nj-merck-idUSnBw055453a+100+BSW20140205
20140205†6:15AM UTC,Amgen And Merck Announce Collaboration To Evaluate Investigational Combination Treatment For Advanced Melanoma,http://www.reuters.com/article/2014/02/05/ca-amgn-merck-collab-idUSnPnLApVhcQ+169+PRN20140205
20140313†9:00AM UTC,Lynda.com and Yodlee join IBM and Merck in commitment to protecting customer data privacy through APEC Certification,http://www.reuters.com/article/2014/03/13/truste-certification-idUSnPnCLzzQkj+164+PRN20140313
20140331†11:21PM UTC,S.Korea to allow sales of Merck's Zilmax from June,http://www.reuters.com/article/2014/04/01/zilpaterol-korea-beef-idUSL4N0MT0O920140401
20140418†12:15PM UTC,Merck extends AZ offer again over Chinese antitrust issues,http://www.reuters.com/article/2014/04/18/us-merck-az-electronic-mt-offer-idUSBREA3H0JF20140418
20140418†12:11PM UTC,UPDATE 1-Merck extends AZ offer again over Chinese antitrust issues,http://www.reuters.com/article/2014/04/18/merck-az-electronic-mt-offer-idUSL6N0NA1O320140418
20140418†11:56AM UTC,Merck extends AZ offer again over Chinese antitrust issues,http://www.reuters.com/article/2014/04/18/merck-az-electronic-mt-offer-idUSWEB00LRA20140418
20140506†5:58PM UTC,Merck executives say not tempted by merger mania,http://www.reuters.com/article/2014/05/06/us-merck-mergers-idUSBREA450ZE20140506
20140506†5:37PM UTC,Tax steroids justify Bayer‚Äôs $14 bln Merck deal,http://www.reuters.com/article/2014/05/06/idUS209207184720140506
20140506†3:05PM UTC,Fitch: Merck Consumer Business Sale Improves Its Core Focus,http://www.reuters.com/article/2014/05/06/ny-fitch-ratings-merck-idUSnBw066914a+100+BSW20140506
20140506†2:45PM UTC,Fitch: Merck Consumer Business Sale Improves Its Core Focus,http://www.reuters.com/article/2014/05/06/fitch-merck-consumer-business-sale-impro-idUSFit69955920140506
20140506†1:48PM UTC,Bayer wins Merck & Co's $14 bln consumer unit auction,http://www.reuters.com/article/2014/05/06/us-merck-co-bayer-idUSKBN0DM0O120140506
20140506†1:10PM UTC,Bayer wins Merck & Co's $14 billion consumer unit auction,http://www.reuters.com/article/2014/05/06/us-merck-co-bayer-idUSBREA450BL20140506
20140506†1:09PM UTC,UPDATE 3-Bayer wins Merck & Co's $14 bln consumer unit auction,http://www.reuters.com/article/2014/05/06/merck-co-bayer-idUSL3N0NS25F20140506
20140506†12:56PM UTC,BRIEF-Merck CEO says would be interested in buying animal health brands at right price,http://www.reuters.com/article/2014/05/06/merck-brief-idUSWEN00D8220140506
20140506†11:27AM UTC,"Merck to seek approval of osteoporosis drug, cites safety risks",http://www.reuters.com/article/2014/05/06/us-merck-research-idUSKBN0DM14K20140506
20140506†11:19AM UTC,"Merck to seek approval of osteoporosis drug, cites safety risks",http://www.reuters.com/article/2014/05/06/merck-research-idUSL2N0NS0U520140506
20140506†10:33AM UTC,BRIEF-Merck KGaA says clarifies will keep consumer health business,http://www.reuters.com/article/2014/05/06/merckkgaa-brief-idUSWEB00MPF20140506
20140506†10:18AM UTC,"Where Stock Activism is Surging ‚Äì Undervalued Spinoff Stocks, TSR ‚Äì Merck, Bayer, Beiersdorf, B/E Aerospace and BG Group",http://www.reuters.com/article/2014/05/06/ny-the-spinoff-report-idUSnBw066346a+100+BSW20140506
20140506†9:53AM UTC,BRIEF-Merck says numerical increase in atrial fibrillation and stroke seen in patients taking osteoporosis drug odanacatib,http://www.reuters.com/article/2014/05/06/merck-brief-idUSWEN00D7Z20140506
20140506†8:59AM UTC,Merck Highlights Progress on Its Strategic Initiative to Sharpen Commercial and R&D; Focus; Drive Growth and Productivity,http://www.reuters.com/article/2014/05/06/ma-merck-idUSnBw066179a+100+BSW20140506
20140506†8:40AM UTC,Merck Announces FDA Acceptance for Review of MK-3475 Biologics License Application for Advanced Melanoma,http://www.reuters.com/article/2014/05/06/ma-merck-idUSnBw065958a+100+BSW20140506
20140506†6:11AM UTC,Merck to sell consumer care business to Bayer for $14 bln,http://www.reuters.com/article/2014/05/06/merck-co-bayer-idUSL3N0NS24A20140506
20140506†6:08AM UTC,BRIEF-Bayer says sees closing of Merck & co OTC deal in second-half 2014,http://www.reuters.com/article/2014/05/06/bayer-results-idUSWEB00MOG20140506
20140506†6:00AM UTC,"Bayer to acquire consumer care business of US-based Merck & Co., Inc. and to engage in strategic pharma cooperation in the field of sGC modulators",http://www.reuters.com/article/2014/05/06/bayer-ag-acqsmerck-idUSnPn18y4ls+80+PRN20140506
20140506†6:00AM UTC,Merck Announces Sale of Consumer Care Business to Bayer AG for $14.2 Billion,http://www.reuters.com/article/2014/05/06/ma-merck-idUSnBw065862a+100+BSW20140506
20140506†10:47AM UTC,Merck sells consumer unit to Bayer,http://www.reuters.com/news/video/videoStory?storyID=84889355
20140717†8:30AM UTC,"Merck's HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Women's Network - USA to Encourage Women Living with HIV to be Vocal"" about their Treatment""",http://www.reuters.com/article/2014/07/17/mercks-hiv-campaign-idUSnPn7tFPn6+8c+PRN20140717
20140717†6:36AM UTC,"Research and Markets: Global Single-Use Bio-Processing Systems Market 2014-2018 With GE Healthcare, Merck & Co, Sartorius Stedim Biotech & ThermoFisher Scientific Dominating",http://www.reuters.com/article/2014/07/17/research-and-markets-idUSnBw175567a+100+BSW20140717
20140804†8:50AM UTC,"Drug Approvals and Earnings Releases - Research Reports on Bristol-Myers, Johnson & Johnson, Merck, Pharmacyclics and Amgen",http://www.reuters.com/article/2014/08/04/bc-ar-idUSnPnbhrQ3h+84+PRN20140804
20140804†8:00AM UTC,Kadimastem to Collaborate with Merck Serono to Advance Combined Efforts in Neurodegenerative Disease Area,http://www.reuters.com/article/2014/08/04/kadimastem-idUSnBw045227a+100+BSW20140804
20140909†5:00PM UTC,Merck to Participate at the Morgan Stanley Global Healthcare Conference,http://www.reuters.com/article/2014/09/08/ny-merck-idUSnBw086504a+100+BSW20140908
20140927†8:30AM UTC,Ligand Earns Milestone Payment Triggered by EU Approval of Merck‚Äôs Captisol-enabled NOXAFIL¬Æ (posaconazole) Concentrate for Solution for Infusion,http://www.reuters.com/article/2014/09/26/ca-ligand-pharmaceutical-idUSnBw265022a+100+BSW20140926
20141015†6:20PM UTC,Merck Announces Pricing of Tender Offers for Eight Series of Notes,http://www.reuters.com/article/2014/10/14/nj-merck-idUSnBw146717a+100+BSW20141014
20141015†4:54PM UTC,Ex-Merck analyst faces insider trading charges on merger tips,http://www.reuters.com/article/2014/10/14/us-usa-merck-co-insidertrading-idUSKCN0I31TY20141014
20141015†4:52PM UTC,UPDATE 2-Ex-Merck analyst faces insider trading charges on merger tips,http://www.reuters.com/article/2014/10/14/usa-merck-co-insidertrading-idUSL2N0S915N20141014
20141015†10:48AM UTC,Former Merck analyst faces insider trading charges on merger tips,http://www.reuters.com/article/2014/10/14/usa-merck-co-insidertrading-idUSL2N0S90ZW20141014
20141015†9:15AM UTC,Research and Markets: Merck's Singulair (Asthma) CysLT1 Receptor Inhibitor - Forecast and Market Analysis to 2023,http://www.reuters.com/article/2014/10/14/research-and-markets-idUSnBw145868a+100+BSW20141014
20141015†7:51AM UTC,Research and Markets: Merck's Dulera Asthma Treatment - Forecast and Market Analysis to 2023,http://www.reuters.com/article/2014/10/14/research-and-markets-idUSnBw145591a+100+BSW20141014
20141120†2:22PM UTC,"Research and Markets: Global Single Use Bioreactor Market Outlook, 2019: Thermo Fischer Scientific, Sartorius, Merck, GE Healthcare & Pall Corp Dominate the $200+ Million Market",http://www.reuters.com/article/2014/11/19/research-and-markets-idUSnBw196545a+100+BSW20141119
20140314†2:47PM UTC,Merck extends offer period for AZ for fifth time,http://www.reuters.com/article/2014/03/14/us-merck-az-idUSBREA2D1JZ20140314
20140314†2:45PM UTC,CORRECTED-UPDATE 1-Merck extends offer period for AZ for fifth time,http://www.reuters.com/article/2014/03/14/merck-az-idUSL6N0MB3FM20140314
20140314†1:40PM UTC,FDA Approves Merck‚Äôs NOXAFIL¬Æ (posaconazole) Injection (18 mg/mL) for Intravenous Use,http://www.reuters.com/article/2014/03/14/nj-merck-idUSnBw145697a+100+BSW20140314
20140314†1:20PM UTC,Merck extends offer period for AZ Electronic Materials,http://www.reuters.com/article/2014/03/14/merck-az-idUSWEB00K9O20140314
20140317†8:15AM UTC,"Ligand Earns $1 Million Milestone Payment Triggered by FDA Approval of Merck‚Äôs NOXAFIL¬Æ (posaconazole) Injection for Intravenous Use, a New Captisol-enabled Formulation",http://www.reuters.com/article/2014/03/17/ca-ligand-pharmaceutical-idUSnBw175405a+100+BSW20140317
20140319†8:00AM UTC,"Approvals, Financial Results, and Stock Movements - Analyst Notes on Merck, Novartis, Raptor, Akorn, and Pacira",http://www.reuters.com/article/2014/03/19/bc-analysts-review-idUSnPn6v6XWF+87+PRN20140319
20140319†8:00AM UTC,"Health Care Stocks Review -- Research on Bristol-Myers Squibb, Johnson & Johnson, Merck & Co. and Eli Lilly",http://www.reuters.com/article/2014/03/19/bc-ie-idUSnPn84H60N+89+PRN20140319
20140320†5:00PM UTC,Merck to Hold First-Quarter 2014 Sales and Earnings Conference Call on April 29,http://www.reuters.com/article/2014/03/20/nj-merck-idUSnBw206447a+100+BSW20140320
20140321†8:05AM UTC,Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT¬Æ (vintafolide) and Companion Imaging Agents FOLCEPRI¬Æ (etarfolatide) and NEOCEPRI¬Æ (Intravenous (IV) folic acid) in Patients with Platinum-Resistant,http://www.reuters.com/article/2014/03/21/nj-merck-idUSnBw215237a+100+BSW20140321
20140324†7:30AM UTC,Merck to Present New Data for Investigational Hepatitis C Treatments MK-5172 and MK-8742 at EASL Annual Meeting/The International Liver Congress‚Ñ¢ 2014,http://www.reuters.com/article/2014/03/24/nj-merck-idUSnBw245392a+100+BSW20140324
20140325†10:00AM UTC,"Merck KGaA names new heads of lab equipment, OTC drugs units",http://www.reuters.com/article/2014/03/25/us-merckkgaa-executives-idUSBREA2O10F20140325
20140325†9:47AM UTC,"Merck KGaA names new heads of lab equipment, OTC drugs units",http://www.reuters.com/article/2014/03/25/merckkgaa-executives-idUSWEB00KQ920140325
20140326†6:27PM UTC,"Merck, Glaxo end co-pay assistance for Obamacare plans",http://www.reuters.com/article/2014/03/26/us-obamacare-pharmaceuticals-idUSBREA2P2B220140326
20140326†6:26PM UTC,"Merck, Glaxo end co-pay assistance for Obamacare plans",http://www.reuters.com/article/2014/03/26/health-obamacare-pharmaceuticals-idUSL1N0MN25N20140326
20140326†10:41AM UTC,Merck plans to propose two-for-one share split,http://www.reuters.com/article/2014/03/26/merck-stocks-idUSWEB00KT220140326
20140326†10:06AM UTC,Merck Licenses NanoBio Technology,http://www.reuters.com/article/2014/03/26/merck-license-nanobio-idUSnPn53hdS6+82+PRN20140326
20140327†1:02PM UTC,Merck names Baxter exec as CFO,http://www.reuters.com/article/2014/03/27/us-merck-co-cfo-idUSBREA2Q1LD20140327
20140327†12:59PM UTC,UPDATE 2-Merck names Baxter exec as CFO,http://www.reuters.com/article/2014/03/27/merck-co-cfo-idUSL4N0MO38320140327
20140327†9:30AM UTC,Merck Executive Wins EnergySMART Energy Innovator Award,http://www.reuters.com/article/2014/03/27/idUSnGNXc6nqmh+1c0+GNW20140327
20140327†8:52AM UTC,Merck appoints Baxter executive as CFO,http://www.reuters.com/article/2014/03/27/us-merck-co-cfo-idUSBREA2Q0VO20140327
20140327†8:45AM UTC,CORRECTED-Merck appoints Baxter executive as CFO,http://www.reuters.com/article/2014/03/27/merck-co-cfo-idUSL4N0MO37P20140327
20140327†7:20AM UTC,"Merck Announces Appointment of Robert M. Davis as Chief Financial Officer; Succeeds Peter N. Kellogg, Who Has Served in the Role Since 2007",http://www.reuters.com/article/2014/03/27/nj-merck-idUSnBw275536a+100+BSW20140327
20140327†7:00AM UTC,"Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany Initiates Phase 1 Dose Escalation Study of TH-302 in Combination With Gemcitabine and Nab-paclitaxel (Abraxane(R)) in Pancreatic Cancer",http://www.reuters.com/article/2014/03/27/idUSnMKWmNDQKa+1de+MKW20140327
20140328†8:00AM UTC,"Positive Opinions, Presentation Schedules of Investigational Data, Clinical Study Results, and Stock Price Movements - Analyst Notes on Johnson & Johnson, Merck, Pfizer, Amgen, and Allergan",http://www.reuters.com/article/2014/03/28/bc-analysts-review-idUSnPnbFJ7c4+98+PRN20140328
20140403†7:05AM UTC,BRIEF-Merck KGaA says signs license agreement with Auxogyn Inc,http://www.reuters.com/article/2014/04/03/merckkgaa-brief-idUSWEB00L5Y20140403
20140404†1:44PM UTC,"Exclusive: Merck wants to test Zilmax on 240,000 cattle but beef industry resists",http://www.reuters.com/article/2014/04/04/us-zilmax-cattle-test-idUSBREA331H520140404
20140404†8:00AM UTC,"Merck, Ferring Pharmaceuticals and the World Health Organization Working Together to Prevent Excessive Bleeding in Women after Childbirth",http://www.reuters.com/article/2014/04/04/nj-merck-idUSnBw045156a+100+BSW20140404
20140406†10:30AM UTC,"Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck‚Äôs Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014",http://www.reuters.com/article/2014/04/06/nj-merck-idUSnBw065058a+100+BSW20140406
20140407†12:35PM UTC,"Technical Pointers on Pharmaceuticals Equities -- Research on Merck, Bristol-Myers Squibb, Johnson & Johnson, and Eli Lilly",http://www.reuters.com/article/2014/04/07/bc-ie-idUSnPn7mLfmt+88+PRN20140407
20140407†8:01AM UTC,"NDA Filings, FDA Approvals, Executive Appointments, Ceased Clinical Trials, and Public Offerings - Analyst Notes on Johnson & Johnson, Pfizer, Merck, GSK, and Intercept",http://www.reuters.com/article/2014/04/07/bc-analysts-review-idUSnPn7vZLT5+8e+PRN20140407
20140407†6:00AM UTC,"Oncothyreon Announces Merck KGaA, Darmstadt, Germany, Initiation of Phase 3 START2 Study with Tecemotide in Stage III Non-Small Cell Lung Cancer",http://www.reuters.com/article/2014/04/07/onty-merckkgaa-study-idUSnPn28r4nP+81+PRN20140407
20140407†3:51AM UTC,"Early Findings Exploring the Relationship of PD-L1 Expression and Clinical Outcomes with MK-3475, Merck‚Äôs Investigational Anti-PD-1 Immunotherapy, Presented at AACR Annual Meeting 2014",http://www.reuters.com/article/2014/04/07/nj-merck-idUSnBw065058a+100+BSW20140407
20140408†8:01AM UTC,"Conference Call Schedules, Clinical Trial Studies, Awards and Accolades, Appointments, and Welfare Initiatives - Analyst Notes on Celgene, Johnson & Johnson, Merck, Sanofi, and UnitedHealth",http://www.reuters.com/article/2014/04/08/bc-analysts-review-idUSnPn2NrqJj+92+PRN20140408
20140409†9:12AM UTC,"Research and Markets: Global Diabetic Nephropathy Market 2014-2018 with Merck & Co, Mitsubishi Tanabe Pharma, Novartis AG & Sanofi S.A. Dominating",http://www.reuters.com/article/2014/04/09/research-and-markets-idUSnBw095811a+100+BSW20140409
20140409†9:00AM UTC,"Lowenstein Sandler, Legal Services of Northwest Jersey, and Merck Present Assistance for Homeless Veterans at the White House",http://www.reuters.com/article/2014/04/09/nj-lowenstein-sandler-idUSnPn50n1Sb+82+PRN20140409
20140410†8:00AM UTC,Xencor Receives Milestone Payment from Merck for Initiation of Phase 1 Clinical Trial of a Biologic Candidate using XmAb¬Æ Antibody Engineering Intellectual Property,http://www.reuters.com/article/2014/04/10/ca-xencor-inc-idUSnPn8yCd8f+88+PRN20140410
20140410†1:17AM UTC,Merck hepatitis C drugs shine in easier to treat patients: study,http://www.reuters.com/article/2014/04/10/us-hepatitis-merck-idUSBREA390B120140410
20140410†1:00AM UTC,Merck hepatitis C drugs shine in easier to treat patients -study,http://www.reuters.com/article/2014/04/10/health-hepatitis-merck-idUSL2N0N12E220140410
20140410†1:00AM UTC,"Merck Announces Results from Studies Evaluating Investigational Hepatitis C Treatments, MK-5172 and MK-8742, in Treatment-Na√Øve Patients with Genotype 1 Infection",http://www.reuters.com/article/2014/04/10/nj-merck-idUSnBw096579a+100+BSW20140410
20140411†12:08PM UTC,"John Daly, Worked With Merck & White House, Receives 5 Stars on Amazon",http://www.reuters.com/article/2014/04/11/idUSnMKWn4MP0a+1cc+MKW20140411
20140411†1:00AM UTC,Merck‚Äôs Investigational Chronic Hepatitis C Combination Therapy MK-5172/MK-8742 Demonstrates Antiviral Activity in Hard-to-Cure Patients with HCV Genotype 1 Infection,http://www.reuters.com/article/2014/04/11/nj-merck-idUSnBw106486a+100+BSW20140411
20140414†7:59PM UTC,Merck's grass pollen allergy drug wins U.S. approval,http://www.reuters.com/article/2014/04/14/us-merck-co-fda-grastek-idUSBREA3D1UD20140414
20140414†7:57PM UTC,UPDATE 1-Merck's grass pollen allergy drug wins U.S. approval,http://www.reuters.com/article/2014/04/14/merck-grastek-idUSL2N0N61RN20140414
20140414†6:36PM UTC,Merck's grass pollen allergy vaccine wins U.S. approval,http://www.reuters.com/article/2014/04/14/merck-co-fda-grastek-idUSL3N0N646A20140414
20140414†6:05PM UTC,ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK(r) (GRAZAX(r)),http://www.reuters.com/article/2014/04/14/idUSnGNX8zV5H8+1ca+GNW20140414
20140414†5:59PM UTC,FDA Approves Merck‚Äôs GRASTEK¬Æ (Timothy Grass Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Grass Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Children and Adults,http://www.reuters.com/article/2014/04/14/nj-merck-idUSnBw146419a+100+BSW20140414
20140414†1:42PM UTC,"Research and Markets: Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating",http://www.reuters.com/article/2014/04/14/research-and-markets-idUSnBw146208a+100+BSW20140414
20140415†8:01AM UTC,"Interim Clinical Study Results, Leadership Appointments, and Earnings Release Schedules - Analyst Notes on Merck, Magellan, ABIOMED, CONMED, and Greatbatch",http://www.reuters.com/article/2014/04/15/bc-analysts-review-idUSnPn7bLhGb+8a+PRN20140415
20140417†6:22PM UTC,FDA Approves Merck‚Äôs RAGWITEK‚Ñ¢ (Short Ragweed Pollen Allergen Extract) Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults,http://www.reuters.com/article/2014/04/17/nj-merck-idUSnBw176511a+100+BSW20140417
20140417†3:58PM UTC,Merck's ragweed pollen allergy drug gets U.S. approval,http://www.reuters.com/article/2014/04/17/us-merck-ragwitek-fda-idUSBREA3G21D20140417
20140417†3:57PM UTC,CORRECTED-Merck's ragweed pollen allergy drug gets U.S. approval,http://www.reuters.com/article/2014/04/17/merck-ragwitek-fda-idUSL3N0N944E20140417
20140417†3:13PM UTC,ALK announces FDA approval for Merck's ragweed sublingual allergy immunotherapy tablet RAGWITEK(r),http://www.reuters.com/article/2014/04/17/idUSnGNX3dn5Yg+1c2+GNW20140417
20140421†4:15PM UTC,Merck among NASA Cargo Launching to Space Station,http://www.reuters.com/article/2014/04/21/nasa-cargo-spacex-idUSnPn6pnptx+80+PRN20140421
20140423†8:00AM UTC,Merck and Award-Winning Actress S. Epatha Merkerson Challenge Americans with Type 2 Diabetes to Get to Their Goals,http://www.reuters.com/article/2014/04/23/merck-diabetesprogram-idUSnPn4NMdG5+9a+PRN20140423
20140424†2:24PM UTC,Fitch Affirms Merck & Co.'s Long-term IDR at 'A+'; Outlook Remains Negative,http://www.reuters.com/article/2014/04/24/ny-fitch-ratings-merck-idUSnBw246448a+100+BSW20140424
20140424†2:11PM UTC,Fitch Affirms Merck & Co.'s Long-term IDR at 'A+'; Outlook Remains Negative,http://www.reuters.com/article/2014/04/24/fitch-affirms-merck-cos-long-term-idr-at-idUSFit69795920140424
20140424†8:00AM UTC,"Quarterly Results, FDA Approvals, Intellectual Property Appeals, New Drug Applications, and Initiated Clinical Trials - Analyst Notes on Johnson & Johnson, Merck, Teva, Bristol-Myers Squibb and AbbVie",http://www.reuters.com/article/2014/04/24/bc-a-idUSnPn8Z5y4M+91+PRN20140424
20140424†2:21AM UTC,BRIEF-Merck KGaA says IIIb study of Kuvan reached primary endpoint,http://www.reuters.com/article/2014/04/24/merckkgaa-brief-idUSWEB00LXG20140424
20140425†2:10PM UTC,"Schedule for Upcoming Earnings Releases -- Research on Nokia, Boston Scientific, Merck & Co., and Bristol-Myers Squibb",http://www.reuters.com/article/2014/04/25/bc-earnings-source-idUSnPn152jxT+81+PRN20140425
20140425†8:00AM UTC,"Drug Approvals, Quarterly Earnings Releases, and Stock Price Updates - Analyst Notes on Merck, Johnson & Johnson, UnitedHealth, Celgene and GW",http://www.reuters.com/article/2014/04/25/bc-analysts-review-idUSnPn6xMcht+88+PRN20140425
20140426†3:21PM UTC,Exclusive: Merck in final talks to sell consumer unit for near $14 billion - sources,http://www.reuters.com/article/2014/04/26/us-merck-co-sale-idUSBREA3P0I220140426
20140428†1:46PM UTC,Reckitt Benckiser confirms talks to buy Merck unit,http://www.reuters.com/article/2014/04/28/us-reckittbenckisergp-idUSBREA3R11520140428
20140428†1:44PM UTC,UPDATE 1-Reckitt Benckiser confirms talks to buy Merck unit,http://www.reuters.com/article/2014/04/28/reckitt-benc-grp-merckco-idUSL6N0NK5FU20140428
20140428†12:46PM UTC,RPT-Reckitt Benckiser confirms talks to buy Merck unit,http://www.reuters.com/article/2014/04/28/reckitt-benc-grp-merck-co-idUSL6N0NK5DE20140428
20140428†12:26PM UTC,Reckitt Benckiser confirms talks to buy Merck unit,http://www.reuters.com/article/2014/04/28/reckitt-benc-grp-merck-co-idUSASM0006FU20140428
20140428†8:30AM UTC,Practice Fusion Teams with Merck on Population Health Management Initiative,http://www.reuters.com/article/2014/04/28/practice-fusion-idUSnPn19FyQl+8a+PRN20140428
20140428†7:30AM UTC,Merck to Hold Investor Briefing at Boston Research Facility,http://www.reuters.com/article/2014/04/28/nj-merck-idUSnBw285451a+100+BSW20140428
20140428†7:00AM UTC,Agenus Announces Collaboration and License Agreement with Merck for Novel Checkpoint Antibody-Based Cancer Immunotherapies,http://www.reuters.com/article/2014/04/28/ma-agenus-inc-idUSnBw285604a+100+BSW20140428
20140428†5:33AM UTC,"Research and Markets: PharmaPoint Report 2014: Prophylactic Hepatitis B Virus Vaccines - Current and Future Players - GSK, Merck, Sanofi, Kaketsuken, Dynavax Technologies",http://www.reuters.com/article/2014/04/28/research-and-markets-idUSnBw285673a+100+BSW20140428
20140429†4:40PM UTC,"Bayer offers animal health assets, cash for Merck's OTC unit -sources",http://www.reuters.com/article/2014/04/29/us-merck-co-bayer-idUSBREA3S12B20140429
20140429†4:39PM UTC,"UPDATE 1-Bayer offers animal health assets, cash for Merck's OTC unit -sources",http://www.reuters.com/article/2014/04/29/merck-co-bayer-idUSL2N0NL1ZW20140429
20140429†4:01PM UTC,"Bayer offers animal health assets, cash for Merck's OTC unit -sources",http://www.reuters.com/article/2014/04/29/merck-co-bayer-idUSL2N0NL1WI20140429
20140429†3:36PM UTC,"Research and Markets: Global Glaucoma Therapeutics Market 2014-2018: Allergan Inc., Merck & Co. Inc., Novartis AG & Pfizer Dominate the Industry",http://www.reuters.com/article/2014/04/29/research-and-markets-idUSnBw296970a+100+BSW20140429
20140429†2:44PM UTC,"Merck first-quarter profit tops estimate, but revenue misses",http://www.reuters.com/article/2014/04/29/us-merck-results-idUSBREA3S0DY20140429
20140429†2:38PM UTC,"UPDATE 2-Merck 1st-quarter profit tops estimate, but revenue misses",http://www.reuters.com/article/2014/04/29/merck-results-idUSL2N0NL0F620140429
20140429†11:45AM UTC,"US STOCKS-Wall St climbs, lifted by Merck, Sprint on rosy earnings",http://www.reuters.com/article/2014/04/29/markets-usa-stocks-idUSL2N0NL12E20140429
20140429†10:42AM UTC,"US STOCKS-Wall St higher as Merck, Sprint shares gain on results",http://www.reuters.com/article/2014/04/29/markets-usa-stocks-idUSL2N0NL0X620140429
20140429†8:34AM UTC,CORRECTED-US STOCKS-Futures gain on earnings; Merck shares up in premarket,http://www.reuters.com/article/2014/04/29/markets-usa-stocks-idUSL2N0NL0FU20140429
20140429†7:23AM UTC,"Merck 1st-quarter profit tops estimate, but revenue misses",http://www.reuters.com/article/2014/04/29/merck-results-idUSL2N0NL0CI20140429
20140429†7:00AM UTC,Merck Announces First-Quarter 2014 Financial Results,http://www.reuters.com/article/2014/04/29/nj-merck-idUSnBw295902a+100+BSW20140429
20140429†11:17AM UTC,Cost cutting boosts Merck's profit,http://www.reuters.com/news/video/videoStory?storyID=84402207
20140430†6:50PM UTC,Exclusive: Merck explores $15 billion-plus drug portfolio sale,http://www.reuters.com/article/2014/04/30/us-merck-sale-exclusive-idUSBREA3T10M20140430
20140430†4:06PM UTC,Merck explores $15 billion-plus drug portfolio sale: sources,http://www.reuters.com/article/2014/04/30/us-merck-sale-idUSKBN0DG1V420140430
20140430†3:55PM UTC,Reckitt Benckiser says no longer in talks with Merck,http://www.reuters.com/article/2014/04/30/us-reckitt-benc-grp-merck-co-idUSBREA3T0S220140430
20140430†3:48PM UTC,UPDATE 2-Reckitt Benckiser says no longer in talks with Merck,http://www.reuters.com/article/2014/04/30/reckitt-benc-grp-merck-co-idUSL6N0NM6GE20140430
20140430†2:23PM UTC,China approves Merck KGaA's takeover of AZ Electronic,http://www.reuters.com/article/2014/04/30/us-china-merck-idUSBREA3T0WG20140430
20140430†2:22PM UTC,UPDATE 2-China approves Merck KGaA's takeover of AZ Electronic,http://www.reuters.com/article/2014/04/30/china-merck-idUSL3N0NM4OQ20140430
20140430†1:46PM UTC,Merck KGaA extends offer period for AZ Electronic seventh time,http://www.reuters.com/article/2014/04/30/merck-az-electronic-mt-idUSL6N0NM6K120140430
20140430†1:24PM UTC,BRIEF-Merck KGaA says gets MOFCOM clearance on AZ Electronics cash offer,http://www.reuters.com/article/2014/04/30/merckkgaa-brief-idUSFWN0NM00L20140430
20140430†1:11PM UTC,Reckitt Benckiser says no longer in talks with Merck,http://www.reuters.com/article/2014/04/30/reckitt-benc-grp-merck-co-idUSL6N0NM6DV20140430
20140430†8:10AM UTC,China approves Merck KGaA's takeover of AZ Electronic,http://www.reuters.com/article/2014/04/30/us-china-merck-idUSBREA3T08920140430
20140430†6:04AM UTC,"Research and Markets: Global Osteoporosis Drugs Market Opportunities With Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate",http://www.reuters.com/article/2014/04/30/research-and-markets-idUSnBw305768a+100+BSW20140430
20140501†4:18PM UTC,REFILE-Bayer nears deal to buy Merck consumer unit -sources,http://www.reuters.com/article/2014/05/01/merck-consumer-idUSL2N0NJ0D720140501
20140501†3:26PM UTC,Bayer nears deal to buy Merck consumer unit: sources,http://www.reuters.com/article/2014/05/01/us-merck-consumer-idUSBREA400SO20140501
20140501†4:18AM UTC,"Technical Data on Equities Reaching New highs -- Research on Banco Santander, Merck, Schlumberger, and Orbital Sciences",http://www.reuters.com/article/2014/05/01/bc-investor-edge-idUSnPn3pGv60+88+PRN20140501
20140502†2:39PM UTC,Merck KGaA eyes Asia sales after completing AZ takeover,http://www.reuters.com/article/2014/05/02/us-merck-azelectronicmaterials-idUSBREA410SG20140502
20140502†2:38PM UTC,UPDATE 1-Merck KGaA eyes Asia sales after completing AZ takeover,http://www.reuters.com/article/2014/05/02/merck-azelectronicmaterials-idUSL6N0NO3XW20140502
20140502†1:48PM UTC,Merck KGaA says completes acquisition of AZ Electronic,http://www.reuters.com/article/2014/05/02/merck-azelectronicmaterials-idUSWEB00MJ920140502
20140502†8:35AM UTC,Merck and Endocyte's ovarian cancer drug fails in trial,http://www.reuters.com/article/2014/05/02/us-merck-co-endocyte-idUSKBN0DI0T520140502
20140502†8:33AM UTC,Merck and Endocyte's ovarian cancer drug fails in trial,http://www.reuters.com/article/2014/05/02/merck-co-endocyte-idUSL3N0NO3HH20140502
20140502†8:01AM UTC,"Approvals from the European Commission and Release of Quarterly Financial Results - Analyst Notes on Merck, Johnson & Johnson, Bristol-Myers Squibb, Teva and AbbVie",http://www.reuters.com/article/2014/05/02/bc-analysts-review-idUSnPn6TV8kV+99+PRN20140502
20140502†8:00AM UTC,Merck and Endocyte Announce Independent DSMB Recommends Vintafolide PROCEED Phase 3 Trial Be Stopped for Futility Following Interim Analysis,http://www.reuters.com/article/2014/05/02/nj-merck-endocyte-idUSnBw025189a+100+BSW20140502
20140502†10:55AM UTC,"AZ spurns Pfizer, Bayer/Merck deal nears",http://www.reuters.com/news/video/videoStory?storyID=84649386
20140505†9:30AM UTC,"Gilead, LinkedIn, Merck, Microsoft and ExxonMobil highlighted as Zacks Bull and Bear of the Day",http://www.reuters.com/article/2014/05/05/il-zacks-investment-idUSnPn6Bk24z+90+PRN20140505
20140505†8:01AM UTC,"Quarterly Earnings Releases, Social Initiatives, and Upcoming Conferences - Analyst Notes on Merck, WellPoint, UnitedHealth, Forest and Celgene",http://www.reuters.com/article/2014/05/05/bc-analystsreviewcom-idUSnPn7KGC2w+9c+PRN20140505
20140508†6:29PM UTC,U.S. FDA approves Merck blood clot preventer,http://www.reuters.com/article/2014/05/08/us-merck-fda-idUSKBN0DO1OF20140508
20140508†6:25PM UTC,U.S. FDA approves Merck blood clot preventer,http://www.reuters.com/article/2014/05/08/merck-fda-idUSL2N0NU2II20140508
20140508†2:12PM UTC,Merck KGaA to delist AZ Electronic Materials,http://www.reuters.com/article/2014/05/08/merck-az-electronic-mt-delisting-idUSL6N0NU6AZ20140508
20140508†12:04PM UTC,Merck KGaA hires Henkel executive Marcus Kuhnert as CFO,http://www.reuters.com/article/2014/05/08/merck-cfo-idUSWEB00MYM20140508
20140508†9:30AM UTC,"The Zacks Analyst Blog Highlights:Ruth's Hospitality Group, Denny's, Bayer, Merck and Johnson & Johnson",http://www.reuters.com/article/2014/05/08/zacks-analyst-blog-idUSnPn45gPq8+84+PRN20140508
20140509†8:56AM UTC,Germany's Merck KGaA ready to join pharma deal frenzy,http://www.reuters.com/article/2014/05/09/us-merck-deals-idUSBREA480FA20140509
20140509†8:54AM UTC,UPDATE 1-Germany's Merck KGaA ready to join pharma deal frenzy,http://www.reuters.com/article/2014/05/09/merck-deals-idUSL6N0NV2E120140509
20140509†4:41AM UTC,Germany's Merck KGaA says ready for more deals,http://www.reuters.com/article/2014/05/09/merck-deals-idUSWEB00N0020140509
20140512†8:00AM UTC,"Earnings Results, Agreements, Study Results, FDA Approvals, and Drug Trial Results - Analyst Notes on Merck, Johnson & Johnson, GlaxoSmithKline, Novartis and Intercept",http://www.reuters.com/article/2014/05/12/bc-ar-idUSnPn5YYpMv+9a+PRN20140512
20140513†7:20AM UTC,"Clinical Trial Results, Acquisitions, Healthcare Partnership, and Pricing of Senior Notes - Analyst Notes on Merck, JNJ, Chelsea, Unitedhealth and Celgene",http://www.reuters.com/article/2014/05/13/bc-analystsreviewcom-idUSnPn7dZJhz+8c+PRN20140513
20140513†2:47AM UTC,Santen Announces the Signing of Agreement Between Merck for the Purchase of Assets in Ophthalmology,http://www.reuters.com/article/2014/05/13/idUSnGNX8246hW+1c1+GNW20140513
20140513†2:15AM UTC,Merck Signs Sale Agreement with Santen for Merck‚Äôs Ophthalmology Products in Japan and Key Markets in Europe and Asia Pacific,http://www.reuters.com/article/2014/05/13/nj-merck-idUSnBw126812a+100+BSW20140513
20140514†6:14PM UTC,"Bristol, Merck, Roche immune therapies are cancer meeting focus",http://www.reuters.com/article/2014/05/14/us-health-cancer-immunotherapy-idUSKBN0DU20C20140514
20140514†5:54PM UTC,"UPDATE 1-Bristol, Merck, Roche immune therapies are cancer meeting focus",http://www.reuters.com/article/2014/05/14/health-cancer-immunotherapy-idUSL1N0O024O20140514
20140514†5:00PM UTC,"Bristol, Merck, Roche immune therapies are cancer meeting darlings",http://www.reuters.com/article/2014/05/14/health-cancer-immunotherapy-idUSL1N0NZ1K320140514
20140514†9:44AM UTC,Research and Markets: Merck's MK-1602 (Migraine) Report - Forecast and Market Analysis to 2023,http://www.reuters.com/article/2014/05/14/research-and-markets-idUSnBw145991a+100+BSW20140514
20140514†8:00AM UTC,The American College of Endocrinology & Merck Urge Patients with Type 2 Diabetes to Work with Their Doctor to Get to Their Blood Sugar Goals,http://www.reuters.com/article/2014/05/14/merck-diabetes-goals-idUSnPn2Cf5Lp+92+PRN20140514
20140514†8:00AM UTC,"Merck‚Äôs Investigational Anti-PD1 Antibody, MK-3475, Active in Three Different Tumor Types: New Data to be Presented at the 2014 ASCO Annual Meeting",http://www.reuters.com/article/2014/05/14/nj-merck-idUSnBw145472a+100+BSW20140514
20140514†2:00AM UTC,Belgium's Ablynx increases cash position after Merck payment,http://www.reuters.com/article/2014/05/14/ablynx-results-idUSL6N0O012620140514
20140515†11:23AM UTC,"Research and Markets: Global PCOS Drugs Market 2014-2018 with Bristol Myers Squibb, Merck & Co., Novartis AG, Sanofi SA & Teva Pharmaceutical Dominating",http://www.reuters.com/article/2014/05/15/research-and-markets-idUSnBw156041a+100+BSW20140515
20140515†9:30AM UTC,"Genpact,Bebe Stores, Merck, Akorn and Bayer highlighted as Zacks Bull and Bear of the Day",http://www.reuters.com/article/2014/05/15/zacks-equity-research-idUSnPn1k3bVr+82+PRN20140515
20140515†7:02AM UTC,"ALK's partner for North America, Merck, announces launch of RAGWITEK(tm) in Canada",http://www.reuters.com/article/2014/05/15/idUSnGNX13B4tL+1c9+GNW20140515
20140515†3:56AM UTC,"Merck KGaA says consumer health assets in U.S., Japan too pricy",http://www.reuters.com/article/2014/05/15/merck-results-consumer-health-idUSL6N0O12AE20140515
20140515†2:56AM UTC,UPDATE 1-Merck KGaA ekes out profit growth on cost cuts,http://www.reuters.com/article/2014/05/15/merck-results-idUSL6N0O116V20140515
20140515†1:29AM UTC,Merck KGaA Q1 profit gains on cost cuts,http://www.reuters.com/article/2014/05/15/merck-results-idUSWEB00N9020140515
20140519†5:00PM UTC,"Merck and Endocyte Announce Withdrawal of Conditional Marketing Authorization Applications for Vintafolide and Companion Imaging Components, Etarfolatide and Intravenous (IV) Folic Acid in Europe",http://www.reuters.com/article/2014/05/19/nj-merck-idUSnBw196556a+100+BSW20140519
20140519†8:19AM UTC,Research and Markets: Parkinson's Disease Sinemet by Merck & Co - Forecast and Market Analysis to 2022,http://www.reuters.com/article/2014/05/19/research-and-markets-idUSnBw195782a+100+BSW20140519
20140520†9:20AM UTC,"Technical Data on Active Stocks -- Research on Freeport-McMoRan Copper & Gold, SLM Corp., Brocade Communications Systems, and Merck & Co.",http://www.reuters.com/article/2014/05/20/bc-i-idUSnPn5Z47M1+92+PRN20140520
20140520†8:00AM UTC,Merck Animal Health Announces FDA Approval of BRAVECTO‚Ñ¢ (fluralaner),http://www.reuters.com/article/2014/05/20/nj-merck-fda-approval-idUSnPnjb3Y4+42+PRN20140520
20140521†8:42AM UTC,"Marketing Authorizations, Study Results Presentations, FDA Response to Drug Application, and New Messaging Services - Analyst Notes on Johnson & Johnson, Merck, Celgene, Novartis and UnitedHealth",http://www.reuters.com/article/2014/05/21/bc-analysts-review-idUSnPn11QdLs+8a+PRN20140521
20140527†12:21PM UTC,Merck Announces Third-Quarter 2014 Dividend,http://www.reuters.com/article/2014/05/27/nj-merck-idUSnBw276232a+100+BSW20140527
20140528†10:00AM UTC,"True Diagnostics Signs Commercialization Agreement With Merck KGaA, Darmstadt, Germany",http://www.reuters.com/article/2014/05/28/idUSnMKWJqnq5a+1e0+MKW20140528
20140529†5:50AM UTC,"Breakthrough Innovation for Animal Health, Upcoming Conference Presentations, and New Treatment Options for Patients - Analyst Notes on Merck, Actavis, Celgene, Bristol-Myers Squibb and GSK",http://www.reuters.com/article/2014/05/29/bc-ar-idUSnPn5nqPkL+85+PRN20140529
20140530†9:08AM UTC,"Dako, an Agilent Technologies Company, and U.S.-based Merck & Co. to collaborate on companion diagnostic test for analysis of tumor PD-L1 levels",http://www.reuters.com/article/2014/05/30/idUSnGNX52JN7s+1cc+GNW20140530
20140530†9:00AM UTC,"Dako, an Agilent Technologies Company, and U.S.-based Merck & Co. to collaborate on companion diagnostic test for analysis of tumor PD-L1 levels",http://www.reuters.com/article/2014/05/30/idUSnHUGdJPR+77+ONE20140530
20140601†9:00PM UTC,Novartis appoints Merck executive as oncology chief ,http://www.reuters.com/article/2014/06/02/us-novartis-appointment-merck-co-idUSKBN0ED00F20140602
20140601†8:16PM UTC,Novartis appoints Merck executive as oncology chief,http://www.reuters.com/article/2014/06/02/novartis-appointment-merckco-idUSL3N0OJ00U20140602
20140601†9:23AM UTC,"First Presentation of Early Data for Pembrolizumab (MK-3475), Merck‚Äôs Investigational Anti-PD-1 Antibody, in Advanced Head and Neck Cancer at ASCO 2014",http://www.reuters.com/article/2014/06/01/il-merck-idUSnBw015057a+100+BSW20140601
20140602†9:00AM UTC,"Seres Health Appoints Former Merck Senior Executive, Roger J. Pomerantz, M.D., F.A.C.P., as Chief Executive Officer and Chairman",http://www.reuters.com/article/2014/06/02/seres-health-appoints-idUSnPn4KZfQ6+9a+PRN20140602
20140602†7:34AM UTC,"Merck immune system-booster effective in skin, lung cancer",http://www.reuters.com/article/2014/06/02/us-health-cancer-merck-co-idUSKBN0ED12120140602
20140602†7:33AM UTC,"First Presentation of Data for Pembrolizumab, Merck‚Äôs Investigational Anti-PD-1 Antibody, in Patients with Previously-Untreated, Advanced Non-Small Cell Lung Cancer (NSCLC) at ASCO 2014",http://www.reuters.com/article/2014/06/02/il-merck-idUSnBw025552a+100+BSW20140602
20140602†7:33AM UTC,Data on Merck‚Äôs Pembrolizumab from Largest Study to Date of Investigational Anti-PD-1 Antibody in Advanced Melanoma Highlighted at ASCO 2014,http://www.reuters.com/article/2014/06/02/il-merck-idUSnBw025550a+100+BSW20140602
20140602†7:30AM UTC,"Merck immune system-booster effective in skin, lung cancer",http://www.reuters.com/article/2014/06/02/health-cancer-merck-co-idUSL1N0OI0P020140602
20140604†9:30AM UTC,"The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Merck, Roche, Pharmacyclics and AbbVie",http://www.reuters.com/article/2014/06/04/il-zacks-investment-idUSnPn9dGyCP+8b+PRN20140604
20140606†12:45PM UTC,Former Merck dealmaker takes aim at colon germ,http://www.reuters.com/article/2014/06/06/us-pomerantz-merck-seres-idUSKBN0EH1Z320140606
20140606†8:00AM UTC,"Merck to Present New Clinical Data on JANUVIA¬Æ (Sitagliptin), Investigational Omarigliptin, and Real-World Data in Patients with Type 2 Diabetes at the 74th Scientific Sessions of the¬†American Diabetes Association",http://www.reuters.com/article/2014/06/06/merck-idUSnBw065051a+100+BSW20140606
20140609†9:20PM UTC,"SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Idenix Pharmaceuticals, Inc. In Connection With The Proposed Sale Of The Company To Merck & Co., Inc.",http://www.reuters.com/article/2014/06/10/md-brower-piven-idUSnBw096532a+100+BSW20140610
20140609†1:13PM UTC,Idenix Pharmaceuticals Trust Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate the Acquisition by Merck,http://www.reuters.com/article/2014/06/09/tx-powers-taylor-idUSnBw096181a+100+BSW20140609
20140609†1:00PM UTC,Merck & Co to buy Idenix to boost hepatitis C drugs portfolio,http://www.reuters.com/article/2014/06/09/us-merck-co-idenix-pharma-idUSKBN0EK0Z720140609
20140609†12:51PM UTC,UPDATE 3-Merck to buy Idenix to boost hepatitis C drugs portfolio,http://www.reuters.com/article/2014/06/09/merck-co-idenix-pharma-idUSL4N0OQ2Y320140609
20140609†11:53AM UTC,Fitch: Merck Buy of Idenix Underscores Therapeutic Add Focus,http://www.reuters.com/article/2014/06/09/ny-fitch-ratings-merck-idUSnBw096040a+100+BSW20140609
20140609†11:34AM UTC,"INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Idenix Pharmaceuticals, Inc. and Its Board of Directors In Connection With the Sale of the Company to Merck",http://www.reuters.com/article/2014/06/09/ny-levi-korsinsky-idUSnBw096009a+100+BSW20140609
20140609†8:58AM UTC,"BRIEF-Merck says triple therapy using Idenix hepatitis drug could speed cures, treat all genotypes",http://www.reuters.com/article/2014/06/09/merck-brief-idUSWEN00DFU20140609
20140609†7:47AM UTC,Merck to buy Idenix for about $3.85 billion,http://www.reuters.com/article/2014/06/09/merck-co-idenix-pharma-idUSL4N0OQ2WL20140609
20140609†7:30AM UTC,Merck to Acquire Idenix,http://www.reuters.com/article/2014/06/09/nj-merck-idUSnBw095610a+100+BSW20140609
20140610†6:12PM UTC,"EQUITY ALERT: The Rosen Law Firm Announces Investigation of Idenix Pharmaceuticals Inc. (IDIX) Concerning the Proposed Acquisition by Merck & Co., Inc. (MRK)",http://www.reuters.com/article/2014/06/10/ny-the-rosen-law-firm-idUSnBw106762a+100+BSW20140610
20140610†11:50AM UTC,"INVESTOR ALERT: Levi & Korsinsky, LLP Announces Investigation of Idenix Pharmaceuticals, Inc. and Its Board of Directors In Connection With the Sale of the Company to Merck",http://www.reuters.com/article/2014/06/10/ny-levi-korsinsky-idUSnBw106330a+100+BSW20140610
20140610†7:58AM UTC,BRIEF-Merck KGaA announces FDA clearance for Auxogyn's embryo viability assessment system,http://www.reuters.com/article/2014/06/10/merckkgaa-brief-idUSWEB00O7N20140610
20140610†5:10AM UTC,"Note Offers, Clinical Trial Enrolments, Conference Schedules, and Technical Updates - Analyst Notes on Illumina, Merck, HCA Holdings, Thermo Fisher Scientific and PTC Therapeutics",http://www.reuters.com/article/2014/06/10/bc-analysts-review-idUSnPn7g80gy+80+PRN20140610
20140612†3:05PM UTC,Merck open to more biotech deals: research chief,http://www.reuters.com/article/2014/06/12/us-merck-perlmutter-idUSKBN0EN26O20140612
20140612†3:03PM UTC,Merck open to more biotech deals - research chief,http://www.reuters.com/article/2014/06/12/merck-perlmutter-idUSL2N0OT1I720140612
20140612†11:38AM UTC,BRIEF-Merck research chief says company aims for big share of hepatitis C market,http://www.reuters.com/article/2014/06/12/merck-brief-idUSWEN00DGJ20140612
20140612†11:35AM UTC,"Merck, Pfizer, HSBC could be big winners from shareholder case",http://www.reuters.com/article/2014/06/12/us-usa-court-halliburton-analysis-idUSKBN0EN10620140612
20140612†1:36AM UTC,BRIEF-Morphosys enters strategic immuno-oncology collaboration with Merck Serono,http://www.reuters.com/article/2014/06/12/morphosys-brief-idUSWEB00OAO20140612
20140612†1:36AM UTC,MorphoSys and Merck Serono Enter Strategic Immuno-Oncology Collaboration,http://www.reuters.com/article/2014/06/12/idUSnGNX425p5F+1c1+GNW20140612
20140612†1:31AM UTC,MorphoSys and Merck Serono Enter Strategic Immuno-Oncology Collaboration,http://www.reuters.com/article/2014/06/12/idUSnHUGdKLT+77+ONE20140612
20140613†8:00AM UTC,Merck Launches Global Patient Registry Supporting Expanded Commitment to Real-World Outcomes Research in Type 2 Diabetes,http://www.reuters.com/article/2014/06/13/nj-merck-idUSnBw135029a+100+BSW20140613
20140613†7:40AM UTC,"Health Care Sector Equities Coverage -- Research on Johnson and Johnson, Medicines Co., Merck, and Novo Nordisk",http://www.reuters.com/article/2014/06/13/bc-investor-edge-idUSnPn5jwQ1W+85+PRN20140613
20140616†9:00PM UTC,"SHAREHOLDER ALERT: Brower Piven Announces The Investigation Of Idenix Pharmaceuticals, Inc. In Connection With The Proposed Sale Of The Company To Merck & Co., Inc.",http://www.reuters.com/article/2014/06/17/md-brower-piven-idUSnBw166595a+100+BSW20140617
20140616†9:30AM UTC,"The Zacks Analyst Blog Highlights:Merck, Idenix Pharmaceuticals, Caterpillar, Boeing, Exxon Mobil and Microsoft",http://www.reuters.com/article/2014/06/16/zacks-blog-idUSnPn2Ft62N+91+PRN20140616
20140617†9:30AM UTC,"The Zacks Analyst Blog Highlights: AbbVie, Gilead, Merck and Idenix Pharmaceuticals",http://www.reuters.com/article/2014/06/17/il-zacks-abbvie-idUSnPnnM0xZ+49+PRN20140617
20140617†4:19AM UTC,Merck KGaA terminates MS drug license agreement with Ono,http://www.reuters.com/article/2014/06/17/us-merck-ono-pharm-idUSKBN0ES0OX20140617
20140617†3:54AM UTC,Merck KGaA terminates MS drug license agreement with Ono,http://www.reuters.com/article/2014/06/17/merck-ono-pharm-idUSWEB00OGP20140617
20140620†7:30AM UTC,Merck Begins Tender Offer to Acquire Idenix,http://www.reuters.com/article/2014/06/20/nj-merck-idUSnBw205051a+100+BSW20140620
20140620†6:10AM UTC,"Conference Call Schedules, Acquisitions, and Public Offerings - Analyst Notes on Johnson & Johnson, Merck, GW, Endocyte and AVEO",http://www.reuters.com/article/2014/06/20/bc-analysts-review-idUSnPn6bwD7D+85+PRN20140620
20140623†7:17PM UTC,Bionomics and Merck Enter New Research Collaboration,http://www.reuters.com/article/2014/06/23/bionomics-merck-idUSnPn3cwd6Y+81+PRN20140623
20140623†7:03PM UTC,Bionomics and Merck Enter New Research Collaboration,http://www.reuters.com/article/2014/06/23/idUSnGNXbClQTQ+1d7+GNW20140623
20140623†5:00PM UTC,Merck to Hold Second-Quarter 2014 Sales and Earnings Conference Call on July 29,http://www.reuters.com/article/2014/06/23/nj-merck-idUSnBw236386a+100+BSW20140623
20140623†8:00AM UTC,Merck Names Michael J. Holston as Future General Counsel; Will Succeed Bruce N. Kuhlik in July 2015,http://www.reuters.com/article/2014/06/23/nj-merck-idUSnBw235434a+100+BSW20140623
20140624†1:33AM UTC,"BRIEF-Merck KGaA, Mersana agree collaboration on next-generation antibody-drug conjugates",http://www.reuters.com/article/2014/06/24/merckkgaa-results-idUSWEB00OPR20140624
20140624†1:30AM UTC,"Mersana and Merck KGaA of Darmstadt, Germany, to Develop Next-Generation Antibody-Drug Conjugates",http://www.reuters.com/article/2014/06/24/ma-mersana-therapeutics-idUSnBw236568a+100+BSW20140624
20140626†8:00AM UTC,Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals,http://www.reuters.com/article/2014/06/26/merck-diabetes-goal-idUSnPnbWjwxZ+91+PRN20140626
20140630†9:42AM UTC,Merck nausea drug works in children in late-stage trial,http://www.reuters.com/article/2014/06/30/us-merck-co-study-idUSKBN0F516S20140630
20140630†9:23AM UTC,UPDATE 1-Merck nausea drug works in children in late-stage trial,http://www.reuters.com/article/2014/06/30/merck-co-study-idUSL4N0PB32Z20140630
20140630†8:22AM UTC,Merck nausea drug works in children in late-stage trial,http://www.reuters.com/article/2014/06/30/merck-co-study-idUSL4N0PB31Z20140630
20140630†8:00AM UTC,Merck Announces Data from Investigational Phase 3 Study on EMEND¬Æ (aprepitant) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Children Undergoing Emetogenic Chemotherapy,http://www.reuters.com/article/2014/06/30/nj-merck-idUSnBw305425a+100+BSW20140630
20140630†6:00AM UTC,"Merck‚Äôs Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma",http://www.reuters.com/article/2014/06/30/nj-merck-idUSnBw305326a+100+BSW20140630
20140630†5:20AM UTC,"Scheduled Conference Calls, License Agreements, Dividends, Preliminary Proxy statements and Initiation of Clinical Studies - Analyst Notes on Merck, Johnson & Johnson, AbbVie, Valeant and GSK",http://www.reuters.com/article/2014/06/30/bc-analystsreviewcom-idUSnPn7L5T2V+95+PRN20140630
20140630†5:02AM UTC,Merck KGaA buys Peer+ in bet on dimmable windows,http://www.reuters.com/article/2014/06/30/merck-windows-idUSWEB00OZW20140630
20140701†11:28AM UTC,UPDATE 1-Bayer broadens healthcare line by keeping Merck's consumer brands,http://www.reuters.com/article/2014/07/01/bayer-brands-idUSL6N0PC4N120140701
20140701†9:50AM UTC,CORRECTED-Bayer broadens healthcare line by keeping Merck's consumer brands,http://www.reuters.com/article/2014/07/01/bayer-brands-idUSL6N0PC2LQ20140701
20140701†6:18AM UTC,electroCore's Funding is $10 Million Oversubscribed by All Parties Including Merck's GHI Fund to Bring It to $50 Million,http://www.reuters.com/article/2014/07/01/nj-electrocore-idUSnBw015617a+100+BSW20140701
20140702†2:33AM UTC,Santen Announces Closing of Asset Purchase Agreement With Respect to Acquisition of Ophthalmology Assets From Merck,http://www.reuters.com/article/2014/07/02/idUSnGNXq9H1J+e5+GNW20140702
20140703†4:00AM UTC,Strong growth at Merck‚Äôs Consumer Health Division builds on 80 years of delivery,http://www.reuters.com/article/2014/07/03/merck-kgaa-idUSnBw035004a+100+BSW20140703
20140703†3:36AM UTC,BRIEF-Merck KGaA completes squeeze-out of AZ Electronic,http://www.reuters.com/article/2014/07/03/merckkgaa-brief-idUSWEB00P7520140703
20140707†5:20AM UTC,"Research and Markets: Global Hypercholesterolemia Market 2014-2018 With AbbVie, Astrazeneca, Merck & Co. & Pfizer Dominating",http://www.reuters.com/article/2014/07/07/research-and-markets-idUSnBw075358a+100+BSW20140707
20140708†3:52PM UTC,"Research and Markets: Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J;'s, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way",http://www.reuters.com/article/2014/07/08/research-and-markets-idUSnBw086623a+100+BSW20140708
20140710†10:00AM UTC,"Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment",http://www.reuters.com/article/2014/07/10/ventana-merckserono-idUSnPnjGdpJ+49+PRN20140710
20140710†5:00AM UTC,"New Board Director, Clinical Trial Results, New Drug Designations and Marketing Authorizations - Analyst Notes on Johnson & Johnson, Merck, Novartis, GSK and Endo",http://www.reuters.com/article/2014/07/10/bc-analystsreviewcom-idUSnPn5dmp2C+81+PRN20140710
20140712†7:04AM UTC,Merck KGaA pharma chief says looking at mid-size deals - paper,http://www.reuters.com/article/2014/07/12/merck-deals-idUSL6N0PN09J20140712
20140714†9:00AM UTC,Merck KGaA‚Äôs Biopharmaceutical Division Appoints Luciano Rossetti as Global Head of R&D;,http://www.reuters.com/article/2014/07/14/merck-kgaa-idUSnBw145643a+100+BSW20140714
20140715†4:05AM UTC,"Research and Markets: Global Animal (Companion & Production) Healthcare Market 2014-2019 Featuring Key Companies, Zoetis, Merck, Merial, Bayer and Novartis",http://www.reuters.com/article/2014/07/15/research-and-markets-idUSnBw155701a+100+BSW20140715
20140721†8:40AM UTC,"Technical Pointers on Pharma Equities -- AbbVie, Johnson and Johnson, Merck, Bristol-Myers Squibb, and Eli Lilly",http://www.reuters.com/article/2014/07/21/bc-investor-edge-idUSnPnb71cdQ+81+PRN20140721
20140723†12:15PM UTC,Merck Announces Fourth-Quarter 2014 Dividend,http://www.reuters.com/article/2014/07/23/nj-merck-idUSnBw236022a+100+BSW20140723
20140723†8:00AM UTC,"Financial Results, Campaign Launch, and New Steps in Facility Planning - Research Reports on Johnson & Johnson, Merck, AstraZeneca, Novartis and Teva",http://www.reuters.com/article/2014/07/23/bc-analysts-review-idUSnPnbHBZrb+9c+PRN20140723
20140724†8:30AM UTC,"Merck Initiates Phase 3 Study of Letermovir, an Investigational Antiviral for Prevention of Cytomegalovirus (CMV) Infection in High-Risk Bone Marrow Transplant Patients",http://www.reuters.com/article/2014/07/24/nj-merck-idUSnBw245207a+100+BSW20140724
20140726†7:48AM UTC,Merck aims to hike revenues in China to 1 billion euro by 2018,http://www.reuters.com/article/2014/07/26/us-merck-china-wirtschaftswoche-idUSKBN0FV0BD20140726
20140726†7:35AM UTC,Merck aims to hike revenues in China to 1 bln eur by 2018,http://www.reuters.com/article/2014/07/26/merck-china-wirtschaftswoche-idUSL6N0Q10AR20140726
20140729†10:37AM UTC,Merck quarterly profit beats estimates; shares gain,http://www.reuters.com/article/2014/07/29/us-merck-results-idUSKBN0FY10320140729
20140729†10:34AM UTC,UPDATE 3-Merck quarterly profit beats estimates; shares gain,http://www.reuters.com/article/2014/07/29/merck-results-idUSL2N0Q40IS20140729
20140729†10:12AM UTC,BRIEF-Merck says not interested in doing deals solely or primarily for tax inversions,http://www.reuters.com/article/2014/07/29/merck-brief-idUSWEN00DQJ20140729
20140729†7:10AM UTC,"Merck beats forecasts, as newer drugs offset generics",http://www.reuters.com/article/2014/07/29/merck-results-idUSL2N0Q30S920140729
20140729†6:56AM UTC,Merck Announces Second-Quarter 2014 Financial Results,http://www.reuters.com/article/2014/07/29/nj-merck-idUSnBw295509a+100+BSW20140729
20140805†1:00PM UTC,Merck Publishes 2013 Global Corporate Responsibility Report,http://www.reuters.com/article/2014/08/05/nj-merck-idUSnBw055121a+100+BSW20140805
20140805†6:00AM UTC,Merck Completes Tender Offer to Acquire Idenix,http://www.reuters.com/article/2014/08/05/nj-merck-idUSnBw055350a+100+BSW20140805
20140806†4:53PM UTC,"Kenneth Frazier, CEO Of Merck, Named BLACK ENTERPRISE Corporate Executive Of The Year",http://www.reuters.com/article/2014/08/06/black-enterprise-awd-idUSnPn977gBf+82+PRN20140806
20140811†9:20AM UTC,"Product Launch, Technical Updates, Clinical Study Results, Completion of Tender Offer, and Financial Result - Research Reports on Medtronic, Covidien, Johnson & Johnson, Merck and Jazz",http://www.reuters.com/article/2014/08/11/bc-analysts-review-idUSnPn3ZF55c+98+PRN20140811
20140814†5:58PM UTC,Merck Statement regarding Role of PNEUMOVAX¬Æ 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults,http://www.reuters.com/article/2014/08/13/nj-merck-idUSnBw136277a+100+BSW20140813
20140814†5:28PM UTC,U.S. FDA approves Merck insomnia drug,http://www.reuters.com/article/2014/08/13/us-merck-insomnia-idUSKBN0GD1WN20140813
20140814†5:27PM UTC,UPDATE 2-U.S. FDA approves Merck insomnia drug,http://www.reuters.com/article/2014/08/13/merck-insomnia-idUSL2N0QJ2BB20140813
20140814†3:46PM UTC,U.S. FDA approves Merck insomnia drug,http://www.reuters.com/article/2014/08/13/merck-insomnia-idUSL2N0QJ2A120140813
20140814†4:07AM UTC,Merck KGaA CEO says looking at interesting takeover targets,http://www.reuters.com/article/2014/08/13/merck-results-deals-idUSL6N0QJ1IJ20140813
20140814†1:28AM UTC,Merck KGaA Q2 core profit up 2.3 pct on AZ Electronic takeover,http://www.reuters.com/article/2014/08/13/merck-results-idUSWEB00RG520140813
20140815†9:00AM UTC,Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals,http://www.reuters.com/article/2014/08/14/nj-merck-diabetes-idUSnPn8bBmC2+8a+PRN20140814
20140816†9:00AM UTC,Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal,http://www.reuters.com/article/2014/08/15/merck-diabetes-event-idUSnPn7ClxVV+93+PRN20140815
20140821†9:20AM UTC,"Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck",http://www.reuters.com/article/2014/08/20/bc-ar-idUSnPn87MN45+8c+PRN20140820
20140821†9:10AM UTC,"Technical Coverage on Pharma Stocks -- Teva Pharmaceutical Industries, AbbVie, Merck, Johnson and Johnson, and Bristol-Myers Squibb",http://www.reuters.com/article/2014/08/20/bc-investor-edge-idUSnPn8ZzGfS+95+PRN20140820
20140821†8:10AM UTC,"Research and Markets: Global Hormone Replacement Therapy Market 2014-2018: Key Vendors are Actavis, Bayer, Merck & Co, Novartis and Novo Nordisk",http://www.reuters.com/article/2014/08/20/research-and-markets-idUSnBw205409a+100+BSW20140820
20140823†10:34AM UTC,"Research and Markets: Global Hodgkins Lymphoma Therapeutics Market 2014-2018: Bristol Myers Squibb, F. Hoffmann-La Roche, Merck & Co & Pfizer Dominate the Industry",http://www.reuters.com/article/2014/08/22/research-and-markets-idUSnBw225420a+100+BSW20140822
20140826†6:14PM UTC,Exclusive: U.S. approval of Merck cancer immunotherapy expected soon,http://www.reuters.com/article/2014/08/25/us-merck-cancer-fda-idUSKBN0GP0VU20140825
20140826†7:00AM UTC,"RPT-Advaxis, Merck to test immune therapies against prostate cancer",http://www.reuters.com/article/2014/08/25/advaxis-merck-co-cancer-idUSL2N0QS2EE20140825
20140826†12:01AM UTC,Advaxis and Merck Form Collaboration to Evaluate Investigational Combination of Two Novel Immunotherapy Candidates for Advanced Prostate Cancer,http://www.reuters.com/article/2014/08/25/idUSnGNX7Xy4Hd+1d2+GNW20140825
20140826†12:01AM UTC,"Advaxis, Merck to test immune therapies against prostate cancer",http://www.reuters.com/article/2014/08/25/advaxis-merck-co-cancer-idUSL2N0QS27G20140825
20140827†12:36PM UTC,Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,http://www.reuters.com/article/2014/08/26/us-pfizer-merck-cancer-idUSKBN0GQ16N20140826
20140827†12:27PM UTC,RPT-UPDATE 2-Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,http://www.reuters.com/article/2014/08/26/pfizer-merck-cancer-idUSL1N0QW1DT20140826
20140827†10:52AM UTC,UPDATE 2-Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,http://www.reuters.com/article/2014/08/26/pfizer-merck-cancer-idUSL1N0QW0QB20140826
20140827†9:07AM UTC,Pfizer to test Xalkori lung cancer drug with Merck immunotherapy,http://www.reuters.com/article/2014/08/26/pfizer-merck-cancer-idUSL1N0QW0ND20140826
20140827†8:00AM UTC,Pfizer And Merck To Collaborate On Study Evaluating Novel Anti-Cancer Combination Regimen,http://www.reuters.com/article/2014/08/26/pfizer-idUSnBw265402a+100+BSW20140826
20140829†9:30AM UTC,"Acquisitions, Appointment, and Vaccine Recommendations - Research Reports on InterMune, Amgen, Johnson & Johnson, Merck and Medtronic",http://www.reuters.com/article/2014/08/28/bc-analystsreviewcom-idUSnPn5WlkJ9+92+PRN20140828
20140902†7:18AM UTC,"Research and Markets: Global Multiple Sclerosis Drugs Market 2014-2018 Featuring Bayer, Biogen Idec, Merck Serono, Novartis & Teva Pharmaceutical",http://www.reuters.com/article/2014/09/01/research-and-markets-idUSnBw015155a+100+BSW20140901
20140903†8:30AM UTC,"Merck to Present New Data in Five Tumor Types from Studies Evaluating Pembrolizumab, the Company‚Äôs Investigational Anti-PD-1 Antibody, at ESMO 2014",http://www.reuters.com/article/2014/09/02/nj-merck-idUSnBw025332a+100+BSW20140902
20140904†9:34AM UTC,"Research and Markets: Global Animal Health Market 2014-2018: Key Vendors Dominating are Bayer, Elanco, Merck Animal Health, Merial & Zoetis",http://www.reuters.com/article/2014/09/03/research-and-markets-idUSnBw035970a+100+BSW20140903
20140905†6:43PM UTC,U.S. approves Merck immune-stimulating drug for melanoma,http://www.reuters.com/article/2014/09/04/us-merck-melanoma-fda-idUSKBN0GZ2GQ20140904
20140905†6:33PM UTC,UPDATE 2-U.S. approves Merck immune-stimulating drug for melanoma,http://www.reuters.com/article/2014/09/04/merck-co-melanoma-fda-idUSL1N0R52D320140904
20140905†3:46PM UTC,"Merck Receives Accelerated Approval of KEYTRUDA¬Æ (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy",http://www.reuters.com/article/2014/09/04/merck-fdaapprkeytruda-idUSnPnBH5xn+58+PRN20140904
20140905†3:15PM UTC,"Merck Receives Accelerated Approval of KEYTRUDA¬Æ (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy",http://www.reuters.com/article/2014/09/04/nj-merck-idUSnBw046251a+100+BSW20140904
20140905†2:56PM UTC,U.S. FDA approves Merck immune-stimulating drug for melanoma,http://www.reuters.com/article/2014/09/04/merck-melanoma-fda-idUSL1N0R529020140904
20140905†9:00AM UTC,Merck‚Äôs Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA,http://www.reuters.com/article/2014/09/04/nj-merck-idUSnBw045618a+100+BSW20140904
20140906†9:46PM UTC,Bristol-Myers sues Merck over U.S. immunotherapy patent,http://www.reuters.com/article/2014/09/06/us-bristol-myers-merck-co-lawsuit-idUSKBN0H102X20140906
20140906†9:25PM UTC,Bristol-Myers sues Merck over U.S. immunotherapy patent,http://www.reuters.com/article/2014/09/06/bristol-myers-merck-co-lawsuit-idUSL1N0R703L20140906
20140906†9:00AM UTC,"Upcoming Presentations, Technical Update, Study Results, and Marketing Authorization Application - Research Reports on Novartis, InterMune, Johnson & Johnson, Amgen and Merck",http://www.reuters.com/article/2014/09/05/bc-analysts-review-idUSnPnCBkhr+58+PRN20140905
20140906†9:00AM UTC,"Research and Markets: Global Hepatitis B Vaccines Market 2014-2018 - GlaxoSmithKline, Merck & Sanofi Pasteur Dominate the Market",http://www.reuters.com/article/2014/09/05/research-and-markets-idUSnBw055403a+100+BSW20140905
20140910†3:08PM UTC,"Broccolini and Magil Laurentian announce the acquisition of the former Merck Canada complex in Kirkland, Quebec",http://www.reuters.com/article/2014/09/09/broccoliniacquisition-idUSnPnb5S4pS+89+PRN20140909
20140910†8:38AM UTC,BRIEF-Merck CEO says tax inversion deals would not fit its corporate strategy,http://www.reuters.com/article/2014/09/09/merck-brief-idUSWEN00DYE20140909
20140910†5:22AM UTC,"Research and Markets: Global Infectious Disease Treatment Market 2014-2018: Key Vendors Are F. Hoffmann-La Roche, Gilead Sciences, GSK, J&J; Merck & Pfizer",http://www.reuters.com/article/2014/09/09/research-and-markets-idUSnBw095467a+100+BSW20140909
20140911†10:00AM UTC,Merck & Co.'s Keytruda is Approved in the United States for the Treatment of Advanced and Unresectable Malignant Melanoma,http://www.reuters.com/article/2014/09/10/decision-resour-merck-idUSnPn56GWVX+8f+PRN20140910
20140913†10:31AM UTC,"Research and Markets: Global Asthma Market 2014-2018: Leading Vendors are AstraZeneca, F. Hoffmann-La Roche, GSK, Merck & Novartis",http://www.reuters.com/article/2014/09/12/research-and-markets-idUSnBw125557a+100+BSW20140912
20140913†10:16AM UTC,"Research and Markets: Global Animal Vaccines Market 2014-2018: Leading Vendors are Bayer HealthCare, Elanco Animal Health, Merck Animal Health, Novartis Animal Health, Sanofi & Zoetis",http://www.reuters.com/article/2014/09/12/research-and-markets-idUSnBw125532a+100+BSW20140912
20140913†10:12AM UTC,Merck KGaA Discontinues Clinical Development Program of Tecemotide as a Monotherapy in Stage III Non-Small Cell Lung Cancer,http://www.reuters.com/article/2014/09/12/bc-merck-kgaa-idUSnPn1JNLRs+9e+PRN20140912
20140913†8:16AM UTC,Merck KGaA ends lung cancer vaccine trials,http://www.reuters.com/article/2014/09/12/us-merck-lungcancer-idUSKBN0H71C820140912
20140913†8:04AM UTC,Merck KGaA ends lung cancer vaccine trials,http://www.reuters.com/article/2014/09/12/merck-lungcancer-idUSWEA00FJQ20140912
20140916†4:59PM UTC,"Merck osteoporosis drug passes trial, but side effects hover",http://www.reuters.com/article/2014/09/15/us-merck-osteoporosis-idUSKBN0HA1Y820140915
20140916†4:51PM UTC,"UPDATE 2-Merck osteoporosis drug passes trial, but side effects hover",http://www.reuters.com/article/2014/09/15/merck-osteoporosis-idUSL1N0RG1NN20140915
20140916†1:56PM UTC,Merck says osteoporosis drug achieves goal in large trial,http://www.reuters.com/article/2014/09/15/merck-osteoporosis-idUSL1N0RG1M020140915
20140916†1:30PM UTC,"Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis",http://www.reuters.com/article/2014/09/15/nj-merck-idUSnBw156286a+100+BSW20140915
20140916†9:15AM UTC,"New Product Launch, Accelerated Drug Approvals, Study Initiation, and Market Activity - Research Reports on Johnson & Johnson, Merck, Medtronic, Pharmacyclics and NPS Pharma",http://www.reuters.com/article/2014/09/15/bc-analysts-review-idUSnPn6bksN5+82+PRN20140915
20140916†2:00AM UTC,Merck Millipore Recognized for Technologically Advanced Products by R&D; Magazine,http://www.reuters.com/article/2014/09/15/merck-millipore-idUSnBw145014a+100+BSW20140915
20140917†9:30AM UTC,"The Zacks Analyst Blog Highlights: Merck KGaA, Lannett, Avanir Pharmaceuticals, Anacor Pharmaceuticals and Helen of Troy",http://www.reuters.com/article/2014/09/16/il-zacks-investments-idUSnPn35Kk4P+89+PRN20140916
20140917†9:21AM UTC,"Research and Markets: Global Hepatitis C Market Report 2014-2018: Leading Vendors are F. Hoffmann-La Roche, Gilead Sciences, J&J;, Merck & Vertex Pharmaceuticals",http://www.reuters.com/article/2014/09/16/research-and-markets-idUSnBw165930a+100+BSW20140916
20140917†5:57AM UTC,Merck KGaA agrees to market Lupin drugs in emerging countries,http://www.reuters.com/article/2014/09/16/us-merck-lupin-idUSKBN0HB0XI20140916
20140917†5:45AM UTC,Merck KGaA agrees to market Lupin drugs in emerging countries,http://www.reuters.com/article/2014/09/16/merck-lupin-idUSWEA00FNM20140916
20140917†5:00AM UTC,"Merck Serono to Broaden Its General Medicines Portfolio in Emerging Markets with Affordable, High-Quality Medicines",http://www.reuters.com/article/2014/09/16/merck-serono-idUSnBw165321a+100+BSW20140916
20140918†1:38PM UTC,Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab,http://www.reuters.com/article/2014/09/17/sun-pharma-idUSnBw176195a+100+BSW20140917
20140918†12:21PM UTC,Merck licenses experimental psoriasis drug to India's Sun Pharma,http://www.reuters.com/article/2014/09/17/us-merck-co-psoriasis-idUSKBN0HC1JG20140917
20140918†10:12AM UTC,Merck licenses experimental psoriasis drug to India's Sun Pharma,http://www.reuters.com/article/2014/09/17/merck-co-psoriasis-idUSL3N0RI4AG20140917
20140918†9:31AM UTC,"Merck Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes",http://www.reuters.com/article/2014/09/17/nj-merck-idUSnBw175586a+100+BSW20140917
20140918†8:30AM UTC,Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for Tildrakizumab,http://www.reuters.com/article/2014/09/17/nj-merck-idUSnBw175589a+100+BSW20140917
20140918†8:00AM UTC,"Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates",http://www.reuters.com/article/2014/09/17/ca-sutro-biopharma-idUSnPn847qdV+81+PRN20140917
20140919†11:01AM UTC,Merck KGaA Strengthens Executive Board,http://www.reuters.com/article/2014/09/18/bc-merck-kgaa-idUSnPnbxYDX2+8e+PRN20140918
20140919†8:45AM UTC,Merck Animal Health to market Neogen's dairy genomic program,http://www.reuters.com/article/2014/09/18/ky-neogen-merck-agree-idUSnPn1nVCN7+8e+PRN20140918
20140919†6:15AM UTC,Merck KGaA seeks partner for immuno-oncology drug by year-end,http://www.reuters.com/article/2014/09/18/us-merck-oncology-idUSKBN0HD0WH20140918
20140919†6:12AM UTC,UPDATE 1-Merck KGaA seeks partner for immuno-oncology drug by year-end,http://www.reuters.com/article/2014/09/18/merck-oncology-idUSL6N0RJ1O520140918
20140919†4:57AM UTC,Merck KGaA seeks immuno-oncology research partner,http://www.reuters.com/article/2014/09/18/merck-oncology-idUSWEA00FQY20140918
20140919†4:29AM UTC,Merck KGaA appoints pharma head Oschmann as deputy CEO,http://www.reuters.com/article/2014/09/18/us-merck-board-idUSKBN0HD0SP20140918
20140919†4:26AM UTC,Merck KGaA appoints pharma head Oschmann as deputy CEO,http://www.reuters.com/article/2014/09/18/merck-board-idUSWEA00FQW20140918
20140920†11:00AM UTC,Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal,http://www.reuters.com/article/2014/09/19/merck-diabetes-hispan-idUSnPnbZyQp8+94+PRN20140919
20140923†8:28PM UTC,"SIGMA-ALDRICH INVESTOR ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Sigma-Aldrich Corporation In Connection with the Sale of the Company to Merck -- SIAL",http://www.reuters.com/article/2014/09/23/lk-sigmaaldrich-alrt-idUSnPn8LLWQy+9e+PRN20140923
20140923†4:01PM UTC,EQUITY ALERT: Rosen Law Firm Announces Investigation of Sigma-Aldrich Corporation Concerning its Proposed Sale to Merck KGaA,http://www.reuters.com/article/2014/09/22/ny-the-rosen-law-firm-idUSnBw226399a+100+BSW20140922
20140923†1:08PM UTC,"SIGMA-ALDRICH INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Sigma-Aldrich Corp. Over the Proposed Sale of the Company to Merck KGaA - SIAL",http://www.reuters.com/article/2014/09/22/sigmaaldrich-alert-idUSnPn4kZC9c+8c+PRN20140922
20140923†12:56PM UTC,Germany's Merck to buy Sigma-Aldrich for $17 billion to boost lab supplies operation,http://www.reuters.com/article/2014/09/22/us-merck-sigma-aldrich-idUSKCN0HH1CK20140922
20140923†12:52PM UTC,UPDATE 3-Germany's Merck to buy Sigma-Aldrich for $17 bln to boost lab supplies operation,http://www.reuters.com/article/2014/09/22/merck-sigma-aldrich-idUSL6N0RN1T420140922
20140923†12:00PM UTC,"SIGMA-ALDRICH INVESTOR ALERT: Levi & Korsinsky, LLP Investigates the Board of Directors of Sigma-Aldrich Corporation In Connection with the Sale of the Company to Merck -- SIAL",http://www.reuters.com/article/2014/09/22/ny-levi-korsinsky-idUSnBw226033a+100+BSW20140922
20140923†11:27AM UTC,SIGMA-ALDRICH SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Merck KGaA,http://www.reuters.com/article/2014/09/22/tx-powers-taylor-idUSnBw225990a+100+BSW20140922
20140923†9:51AM UTC,Block & Leviton LLP Investigates Sigma-Aldrich Corporation for Possible Breaches of Fiduciary Duty in Connection with Its Merger with Merck KGaA,http://www.reuters.com/article/2014/09/22/block-leviton-invest-idUSnPn307nt4+80+PRN20140922
20140923†9:51AM UTC,Merck still sees investment grade ratings after Sigma-Aldrich deal,http://www.reuters.com/article/2014/09/22/us-merck-sigma-aldrich-ratings-idUSKCN0HH1W620140922
20140923†8:58AM UTC,Merck still sees investment grade ratings after Sigma-Aldrich deal,http://www.reuters.com/article/2014/09/22/us-merck-sigma-aldrich-ratings-idUSKCN0HH1R120140922
20140923†6:28AM UTC,Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry,http://www.reuters.com/article/2014/09/22/merck-kgaa-idUSnBw225465a+100+BSW20140922
20140923†6:10AM UTC,Merck KGaA to buy Sigma-Aldrich for $17 bln,http://www.reuters.com/article/2014/09/22/merck-sigma-aldrich-idUSWEA00FTZ20140922
20140924†12:14PM UTC,INVESTOR ALERT: The Law Offices of Vincent Wong Investigates the Board of Directors of Sigma-Aldrich Corporation Regarding the Fairness of the Sale of the Company to Merck,http://www.reuters.com/article/2014/09/23/ny-law-offs-vincent-wong-idUSnBw236258a+100+BSW20140923
20140924†9:05AM UTC,"Regulatory Approval, Presentation of Data, Appointment, Clinical Study Results, and Increase in Quarterly Dividend - Research Reports on Johnson & Johnson, Merck, Medtronic, Amgen and Covidien",http://www.reuters.com/article/2014/09/23/bc-analysts-review-idUSnPn905035+80+PRN20140923
20140924†9:00AM UTC,"Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sigma-Aldrich Corporation. Concerning its Proposed Sale to Merck --SIAL",http://www.reuters.com/article/2014/09/23/bgg-investigate-sial-idUSnPn1BQg0P+99+PRN20140923
20140924†8:30AM UTC,Banks line up $15.6 billion loan for Merck's Sigma-Aldrich buy,http://www.reuters.com/article/2014/09/23/us-merck-loans-idUSKCN0HI19820140923
20140924†8:17AM UTC,RLPC-Banks line up $15.6 bn loan for Merck's Sigma-Aldrich buy,http://www.reuters.com/article/2014/09/23/merck-loans-idUSL6N0RO38520140923
20140924†4:34AM UTC,"Research and Markets: Global Pneumococcal Vaccines Market 2014-2018: GlaxoSmithKline, Merck & Pfizer Dominate the Industry",http://www.reuters.com/article/2014/09/23/research-and-markets-idUSnBw235390a+100+BSW20140923
20140925†5:00PM UTC,Merck to Hold Third-Quarter 2014 Sales and Earnings Conference Call on October 27,http://www.reuters.com/article/2014/09/24/nj-merck-idUSnBw246260a+100+BSW20140924
20140925†1:43PM UTC,"Research and Markets: PharmaPoint: Asthma - Current and Future Players Report: GSK, Merck & Co, AstraZeneca/MedImmune, Novartis, Roche/Genentech, Teva & Boehringer Ingelheim",http://www.reuters.com/article/2014/09/24/research-and-markets-idUSnBw246207a+100+BSW20140924
20140925†7:31AM UTC,WiserTogether Raises $9 Million in Series B Led by Martin Ventures and Merck Global Health Innovation Fund,http://www.reuters.com/article/2014/09/24/dc-wisertogether-fund-idUSnPn4rHbKF+8b+PRN20140924
20140926†9:20AM UTC,"Pharma Stocks Review - AbbVie, Merck, Johnson and Johnson, GlaxoSmithKline, and Bristol-Myers Squibb",http://www.reuters.com/article/2014/09/25/bc-investor-edge-idUSnPn60LWmC+8d+PRN20140925
20140926†7:03AM UTC,"Research and Markets: Acute Coronary Syndrome - Current and Future Players: Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, GSK, Janssen Pharma, Merck, Pfizer & Sanofi",http://www.reuters.com/article/2014/09/25/research-and-markets-idUSnBw255354a+100+BSW20140925
20140929†3:51AM UTC,Merck drug extends immune system fight to stomach cancer,http://www.reuters.com/article/2014/09/28/us-health-cancer-merck-idUSKCN0HN07J20140928
20140929†3:15AM UTC,Merck Announces First Presentation of Data on the Investigational Use of KEYTRUDA¬Æ (pembrolizumab) in Patients with Advanced Gastric Cancer at ESMO 2014,http://www.reuters.com/article/2014/09/28/nj-merck-idUSnBw285025a+100+BSW20140928
20140929†3:15AM UTC,Merck drug extends immune system fight to stomach cancer,http://www.reuters.com/article/2014/09/28/health-cancer-merck-idUSL6N0RS04820140928
20140930†2:06PM UTC,"Research and Markets: Global Therapeutic Vaccines Market Outlook 2019 Featuring GSK, Merck, Novartis, Pfizer, Sanofi Avnetis & Serum Institute",http://www.reuters.com/article/2014/09/29/research-and-markets-idUSnBw296373a+100+BSW20140929
20140930†9:00AM UTC,Merck Partners with eSSENTIAL Accessibility to offer app for people with disabilities,http://www.reuters.com/article/2014/09/29/merk-joins-essential-idUSnPn3hTf8M+89+PRN20140929
20140930†5:19AM UTC,Merck immunotherapy drug shows promise in bladder cancer,http://www.reuters.com/article/2014/09/29/us-health-cancer-merck-idUSKCN0HO0QO20140929
20140930†5:00AM UTC,Merck Announces First Presentation of Early Data on the Investigational Use of KEYTRUDA¬Æ (pembrolizumab) in Patients with Advanced Bladder Cancer at ESMO 2014,http://www.reuters.com/article/2014/09/29/nj-merck-idUSnBw295263a+100+BSW20140929
20140930†5:00AM UTC,Merck immunotherapy drug shows promise in bladder cancer,http://www.reuters.com/article/2014/09/29/health-cancer-merck-idUSL6N0RT0N420140929
20140930†4:00AM UTC,Product Innovations and Geographical Expansion Drive Sustained Merck Consumer Health Business Growth,http://www.reuters.com/article/2014/09/29/merck-idUSnBw295060a+100+BSW20140929
20141002†11:31AM UTC,BRIEF-Bayer completes takeover of Merck & Co OTC drug unit,http://www.reuters.com/article/2014/10/01/bayer-merck-co-ma-idUSFWN0RV02P20141001
20141002†11:30AM UTC,Merck Completes Sale of Consumer Care Business to Bayer AG for $14.2 Billion,http://www.reuters.com/article/2014/10/01/nj-merck-idUSnBw016220a+100+BSW20141001
20141002†11:29AM UTC,BRIEF-Bayer closes buy of Merck & Co consumer care business,http://www.reuters.com/article/2014/10/01/bayer-merck-co-ma-idUSFWN0RV02Q20141001
20141002†9:10AM UTC,"Legal Settlement, Data Presentation, Welfare Initiatives, Acquisition Talks, and Study Results - Research Reports on Shire, Merck, Medtronic, Salix and Johnson & Johnson",http://www.reuters.com/article/2014/10/01/bc-analysts-review-idUSnPn4tJ7bs+88+PRN20141001
20141003†8:22AM UTC,"Research and Markets: Cell Isolation/Cell Separation Market Outlook 2019: Key Vendors are BD Biosciences, Danaher, GE, Merck Millipore, Miltenyi Biotec, pluriSelect, STEMCELL, Sigma-Aldrich, Terumo BCT, Thermo Fisher Scienti",http://www.reuters.com/article/2014/10/02/research-and-markets-idUSnBw025544a+100+BSW20141002
20141004†7:00PM UTC,"SIGMA-ALDRICH INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Sigma-Aldrich Corp. (SIAL) Over the Proposed Sale of the Company to Merck KGaA",http://www.reuters.com/article/2014/10/03/ny-faruqi-faruqi-idUSnBw035721a+100+BSW20141003
20141004†9:00AM UTC,Merck Congratulates Ecuador as Second Country to Receive PAHO/WHO Verification of Elimination of River Blindness,http://www.reuters.com/article/2014/10/03/nj-merck-idUSnBw035070a+100+BSW20141003
20141007†3:18PM UTC,Fitch Rates Merck's EUR Debt Offering 'A+'; Outlook Negative,http://www.reuters.com/article/2014/10/06/ny-fitch-ratings-merck-idUSnBw066470a+100+BSW20141006
20141007†2:10PM UTC,Fitch Rates Merck's EUR Debt Offering 'A+'; Outlook Negative,http://www.reuters.com/article/2014/10/06/fitch-rates-mercks-eur-debt-offering-a-o-idUSFit78182020141006
20141007†1:36PM UTC,New Issue- Merck & Co prices multi tranche deal,http://www.reuters.com/article/2014/10/06/idUSL3N0S13D120141006
20141007†12:44PM UTC,Research and Markets: Global Laboratory Filtration Market Outlook 2019: Pall Corporation and Merck Millipore Dominates the $2.53 Billion Industry,http://www.reuters.com/article/2014/10/06/research-and-markets-idUSnBw066266a+100+BSW20141006
20141007†12:28PM UTC,Merck Prices EUR 2.5 Billion Debt Offering,http://www.reuters.com/article/2014/10/06/nj-merck-idUSnBw066239a+100+BSW20141006
20141007†3:44AM UTC,M+W Group Receives Major Contract for Merck's New Pharmaceutical Facility in China,http://www.reuters.com/article/2014/10/06/idUSnHUG6kgXc5+1c4+ONE20141006
20141007†3:24AM UTC,Merck Announces Proposed Public Debt Offering,http://www.reuters.com/article/2014/10/06/nj-merck-co-idUSnBw065346a+100+BSW20141006
20141007†3:18AM UTC,Merck Announces Tender Offers for Eight Series of Notes,http://www.reuters.com/article/2014/10/06/nj-merck-co-idUSnBw065343a+100+BSW20141006
20141008†3:00AM UTC,"Merck Serono to Collaborate with The Institute of Cancer Research, London, and Wellcome Trust to Co-Develop Anti-Cancer Drugs",http://www.reuters.com/article/2014/10/07/merck-serono-idUSnBw075157a+100+BSW20141007
20141009†7:40PM UTC,Merck & Co. Executive Pamela Demain Elected President of Licensing Executives Society (U.S.A. and Canada),http://www.reuters.com/article/2014/10/08/ca-licensing-executives-idUSnBw086614a+100+BSW20141008
20141009†4:22PM UTC,"In $250 Million Class Action Gender Discrimination Suit Against Merck, Court Denies Merck's Motion To Dismiss",http://www.reuters.com/article/2014/10/08/sanford-heisler-merck-idUSnPn80ddgc+80+PRN20141008
20141009†11:13AM UTC,Merck to Present New Data from Clinical Studies Evaluating Investigational Hepatitis C Treatment Grazoprevir/Elbasvir (MK-5172/MK-8742) at the 65th American Association for the Study of Liver Diseases Annual Meeting,http://www.reuters.com/article/2014/10/08/nj-merck-idUSnBw086093a+100+BSW20141008
20141014†8:35AM UTC,"Welfare Initiatives, Clinical Data Presentation, Financing Plan, Regulatory Disclosure, and Positive Drug Trials - Research Reports on Johnson & Johnson, Merck, Medtronic, Covidien and Amgen",http://www.reuters.com/article/2014/10/13/bc-analysts-review-idUSnPn2l93fB+81+PRN20141013
20141016†4:08PM UTC,Merck unit to pay $31 million to settle fraud claims by U.S. states,http://www.reuters.com/article/2014/10/15/us-pharmaceuticals-remeron-idUSKCN0I42IO20141015
20141016†4:04PM UTC,Merck unit to pay $31 mln to settle fraud claims by U.S. states,http://www.reuters.com/article/2014/10/15/pharmaceuticals-remeron-idUSL2N0SA22920141015
20141016†8:00AM UTC,Merck Announces Final Results of Tender Offers for Eight Series of Notes,http://www.reuters.com/article/2014/10/15/nj-merck-idUSnBw155304a+100+BSW20141015
20141018†2:59AM UTC,"Roche, Merck extend immunotherapy fight to breast cancer",http://www.reuters.com/article/2014/10/17/us-roche-results-cancer-idUSKCN0I60HA20141017
20141018†2:45AM UTC,"Roche, Merck extend immunotherapy fight to breast cancer",http://www.reuters.com/article/2014/10/17/uk-roche-results-cancer-idUSKCN0I51ZM20141017
20141018†2:41AM UTC,"UPDATE 1-Roche, Merck extend immunotherapy fight to breast cancer",http://www.reuters.com/article/2014/10/17/roche-results-cancer-idUSL6N0SC0IR20141017
20141021†8:00AM UTC,Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals,http://www.reuters.com/article/2014/10/20/merck-diabetes-goals-idUSnPn5fRJHk+8e+PRN20141020
20141021†8:00AM UTC,US FDA Accepts for Review a Biologics License Application for Merck and Sanofi Pasteur‚Äôs Investigational Pediatric Hexavalent Vaccine,http://www.reuters.com/article/2014/10/20/nj-merck-idUSnBw205262a+100+BSW20141020
20141022†9:00AM UTC,"Merger Deal Updates, Dividend, Dispute Settlement, Regulatory Application Submission, and Preliminary Results - Research Reports on Shire, Johnson & Johnson, Merck, Amgen and HCA",http://www.reuters.com/article/2014/10/21/bc-analysts-review-idUSnPn4QXDXb+9e+PRN20141021
20141024†11:46AM UTC,"Research and Markets: Global Affinity Chromatography Reagents Market 2014-2018: Key Vendors are Agilent Technologies, Merck, Thermo Fisher Scientific & Waters",http://www.reuters.com/article/2014/10/23/research-and-markets-idUSnBw236110a+100+BSW20141023
20141028†3:26PM UTC,Weak Merck sales overshadow third-quarter cost cuts,http://www.reuters.com/article/2014/10/27/us-merck-co-results-idUSKBN0IG12620141027
20141028†3:24PM UTC,UPDATE 3-Weak Merck sales overshadow Q3 cost cuts,http://www.reuters.com/article/2014/10/27/merck-co-results-idUSL1N0SM0NP20141027
20141028†9:30AM UTC,"Twitter, DuPont, Bank of Americaand Merck are part of Zacks Earnings Preview:",http://www.reuters.com/article/2014/10/27/il-zacksinvestment-idUSnPn3537nT+81+PRN20141027
20141028†7:18AM UTC,"Merck beats Q3 forecast, cost cuts offset Gardasil decline",http://www.reuters.com/article/2014/10/27/merck-co-results-idUSL2N0SJ22Y20141027
20141028†7:00AM UTC,Merck Announces Third-Quarter 2014 Financial Results,http://www.reuters.com/article/2014/10/27/nj-merck-idUSnBw275422a+100+BSW20141027
20141028†6:45AM UTC,Merck Receives FDA Breakthrough Therapy Designation for KEYTRUDA¬Æ (pembrolizumab) in Advanced Non-Small Cell Lung Cancer,http://www.reuters.com/article/2014/10/27/nj-merck-idUSnBw275286a+100+BSW20141027
20141028†10:20AM UTC,Generics cut into Merck's profit,http://www.reuters.com/news/video/videoStory?storyID=97724673
20141030†10:20AM UTC,"Our World With Black Enterprise TV Show, Featuring Hollywood Hitmaker Will Packer and Merck CEO Kenneth Frazier, To Premiere November 1",http://www.reuters.com/article/2014/10/29/black-enterprise-tv-idUSnPn7kqKPC+87+PRN20141029
20141031†9:15AM UTC,"Financial Results, Program Expansion, Product Launch, and Share Dealings - Research Reports on Merck, Johnson & Johnson, Amgen, Medtronic and Shire",http://www.reuters.com/article/2014/10/30/bc-analysts-review-idUSnPn4BjdCC+93+PRN20141030
20141101†4:55AM UTC,"Research and Markets: Global Pediatric Vaccine Market 2014-2018: Key Vendors are GlaxoSmithKline, Merck, Pfizer and Sanofi",http://www.reuters.com/article/2014/10/31/research-and-markets-idUSnBw315146a+100+BSW20141031
20141104†4:01PM UTC,"Codexis Appoints Pam P. Cheng, Merck Global Executive, to Board of Directors",http://www.reuters.com/article/2014/11/03/idUSnGNXmBFbx+ec+GNW20141103
20141104†9:30AM UTC,"The Zacks Analyst Blog Highlights: Goldman Sachs Group, Visa, DuPont, Merck and Pfizer",http://www.reuters.com/article/2014/11/03/zacks-goldmansachs-idUSnPn5GSwrk+98+PRN20141103
20141104†8:52AM UTC,Merck Animal Health Launches Awareness Campaign to Support Pet Diabetes Month‚Ñ¢,http://www.reuters.com/article/2014/11/03/nj-merckanimalhealth-idUSnPn1xvpdk+80+PRN20141103
20141104†6:59AM UTC,"Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Completes Target Enrollment in the TH-302 Phase 3 MAESTRO Study in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma",http://www.reuters.com/article/2014/11/03/idUSnMKW7Lz6ka+1d0+MKW20141103
20141104†5:00AM UTC,Merck Announces Data from 48-Week Phase 2b Study of Investigational HIV Therapy Doravirine (MK-1439) in Treatment-Naive Patients,http://www.reuters.com/article/2014/11/03/nj-merck-idUSnBw035159a+100+BSW20141103
20141105†8:55AM UTC,"Pharma Stocks on our Radar - Pfizer, Merck, Sanofi, Shire, and Zogenix",http://www.reuters.com/article/2014/11/04/bc-investor-edge-idUSnPn3hsvbP+81+PRN20141104
20141106†2:09PM UTC,Merck takes steps to return Zilmax to U.S. cattle market,http://www.reuters.com/article/2014/11/05/us-merck-co-fda-idUSKBN0IP1VI20141105
20141106†2:06PM UTC,UPDATE 1-Merck takes steps to return Zilmax to U.S. cattle market,http://www.reuters.com/article/2014/11/05/merck-co-fda-idUSL4N0SV76820141105
20141106†9:52AM UTC,Merck says animal food additive Zilmax seen safe in review,http://www.reuters.com/article/2014/11/05/merck-co-fda-idUSL4N0SV6FT20141105
20141106†8:30AM UTC,"Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps",http://www.reuters.com/article/2014/11/05/nj-merck-animal-health-idUSnBw055127a+100+BSW20141105
20141107†9:08AM UTC,"New Studies Investigating the Use of KEYTRUDA¬Æ (pembrolizumab), Merck‚Äôs Anti-PD-1 Therapy, in Advanced Melanoma Compared to Chemotherapy, in Classical Hodgkin Lymphoma and in Triple Negative Breast Cancer, to be Presented",http://www.reuters.com/article/2014/11/06/nj-merck-idUSnBw065811a+100+BSW20141106
20141107†7:25AM UTC,BIND Therapeutics Announces Agreement with Merck to Develop Targeted Accurin‚Ñ¢ Nanomedicines for Oncology,http://www.reuters.com/article/2014/11/06/ma-bind-therapeutics-idUSnBw065097a+100+BSW20141106
20141108†11:00AM UTC,Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal,http://www.reuters.com/article/2014/11/07/merck-diabetes-a1c-idUSnPnbTgx7Q+91+PRN20141107
20141108†8:50AM UTC,"Collaboration, Breakthrough Therapy Designation, Clinical Trial Data, Voting Rights, and Financial Results - Research Reports on Johnson & Johnson, Merck, Amgen, Shire and HCA",http://www.reuters.com/article/2014/11/07/bc-analysts-review-idUSnPnkS5cD+49+PRN20141107
20141110†7:16PM UTC,Merck four-week hep C regimen with Gilead's Sovaldi comes up short,http://www.reuters.com/article/2014/11/10/us-merck-co-hepatitis-idUSKCN0IU00K20141110
20141110†7:03PM UTC,Merck 4-week hep C regimen with Gilead's Sovaldi comes up short,http://www.reuters.com/article/2014/11/10/merck-co-hepatitis-idUSL1N0SX36J20141110
20141110†6:53PM UTC,Interim Data from Proof-of-Concept Study of Merck‚Äôs Investigational Hepatitis C Treatment Grazoprevir/Elbasvir in Combination with a Nucleotide Inhibitor (C-SWIFT study) Presented at The Liver Meeting¬Æ,http://www.reuters.com/article/2014/11/09/ma-merck-idUSnBw095032a+100+BSW20141109
20141111†3:34PM UTC,"Merck expects no writedowns for Zetia, Vytorin cholesterol drugs",http://www.reuters.com/article/2014/11/10/us-merck-zetia-idUSKCN0IU26J20141110
20141111†3:32PM UTC,"Merck expects no writedowns for Zetia, Vytorin cholesterol drugs",http://www.reuters.com/article/2014/11/10/merck-zetia-idUSL2N0T01XD20141110
20141112†10:07AM UTC,"Research and Markets: Global Hospital Pharmaceuticals Market Outlook 2020: AstraZeneca, Bayer, Eli Lilly and Co, GSK, J&J;, Merck Pfizer & Sanofi-Aventis Dominate the $10 Billion Market",http://www.reuters.com/article/2014/11/11/research-and-markets-idUSnBw115990a+100+BSW20141111
20141112†8:00AM UTC,Merck Announces Results from Phase 2 Study of Investigational Chronic Hepatitis C Treatment Grazoprevir/Elbasvir in Genotype 1 Infected Treatment-Na√Øve and Difficult-to-Cure Patients,http://www.reuters.com/article/2014/11/11/ma-merck-idUSnBw115163a+100+BSW20141111
20141113†5:02PM UTC,U.S. gene study raises hope for Merck cholesterol drug Zetia,http://www.reuters.com/article/2014/11/12/us-heart-health-gene-idUSKCN0IW2LZ20141112
20141113†5:00PM UTC,U.S. gene study raises hope for Merck cholesterol drug Zetia,http://www.reuters.com/article/2014/11/12/heart-health-gene-idUSL2N0T22A520141112
20141113†4:57PM UTC,Future of Merck cholesterol sales could hang on long-awaited study,http://www.reuters.com/article/2014/11/12/us-health-heart-merck-idUSKCN0IW2LD20141112
20141114†4:57AM UTC,Merck KGaA rules out larger acquisitions for now,http://www.reuters.com/article/2014/11/13/merck-results-deals-idUSL6N0T32TP20141113
20141114†2:35AM UTC,UPDATE 1-Merck KGaA core earnings up 3 percent on AZ takeover,http://www.reuters.com/article/2014/11/13/merck-results-idUSL6N0T30N820141113
20141114†1:16AM UTC,Merck KGaA core earnings up 3 percent on AZ takeover,http://www.reuters.com/article/2014/11/13/merck-results-idUSFWN0T203F20141113
20141117†4:25AM UTC,Merck Announces Positive Study Investigating the Use of KEYTRUDA¬Æ (pembrolizumab) Compared to Chemotherapy in Patients with Ipilimumab-Refractory Advanced Melanoma,http://www.reuters.com/article/2014/11/16/merck-idUSnBw165033a+100+BSW20141116
20141118†12:42PM UTC,"Merck's Zetia cuts heart attack, stroke risk in long-awaited study",http://www.reuters.com/article/2014/11/17/us-health-heart-merck-cholesterol-idUSKCN0J11TX20141117
20141118†12:41PM UTC,"UPDATE 1-Merck's Zetia cuts heart attack, stroke risk in long-awaited study",http://www.reuters.com/article/2014/11/17/health-heart-merck-cholesterol-idUSL2N0T71KQ20141117
20141118†11:37AM UTC,"Merck's Zetia cuts heart attack, stroke risk in long-awaited study",http://www.reuters.com/article/2014/11/17/health-heart-merck-cholesterol-idUSL2N0T71DH20141117
20141118†8:52AM UTC,Pfizer dampens Astra bid hopes with German Merck cancer deal,http://www.reuters.com/article/2014/11/17/us-merck-pfizer-idUSKCN0J10LR20141117
20141118†8:48AM UTC,Merck says long-term cholesterol drug study met primary endpoint,http://www.reuters.com/article/2014/11/17/us-merck-trial-idUSKCN0J11F120141117
20141118†8:46AM UTC,Merck says long-term cholesterol drug study met primary endpoint,http://www.reuters.com/article/2014/11/17/merck-trial-idUSL2N0T70WK20141117
20141118†8:30AM UTC,Merck Announces that IMPROVE-IT Achieved Primary Endpoint; Data to be Presented at American Heart Association Scientific Sessions Today,http://www.reuters.com/article/2014/11/17/nj-merck-idUSnBw175264a+100+BSW20141117
20141118†5:35AM UTC,UPDATE 2-Pfizer dampens Astra bid hopes with German Merck cancer deal,http://www.reuters.com/article/2014/11/17/merck-pfizer-idUSL6N0T715V20141117
20141118†4:27AM UTC,Merck KGaA says Pfizer deal exclusive ,http://www.reuters.com/article/2014/11/17/us-merck-pfizer-exclusivity-idUSKCN0J10R420141117
20141118†3:40AM UTC,"Merck KGaA, Darmstadt, Germany, Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology",http://www.reuters.com/article/2014/11/17/merck-kgaa-idUSnBw175354a+100+BSW20141117
20141118†3:10AM UTC,"German Merck, Pfizer in cancer immunotherapy deal",http://www.reuters.com/article/2014/11/17/us-merck-pfizer-idUSKCN0J10LP20141117
20141118†2:53AM UTC,"Pfizer Forms Global Strategic Alliance with Merck KGaA, Germany, to Jointly Develop and Commercialize Anti-PD-L1 to Accelerate Presence in Immuno-Oncology",http://www.reuters.com/article/2014/11/17/pfizer-idUSnBw165100a+100+BSW20141117
20141121†1:15PM UTC,"TechNavio Names Pfizer, Merck, F. Hoffmann-La Roche as Top Companies in the Global Human Growth Hormone Market",http://www.reuters.com/article/2014/11/20/technavio-research-idUSnBw206127a+100+BSW20141120
20141125†11:47AM UTC,Merck buys rights to NewLink's experimental Ebola vaccine,http://www.reuters.com/article/2014/11/24/us-health-ebola-merck-idUSKCN0J814A20141124
20141125†11:46AM UTC,UPDATE 2-Merck buys rights to NewLink's experimental Ebola vaccine,http://www.reuters.com/article/2014/11/24/health-ebola-merck-idUSL3N0TE3O620141124
20141125†8:16AM UTC,Merck buys rights to NewLink's experimental Ebola vaccine,http://www.reuters.com/article/2014/11/24/health-ebola-merck-idUSL3N0TE3FT20141124
20141125†8:00AM UTC,"Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes",http://www.reuters.com/article/2014/11/24/nj-merck-idUSnBw245122a+100+BSW20141124
20141125†7:30AM UTC,Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine,http://www.reuters.com/article/2014/11/24/idUSnGNX683W5v+1c4+GNW20141124
20141125†7:30AM UTC,Merck and NewLink Genetics Enter Into Licensing and Collaboration Agreement for Investigational Ebola Vaccine,http://www.reuters.com/article/2014/11/24/nj-merck-newlink-idUSnBw245161a+100+BSW20141124
20141126†1:00PM UTC,Merck Announces Increased Quarterly Dividend,http://www.reuters.com/article/2014/11/25/nj-merck-idUSnBw256059a+100+BSW20141125
20141129†9:18AM UTC,"Germany's Merck aims to grow, not sell $1 billion consumer health arm",http://www.reuters.com/article/2014/11/28/us-merck-consumers-idUSKCN0JC1D120141128
20141129†9:13AM UTC,"Germany's Merck aims to grow, not sell $1 bln consumer health arm",http://www.reuters.com/article/2014/11/28/merck-consumers-idUSL6N0TI29Z20141128
20141129†4:00AM UTC,Merck‚Äôs Consumer Health division sparks debate on the future of the OTC sector,http://www.reuters.com/article/2014/11/28/merck-idUSnBw285044a+100+BSW20141128
20141202†9:30AM UTC,"American Airlines, Stone Energy, GlaxoSmithKline, Merck and NewLink Genetics highlighted as Zacks Bull and Bear of the Day",http://www.reuters.com/article/2014/12/01/il-zacks-aal-idUSnPn6wLs8c+88+PRN20141201
20141202†8:00AM UTC,"Merck's HIV Education Campaign, I Design, Reveals Video and Poem Created by the HIV Community in Honor of World AIDS Day",http://www.reuters.com/article/2014/12/01/merck-world-aids-day-idUSnPn8n9G0z+84+PRN20141201
20141203†11:13AM UTC,No serious side effects in Merck/Newlink Ebola vaccine test,http://www.reuters.com/article/2014/12/02/us-health-ebola-vaccine-idUSKCN0JG0WY20141202
20141203†5:58AM UTC,UPDATE 1-No serious side effects in Merck/Newlink Ebola vaccine test,http://www.reuters.com/article/2014/12/02/health-ebola-vaccine-idUSL6N0TM1PJ20141202
20141203†5:05AM UTC,No serious side effects in Merck/Newlink Ebola vaccine test,http://www.reuters.com/article/2014/12/02/health-ebola-vaccine-idUSL6N0TM1LX20141202
20141205†1:15PM UTC,"REG-Sanofi : Merial acquires Merck manufacturing facility in Barceloneta, Puerto Rico",http://www.reuters.com/article/2014/12/04/idUSnHUGc4DlB4+1ca+ONE20141204
20141206†9:31PM UTC,Merck in talks to acquire Cubist Pharmaceuticals for more than $7 billion: NYT,http://www.reuters.com/article/2014/12/06/us-merck-co-m-a-cubist-pharm-idUSKCN0JK01T20141206
20141206†12:30PM UTC,Sigma-Aldrich Stockholders Approve Acquisition By Merck KGaA,http://www.reuters.com/article/2014/12/05/mo-sial-merck-kgaa-idUSnPn57JlnC+89+PRN20141205
20141207†1:06PM UTC,Merck immunotherapy drug shows promise against lymphoma: study,http://www.reuters.com/article/2014/12/06/us-merck-lymphoma-idUSKBN0JK0P220141206
20141207†1:00PM UTC,"Data Investigating KEYTRUDA¬Æ (pembrolizumab), Merck‚Äôs Anti-PD-1 Therapy, in Patients with Classical Hodgkin Lymphoma Presented at ASH Annual Meeting",http://www.reuters.com/article/2014/12/06/ca-merck-idUSnBw065008a+100+BSW20141206
20141207†1:00PM UTC,Merck immunotherapy drug shows promise against lymphoma -study,http://www.reuters.com/article/2014/12/06/merck-lymphoma-idUSL2N0TN2GL20141206
20141209†6:44PM UTC,Merck to take on superbugs with Cubist Pharma buy,http://www.reuters.com/article/2014/12/08/us-cubist-pharma-m-a-merck-idUSKBN0JM19X20141208
20141209†6:41PM UTC,Merck to take on superbugs with Cubist Pharma buy,http://www.reuters.com/article/2014/12/08/cubist-pharma-ma-merck-idUSL1N0TS0WM20141208
20141209†6:38PM UTC,UPDATE 4-Merck to take on superbugs with Cubist Pharma buy,http://www.reuters.com/article/2014/12/08/cubist-pharma-ma-merck-idUSL3N0TS3VA20141208
20141209†4:20PM UTC,New Trial Initiated Evaluating Amgen's Talimogene Laherparepvec In Combination With Merck's Anti-PD-1 Therapy KEYTRUDA¬Æ (Pembrolizumab) For Advanced Melanoma,http://www.reuters.com/article/2014/12/08/amgen-trial-idUSnPn1bMwgs+88+PRN20141208
20141209†3:44PM UTC,Breakingviews: Merck bets $8.4 bln on more profitable antibiotics,http://www.reuters.com/article/2014/12/08/cubist-pharm-ma-merck-co-breakingviews-idUSL1N0TS1VZ20141208
20141209†3:40PM UTC,Merck bets $8.4 bln on more profitable antibiotics,http://www.reuters.com/article/2014/12/08/idUS320885456720141208
20141209†2:14PM UTC,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co.",http://www.reuters.com/article/2014/12/08/ny-levi-korsinsky-idUSnBw086259a+100+BSW20141208
20141209†12:54PM UTC,Cubist options unusually active before Merck deal,http://www.reuters.com/article/2014/12/08/us-cubist-m-a-options-idUSKBN0JM20U20141208
20141209†12:50PM UTC,Cubist options unusually active before Merck deal,http://www.reuters.com/article/2014/12/08/cubist-ma-options-idUSL1N0TS13K20141208
20141209†11:57AM UTC,"CUBIST PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Merck & Co., Inc.",http://www.reuters.com/article/2014/12/08/tx-powers-taylor-llp-idUSnBw086030a+100+BSW20141208
20141209†11:28AM UTC,New Issue- Merck prices dual tranche deal,http://www.reuters.com/article/2014/12/08/idUSL3N0TS4J520141208
20141209†10:32AM UTC,Block & Leviton LLP Investigates Cubist Pharmaceuticals Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Proposed Acquisition by Merck & Co.,http://www.reuters.com/article/2014/12/08/ma-block-leviton-ll-idUSnPn8j86L2+82+PRN20141208
20141209†10:30AM UTC,"Cubist Pharmaceuticals, Inc. Shareholder Alert: Bernstein Liebhard LLP Announces Investigation Of Acquisition By Merck",http://www.reuters.com/article/2014/12/08/ny-bernsteinliebhard-idUSnPn6ywSj0+84+PRN20141208
20141209†9:04AM UTC,"Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Cubist Pharmaceuticals Inc. Concerning its Proposed Sale to Merck & Co. -CBST",http://www.reuters.com/article/2014/12/08/bronstein-cbst-merck-idUSnPn81zMjT+85+PRN20141208
20141209†8:43AM UTC,"CUBIST PHARMACEUTICALS ALERT: Johnson & Weaver, LLP Investigates the Fairness of Price and Process in Proposed Sale of Cubist Pharmaceuticals, Inc. to Merck",http://www.reuters.com/article/2014/12/08/ca-johnson-weaver-idUSnBw085637a+100+BSW20141208
20141209†7:30AM UTC,Advaxis Announces FDA Acceptance of Its Investigational New Drug Application to Commence Clinical Trials of ADXS-PSA in Combination With Merck's KEYTRUDA(R) (pembrolizumab) for Prostate Cancer,http://www.reuters.com/article/2014/12/08/idUSnGNXch1mql+1c0+GNW20141208
20141209†7:10AM UTC,"Merck takes aim at superbugs, to buy Cubist in $9.5 bln deal",http://www.reuters.com/article/2014/12/08/cubist-pharma-ma-merck-idUSL3N0TS3IO20141208
20141209†7:00AM UTC,Merck to Acquire Cubist Pharmaceuticals for $102 Per Share in Cash,http://www.reuters.com/article/2014/12/08/nj-merck-idUSnBw085433a+100+BSW20141208
20141209†10:30AM UTC,Merck buys Cubist for $8.4 billion,http://www.reuters.com/news/video/videoStory?storyID=100921217
20141210†9:32PM UTC,"Acquisition of Cubist Pharmaceuticals, Inc. (CBST) by Merck & Co., Inc. (MRK) May Not Be in Shareholders' Best Interests",http://www.reuters.com/article/2014/12/10/robbins-arroyo-idUSnPn3kDyTF+8b+PRN20141210
20141210†6:54PM UTC,Cubist sales force seen as potential boon for Merck intestinal drug,http://www.reuters.com/article/2014/12/09/us-merck-antibiotics-idUSKBN0JN2NY20141209
20141210†6:52PM UTC,Cubist sales force seen as potential boon for Merck intestinal drug,http://www.reuters.com/article/2014/12/09/merck-antibiotics-idUSL1N0TT2FU20141209
20141210†6:18PM UTC,"Merck says still plans to buy Cubist, despite patent setback",http://www.reuters.com/article/2014/12/09/cubist-pharm-ma-merck-co-idUSL1N0TT0TD20141209
20141210†6:14PM UTC,"Merck says still plans to buy Cubist, despite patent setback",http://www.reuters.com/article/2014/12/09/us-cubist-pharm-m-a-merck-co-idUSKBN0JN1K820141209
20141210†6:13PM UTC,"UPDATE 2-Merck says still plans to buy Cubist, despite patent setback",http://www.reuters.com/article/2014/12/09/cubist-pharm-ma-merck-co-idUSL1N0TT0TF20141209
20141210†4:15PM UTC,"Research and Markets: Global Human Growth Hormone Market 2015-2019: Key Vendors are F. Hoffmann-La Roche, Merck Serono, Novo Nordisk and Pfizer",http://www.reuters.com/article/2014/12/09/research-and-markets-idUSnBw096595a+100+BSW20141209
20141210†3:36PM UTC,Merck gives in to M&A; frenzy risk assessment,http://www.reuters.com/article/2014/12/09/idUS429476679220141209
20141210†1:07PM UTC,Breakingviews: Merck gives in to M&A; frenzy risk assessment,http://www.reuters.com/article/2014/12/09/cubist-pharm-ma-merck-co-breakingviews-idUSL1N0TT1OQ20141209
20141210†11:49AM UTC,"SHAREHOLDER ALERT: Levi & Korsinsky, LLP Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co. -- CBST",http://www.reuters.com/article/2014/12/09/levi-alert-cubist-idUSnPn3ZTQ2s+9c+PRN20141209
20141210†8:59AM UTC,"Merck says still plans Cubist purchase, despite patent setback",http://www.reuters.com/article/2014/12/09/cubist-pharm-ma-merck-co-idUSL1N0TT0RX20141209
20141210†8:11AM UTC,Merck Statement Regarding CUBICIN Patent Litigation,http://www.reuters.com/article/2014/12/09/nj-merck-idUSnBw095647a+100+BSW20141209
20141210†5:00AM UTC,"Zymeworks Inc. and Merck & Co., Inc. Extend and Expand Bi-specific Antibody Therapeutics Collaboration",http://www.reuters.com/article/2014/12/09/zymeworks-idUSnBw095279a+100+BSW20141209
20141210†4:30AM UTC,Merck to take on superbugs with Cubist Pharma buy,http://www.reuters.com/article/2014/12/09/us-cubist-pharma-m-a-merck-idUSKBN0JM19X20141209
20141211†12:51PM UTC,"CBST SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. Regarding the Fairness of the Sale of the Company to Merck & Co.",http://www.reuters.com/article/2014/12/10/ny-levi-korsinsky-idUSnBw106187a+100+BSW20141210
20141211†9:30AM UTC,"Merck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public Policy and Population Health",http://www.reuters.com/article/2014/12/10/nj-merck-idUSnBw105127a+100+BSW20141210
20141211†8:50AM UTC,RPT-Cubist sales force seen as potential boon for Merck intestinal drug,http://www.reuters.com/article/2014/12/10/merck-antibiotics-idUSL1N0TU0UU20141210
20141211†8:45AM UTC,"International Breast Cancer Study Group, Breast International Group and Merck Announce Opening of International PANACEA Study of Patients with HER2+ Breast Cancer",http://www.reuters.com/article/2014/12/10/tx-merck-idUSnBw105070a+100+BSW20141210
20141211†8:30AM UTC,"Data Investigating KEYTRUDA¬Æ (pembrolizumab), Merck‚Äôs Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast Cancer Presented at 2014 San Antonio Breast Cancer Symposium",http://www.reuters.com/article/2014/12/10/nj-merck-idUSnBw105073a+100+BSW20141210
20141213†8:30PM UTC,"CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST",http://www.reuters.com/article/2014/12/13/faruqi-faruqi-investi-idUSnPn58WKz8+8c+PRN20141213
20141213†10:19AM UTC,"CBST SHAREHOLDER ALERT: The Law Offices of Vincent Wong Launches Investigation of the Board of Directors of Cubist Pharmaceuticals, Inc. in Connection With the Fairness of the Sale of the Company to Merck & Co.",http://www.reuters.com/article/2014/12/12/ny-law-offs-vincent-wong-idUSnBw125468a+100+BSW20141212
20141213†9:10AM UTC,"Technical Data on Pharma Stocks - Pfizer, Merck, AbbVie, Akorn, and The Medicines",http://www.reuters.com/article/2014/12/12/bc-investor-edge-idUSnPnb3yN9p+84+PRN20141212
20141216†4:24PM UTC,TRLPC: Merck looks for $8B bridge for Cubist acquisition,http://www.reuters.com/article/2014/12/15/merck-bridge-idUSL1N0TZ29F20141215
20141216†9:30AM UTC,"The Zacks Analyst Blog Highlights: Chevron, Statoil, Merck, Boeing and General Electric",http://www.reuters.com/article/2014/12/15/il-zacks-analystblog-idUSnPnbDh4fD+91+PRN20141215
20141217†4:18PM UTC,"Research and Markets: Global Herpes Market Report 2014-2018 - Key Vendors are Gilead Sciences, GSK, Merck & Novartis",http://www.reuters.com/article/2014/12/16/research-and-markets-idUSnBw166579a+100+BSW20141216
20141217†3:01PM UTC,"Research and Markets: Asia Pacific Osteoporosis Drugs (Antiresorptives & Anabolics) Market 2015-2019 with Amgen, Eli Lilly, Merck & Novartis Dominating",http://www.reuters.com/article/2014/12/16/research-and-markets-idUSnBw166452a+100+BSW20141216
20141219†11:06AM UTC,New GSK shingles vaccine may challenge Merck after strong test data,http://www.reuters.com/article/2014/12/18/us-gsk-shingles-idUSKBN0JW1F820141218
20141219†11:00AM UTC,UPDATE 1-New GSK shingles vaccine may challenge Merck after strong test data,http://www.reuters.com/article/2014/12/18/gsk-shingles-idUSL6N0U23MY20141218
20141219†8:00AM UTC,Enumeral and Merck Form Collaboration for Predicting Clinical Drug Response with Human-driven Immune Profiling Platform,http://www.reuters.com/article/2014/12/18/ma-enumeral-biomedical-idUSnBw185203a+100+BSW20141218
20141219†7:30AM UTC,"Merck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers",http://www.reuters.com/article/2014/12/18/nj-merck-idUSnBw185052a+100+BSW20141218
20141219†4:26AM UTC,REFILE-BRIEF-India's Merck Ltd says board recommends to appoint Anand Nambiar as MD,http://www.reuters.com/article/2014/12/18/merck-brief-idUSWNAS00B9Z20141218
20141220†8:00AM UTC,Merck Begins Tender Offer to Acquire Cubist,http://www.reuters.com/article/2014/12/19/nj-merck-cubist-idUSnBw195068a+100+BSW20141219
20141220†12:34AM UTC,Merckx and Ickx feted as Belgium's speed demons,http://www.reuters.com/article/2014/12/19/us-people-belgium-merckx-ickx-idUSKBN0JX0CU20141219
20141223†12:28PM UTC,Harris & Harris Group Notes Publicly Traded Portfolio Company Enumeral Biomedical's Collaboration With Merck,http://www.reuters.com/article/2014/12/22/idUSnGNX6ZT4XX+1db+GNW20141222
20141223†8:00AM UTC,"NewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award",http://www.reuters.com/article/2014/12/22/idUSnGNXb1M4P7+1ca+GNW20141222
20141224†9:44AM UTC,"Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance",http://www.reuters.com/article/2014/12/23/sigma-aldrich-merck-idUSnPnYSXdp+5c+PRN20141223
20141230†9:00AM UTC,"EnWave Signs Non-Exclusive License With Merck, Agrees to Build Second Generation Radiant Energy Vacuum Dryer",http://www.reuters.com/article/2014/12/29/idUSnMKW1Rbbka+1d0+MKW20141229
20150106†9:00AM UTC,"REPEAT - EnWave Signs Non-Exclusive License With Merck, Agrees to Build Second Generation Radiant Energy Vacuum Dryer",http://www.reuters.com/article/2015/01/05/idUSnMKWSmDKZa+1ee+MKW20150105
20150106†8:00AM UTC,Merck to Hold Fourth-Quarter and Full-Year 2014 Sales and Earnings Conference Call on February 4,http://www.reuters.com/article/2015/01/05/nj-merck-idUSnBw055105a+100+BSW20150105
20150106†7:58AM UTC,Merck-NewLink Ebola vaccine trial resumes at lower dose: Geneva hospital,http://www.reuters.com/article/2015/01/05/us-health-ebola-vaccine-idUSKBN0KE0XP20150105
20150106†7:53AM UTC,Merck-NewLink Ebola vaccine trial resumes at lower dose -Geneva hospital,http://www.reuters.com/article/2015/01/05/health-ebola-vaccine-idUSL6N0UK1JQ20150105
20150107†8:50AM UTC,"Scaling New Heights: Complimentary Research on Stereotaxis, Kite Pharma, ISIS Pharma, Merck and General Motors",http://www.reuters.com/article/2015/01/06/bc-analysts-review-idUSnPn4pY5Bq+8a+PRN20150106
20150110†10:33AM UTC,Research and Markets: Eli Lilly/BMS/Merck KGaA's Erbitux (Colorectal Cancer) - Forecast and Market Analysis to 2023,http://www.reuters.com/article/2015/01/09/research-and-markets-idUSnBw095556a+100+BSW20150109
20150110†10:25AM UTC,"Research and Markets: PharmaPoint Report: Colorectal Cancer - Current and Future Players: Roche/Genentech, Sanofi, Eli Lilly and Co, Merck KGaA, Bayer & Taiho Pharmaceutical",http://www.reuters.com/article/2015/01/09/research-and-markets-idUSnBw095536a+100+BSW20150109
20150110†8:00AM UTC,Merck to Present at the 33rd Annual J.P. Morgan Healthcare Conference,http://www.reuters.com/article/2015/01/09/nj-merck-idUSnBw095267a+100+BSW20150109
20150113†3:36PM UTC,"Merck, Bristol heat up immunotherapy race in lung cancer",http://www.reuters.com/article/2015/01/12/us-bristol-myers-merck-co-lung-idUSKBN0KL26320150112
20150113†3:34PM UTC,"Merck, Bristol heat up immunotherapy race in lung cancer",http://www.reuters.com/article/2015/01/12/bristol-myers-merck-co-lung-idUSL1N0UR1ZB20150112
20150113†11:06AM UTC,"Merck speeds up drug-submission plans for Hep C, lung cancer",http://www.reuters.com/article/2015/01/12/us-merck-co-cancerdrug-idUSKBN0KL0EA20150112
20150113†10:56AM UTC,"UPDATE 1-Merck speeds up drug-submission plans for Hep C, lung cancer",http://www.reuters.com/article/2015/01/12/merck-co-cancerdrug-idUSL3N0UR3LU20150112
20150113†7:00AM UTC,Merck Provides Update on Strategic Actions to Transform the Company and Build a Platform for Sustained Future Growth at the 33rd Annual J.P. Morgan Healthcare Conference,http://www.reuters.com/article/2015/01/12/nj-merck-idUSnBw125259a+100+BSW20150112
20150113†1:50AM UTC,"Merck speeds up drug-submission plans for Hep C, lung cancer -WSJ",http://www.reuters.com/article/2015/01/12/merck-co-cancerdrug-idUSL3N0UR20N20150112
20150114†9:05AM UTC,"Lilly to test combinations with Merck, Bristol-Myers' cancer drugs",http://www.reuters.com/article/2015/01/13/us-lilly-study-idUSKBN0KM1HC20150113
20150114†9:02AM UTC,"Lilly to test combinations with Merck, Bristol-Myers' cancer drugs",http://www.reuters.com/article/2015/01/13/lilly-study-idUSL3N0US4IG20150113
20150114†8:00AM UTC,Moderna Announces License and Collaboration Agreement with Merck to Develop Messenger RNA-based Antiviral Vaccines and Passive Immunity Therapies,http://www.reuters.com/article/2015/01/13/ma-moderna-merck-idUSnPn728XKb+86+PRN20150113
20150114†8:00AM UTC,"Lilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer",http://www.reuters.com/article/2015/01/13/nj-merck-idUSnBw135234a+100+BSW20150113
20150115†8:30AM UTC,Practice Fusion Announces Positive Results of Population Health Vaccine Initiative Conducted in Collaboration with Merck,http://www.reuters.com/article/2015/01/14/practice-fusion-idUSnPnXHkgb+58+PRN20150114
20150120†8:02AM UTC,Exclusive: Merck funds tests of lower Zilmax doses as seen seeking way to resume sales,http://www.reuters.com/article/2015/01/19/us-merck-co-zilmax-idUSKBN0KS18020150119
20150122†8:00AM UTC,Merck Completes Tender Offer to Acquire Cubist,http://www.reuters.com/article/2015/01/21/nj-merck-idUSnBw215472a+100+BSW20150121
20150123†3:29PM UTC,"Merck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist‚Äôs 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes due 2018 and 1.875% Convertible Senior N",http://www.reuters.com/article/2015/01/22/nj-merck-idUSnBw226325a+100+BSW20150122
20150127†8:30AM UTC,Merck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO¬Æ (tedizolid phosphate),http://www.reuters.com/article/2015/01/26/nj-merck-idUSnBw265079a+100+BSW20150126
20150128†11:25AM UTC,TransCelerate BioPharma Welcomes Merck & Co. and Novo Nordisk to its Membership Roster,http://www.reuters.com/article/2015/01/27/pa-transcelerate-biophar-idUSnBw275200a+100+BSW20150127
20150130†10:28AM UTC,"Global Ankylosing Spondylitis Market 2015-2019: Key Vendors are Abbvie, Amgen, Janssen Pharmaceuticals, Merck & Co and Pfizer",http://www.reuters.com/article/2015/01/29/idUSnGNX8Ykrpf+1d0+GNW20150129
20150130†4:30AM UTC,Merck Selects CRedit360 to Manage Sustainability Data Consistently across Their Global Organisation,http://www.reuters.com/article/2015/01/29/credit-idUSnBw295031a+100+BSW20150129
20150131†8:45AM UTC,"Technical Commentary on Pharma Stocks -- Merck, AbbVie, Bristol-Myers Squibb, Shire, and Mallinckrodt",http://www.reuters.com/article/2015/01/30/bc-investor-edge-idUSnPn6WGFzB+9d+PRN20150130
20150203†2:10AM UTC,"BRIEF-Germany's Merck says takes back marketing for products in diabetes, thyroid franchises in Russia",http://www.reuters.com/article/2015/02/02/merck-russia-idUSFWN0V902P20150202
20150204†8:00AM UTC,"Merck's Insomnia Medicine BELSOMRA¬Æ (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States",http://www.reuters.com/article/2015/02/03/merck-insomnia-drug-idUSnPn75qY2R+85+PRN20150203
20150204†8:00AM UTC,"Merck‚Äôs Insomnia Medicine BELSOMRA¬Æ (suvorexant) C-IV, the First and Only Orexin Receptor Antagonist, Now Available in the United States",http://www.reuters.com/article/2015/02/03/nj-merck-idUSnBw035100a+100+BSW20150203
20150206†7:37PM UTC,Merck Prices $8.0 Billion Debt Offering,http://www.reuters.com/article/2015/02/06/nj-merck-co-idUSnBw056688a+100+BSW20150206
20150207†1:07PM UTC,Fitch Rates Merck's Debt Offering 'A+'; Outlook Negative,http://www.reuters.com/article/2015/02/06/ny-fitch-ratings-merck-idUSnBw065690a+100+BSW20150206
20150210†1:02PM UTC,Ex-Merck analyst facing insider trading charges to plead guilty - lawyer,http://www.reuters.com/article/2015/02/09/insidertrading-merck-co-idUSL1N0VJ1NF20150209
20150210†12:56PM UTC,Ex-Merck analyst facing insider trading charges to plead guilty: lawyer,http://www.reuters.com/article/2015/02/09/us-insidertrading-merck-co-idUSKBN0LD22S20150209
20150210†12:50PM UTC,Ex-Merck analyst facing insider trading charges to plead guilty -lawyer,http://www.reuters.com/article/2015/02/09/insidertrading-merck-co-idUSL1N0VJ1J320150209
20150210†8:04AM UTC,Aventura Raises $14 Million Series C Financing Co-Led by Safeguard Scientifics and Merck GHIF,http://www.reuters.com/article/2015/02/09/idUSnGNX9Xm84x+1d0+GNW20150209
20150211†8:00AM UTC,"International GPCR Consortium Announces Addition of New Members Novo Nordisk and Merck & Co., Inc",http://www.reuters.com/article/2015/02/10/gpcr-consortium-adds-idUSnPn5Kd6SJ+93+PRN20150210
20150214†12:24AM UTC,BRIEF-Merck takes full promotional responsibility for Erbitux in Japan,http://www.reuters.com/article/2015/02/13/idUSFWN0VM0A320150213
20150220†5:00PM UTC,Ex-Merck analyst pleads guilty to U.S. insider trading charges,http://www.reuters.com/article/2015/02/19/insidertrading-merck-co-plea-idUSL1N0VT30A20150219
20150220†4:55PM UTC,Ex-Merck analyst pleads guilty to U.S. insider trading charges,http://www.reuters.com/article/2015/02/19/insidertrading-merck-co-plea-idUSL1N0VT2TM20150219
20150220†8:30AM UTC,NewLink Genetics Corporation Announces Clinical Development Milestone Achieved With Merck for Ebola Vaccine Candidate,http://www.reuters.com/article/2015/02/19/idUSnGNX3swktf+1c0+GNW20150219
20150224†6:22PM UTC,"Merck, on Behalf of Its Wholly Owned Subsidiary Cubist Pharmaceuticals, Announces Results of Tender Offer for Cubist‚Äôs 2.50% Convertible Senior Notes Due 2017, 1.125% Convertible Senior Notes Due 2018 and 1.875% Convertibl",http://www.reuters.com/article/2015/02/23/nj-merck-idUSnBw236525a+100+BSW20150223
20150224†7:00AM UTC,"NGM and Merck Announce Broad Strategic Collaboration to Discover, Develop and Commercialize Novel Biologic Therapeutics",http://www.reuters.com/article/2015/02/23/ca-merck-ngm-idUSnBw235260a+100+BSW20150223
20150225†12:51PM UTC,Merck Announces Second-Quarter 2015 Dividend,http://www.reuters.com/article/2015/02/24/nj-merck-idUSnBw246433a+100+BSW20150224
20150225†3:00AM UTC,Merck places children's HIV drug in shared non-profit patent pool,http://www.reuters.com/article/2015/02/24/us-health-aids-merck-co-idUSKBN0LS0JX20150224
20150225†3:00AM UTC,Merck places children's HIV drug in shared non-profit patent pool,http://www.reuters.com/article/2015/02/24/health-aids-merck-co-idUSL5N0VX3HK20150224
20150225†3:00AM UTC,Merck Announces Collaboration with the Medicines Patent Pool to Expand Access to Pediatric Formulations of Raltegravir in Developing Countries,http://www.reuters.com/article/2015/02/24/nj-merck-idUSnBw245310a+100+BSW20150224
20150227†3:18PM UTC,"Merck‚Äôs 9-Valent HPV Vaccine, GARDASIL¬Æ9, Recommended by CDC‚Äôs Advisory Committee on Immunization Practices for Females Aged 9-26 and Males Aged 9-21",http://www.reuters.com/article/2015/02/26/nj-merck-idUSnBw266541a+100+BSW20150226
20150228†3:52AM UTC,"Research and Markets: Global Congestive Heart Failure Drugs Market 2015-2019 with AstraZeneca, Bristol-Myers Squibb, GSK, Merck & Co., Mylan, Novartis, Pfizer, Sanofi & Valeant Pharmaceuticals Dominating",http://www.reuters.com/article/2015/02/27/research-and-markets-idUSnBw275153a+100+BSW20150227
20150303†8:00AM UTC,Merck to Present at the 35th Annual Cowen Health Care Conference,http://www.reuters.com/article/2015/03/02/nj-merck-idUSnBw025085a+100+BSW20150302
20150304†6:01AM UTC,Germany's Merck sees slight core profit rise in 2015,http://www.reuters.com/article/2015/03/03/us-merck-results-idUSKBN0LZ0H120150303
20150304†5:58AM UTC,UPDATE 2-Germany's Merck sees slight core profit rise in 2015,http://www.reuters.com/article/2015/03/03/merck-results-idUSL5N0W50FL20150303
20150304†1:14AM UTC,Merck KGaA sees slight increase in 2015 adj core earnings,http://www.reuters.com/article/2015/03/03/merck-results-idUSF9N0VD00Y20150303
20150305†6:30PM UTC,Eisai and Merck Enter Collaboration to Explore Novel Combination Regimens of Anti-PD-1 Therapy with Multi-targeting RTK Inhibitor and Microtubule Dynamics Inhibitor in Multiple Types of Cancer,http://www.reuters.com/article/2015/03/04/nj-merck-idUSnBw045961a+100+BSW20150304
20150306†5:02AM UTC,Merck-NewLink Ebola vaccine Phase III trial to start March 7,http://www.reuters.com/article/2015/03/05/health-ebola-vaccine-idUSL5N0W725E20150305
20150310†5:50PM UTC,Hagens Berman Files Wrongful Death Lawsuit Against Merck for Suicide Allegedly Linked to Hair Loss Drug Propecia,http://www.reuters.com/article/2015/03/09/wa-hagens-berman-idUSnBw096542a+100+BSW20150309
20150310†2:01PM UTC,"Research and Markets: Global Infertility Market 2015-2019: Key Vendors are Bayer Healthcare, CooperSurgical, Ferring Pharmaceuticals & Merck & Co.",http://www.reuters.com/article/2015/03/09/research-and-markets-idUSnBw096242a+100+BSW20150309
20150310†9:30AM UTC,"Pharma Equities Technical Data - Merck, AbbVie, Bristol-Myers Squibb, Eli Lilly, and Lannett",http://www.reuters.com/article/2015/03/09/bc-investor-edge-idUSnPnbjT661+88+PRN20150309
20150310†7:00AM UTC,Opexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna¬Æ for Multiple Sclerosis,http://www.reuters.com/article/2015/03/09/tx-opexa-therapeutics-idUSnBw095231a+100+BSW20150309
20150311†9:23AM UTC,"BRIEF-Merck Serono, Illumina to collaborate on cancer diagnostics",http://www.reuters.com/article/2015/03/10/idUSFWN0WC02Z20150310
20150311†9:00AM UTC,Illumina Announces Strategic Collaboration with Merck Serono to Expand Companion Diagnostics for Oncology,http://www.reuters.com/article/2015/03/10/ca-illumina-inc-idUSnBw105168a+100+BSW20150310
20150311†8:00AM UTC,Merck to Present at the Barclays Global Healthcare Conference,http://www.reuters.com/article/2015/03/10/nj-merck-idUSnBw105028a+100+BSW20150310
20150312†3:51AM UTC,Merck cancer drug is first approved under UK early access scheme,http://www.reuters.com/article/2015/03/11/us-health-britain-cancer-merck-co-idUSKBN0M70M320150311
20150312†3:38AM UTC,Merck cancer drug is first approved under UK early access scheme,http://www.reuters.com/article/2015/03/11/health-britain-cancer-merck-co-idUSL5N0WD10N20150311
20150205†2:44PM UTC,"Merck says hepatitis C treatment to lose breakthrough"" status""",http://www.reuters.com/article/2015/02/04/us-merck-co-results-idUSKBN0L81BX20150204
20150205†2:10PM UTC,"UPDATE 3-Merck says hepatitis C treatment to lose breakthrough"" status""",http://www.reuters.com/article/2015/02/04/merck-co-results-idUSL1N0VE0Q920150204
20150205†7:27AM UTC,"Merck issues cautious 2015 forecast, citing dollar",http://www.reuters.com/article/2015/02/04/merck-co-results-idUSL1N0VD29V20150204
20150205†7:02AM UTC,Merck Announces Fourth-Quarter and Full-Year 2014 Financial Results,http://www.reuters.com/article/2015/02/04/nj-merck-idUSnBw045459a+100+BSW20150204
20150331†8:00AM UTC,Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy,http://www.reuters.com/article/2015/03/30/intrexonmerckserono-idUSnPn2m9F48+84+PRN20150330
20150331†8:00AM UTC,Merck Serono and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy,http://www.reuters.com/article/2015/03/30/merck-intrexon-collab-idUSnPn7232Mq+82+PRN20150330
20150331†8:00AM UTC,"The Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany, and Intrexon Announce Agreement for the Development and Commercialization of CAR-T Therapy",http://www.reuters.com/article/2015/03/30/merck-intrexon-car-t-idUSnPn1ydytQ+81+PRN20150330
20150331†8:00AM UTC,ZIOPHARM-Intrexon Synthetic Immuno-Oncology Programs Strengthened Through Collaboration With Merck Serono,http://www.reuters.com/article/2015/03/30/idUSnGNX4jzyyc+1c0+GNW20150330
20150418†9:05AM UTC,"Be On Top of the Latest Updates: Complementary Research on Merck, General Electric Company, Halliburton, Sirius XM Holdings and Rite Aid",http://www.reuters.com/article/2015/04/17/bc-analysts-review-idUSnPn1DcYR2+96+PRN20150417
20150418†4:21AM UTC,BRIEF-Merck KGaA confirms full year outlook,http://www.reuters.com/article/2015/04/17/idUSFWN0XD07I20150417
20150524†7:39AM UTC,Germany's Merck expects drug division to drive growth: Euro am Sonntag,http://www.reuters.com/article/2015/05/23/us-merck-outlook-idUSKBN0O80CF20150523
20150524†7:07AM UTC,Germany's Merck expects drug division to drive growth-Euro am Sonntag,http://www.reuters.com/article/2015/05/23/merck-outlook-idUSL5N0YE06O20150523
20150611†8:46AM UTC,"Merck and Samsung Bioepis Announce Pivotal Phase 3 Studies for Investigational Biosimilars SB4, Enbrel (Etanercept), and SB2, Remicade (Infliximab), Met Primary Endpoints",http://www.reuters.com/article/2015/06/10/nj-merck-idUSnBw105662a+100+BSW20150610
20150804†4:23PM UTC,Codexis Announces CodeEvolver Technology Transfer and License Agreement With Merck,http://www.reuters.com/article/idUSnGNX8PtRFn+1d6+GNW20150803
20150804†11:09AM UTC,"Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics",http://www.reuters.com/article/ma-nano-c-merck-kgaa-idUSnPn2rRQHG+8f+PRN20150803
20150909†8:30AM UTC,"Merck and Samsung Bioepis Announce Approval of BRENZYS‚Ñ¢ (Etanercept), a Biosimilar of Enbrel, in Korea",http://www.reuters.com/article/nj-merck-idUSnBw085550a+100+BSW20150908
20150909†8:00AM UTC,Judge nixes Apotex's former expert in new role for Merck,http://www.reuters.com/article/health-expert-idUSL1N11E0L620150908
20150909†8:00AM UTC,Enumeral Achieves First Milestone in Merck Collaboration,http://www.reuters.com/article/ma-enumeral-biomedical-idUSnBw085207a+100+BSW20150908
20151015†4:12AM UTC,Germany's Merck KGaA scraps unit brands,http://www.reuters.com/article/us-merck-brand-idUSKCN0S80PC20151014
20151015†3:15AM UTC,Germany's Merck KGaA scraps unit brands,http://www.reuters.com/article/merck-brand-idUSFWN12D01C20151014
20151120†6:30AM UTC,Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial,http://www.reuters.com/article/lilly-merck-trial-idUSnPn6LF2wY+99+PRN20151119
20151208†8:00AM UTC,"Merck Announces Samsung Bioepis Receives Approval of RENFLEXIS‚Ñ¢ (Infliximab), a Biosimilar of Remicade, in Korea",http://www.reuters.com/article/nj-merck-idUSnBw075084a+100+BSW20151207
20151208†7:08AM UTC,Merck immunotherapy Keytruda shows promise in multiple myeloma trial,http://www.reuters.com/article/us-health-blood-merck-idUSKBN0TQ1BR20151207
20151208†7:00AM UTC,Merck immunotherapy Keytruda shows promise in multiple myeloma trial,http://www.reuters.com/article/health-blood-merck-idUSL1N13T2GW20151207
20151208†4:11AM UTC,"UPDATE 2-Merck KGaA, Threshold drug fails in late-stage cancer trials",http://www.reuters.com/article/merck-threshold-pharma-cancer-idUSL8N13W0FP20151207
20151208†3:42AM UTC,"Merck KGaA, Darmstadt, Germany, Decides Not to Pursue Evofosfamide Further in Soft Tissue Sarcoma and Pancreatic Cancer",http://www.reuters.com/article/bc-merck-kgaa-idUSnPn8LblhQ+91+PRN20151207
20151208†1:56AM UTC,"Merck KGaA, Threshold drug fails in late-stage cancer trials",http://www.reuters.com/article/us-merck-threshold-pharma-cancer-idUSKBN0TQ0IQ20151207
20151208†1:32AM UTC,"Merck KGaA, Threshold drug fails in late-stage cancer trials",http://www.reuters.com/article/merck-threshold-pharma-cancer-idUSFWN13T01520151207
20150314†5:35PM UTC,Merck expects to be denied approval for sugammadex injection again,http://www.reuters.com/article/2015/03/13/us-merck-co-fda-idUSKBN0M92GE20150313
20150314†5:33PM UTC,UPDATE 1-Merck expects to be denied approval for sugammadex injection again,http://www.reuters.com/article/2015/03/13/merck-co-fda-idUSL4N0WF5B820150313
20150314†4:37PM UTC,Merck expects to be denied approval for sugammadex injection again,http://www.reuters.com/article/2015/03/13/merck-co-fda-idUSL4N0WF59O20150313
20150314†4:02PM UTC,Merck Provides Regulatory Update on Investigational Medicine Sugammadex Injection,http://www.reuters.com/article/2015/03/13/nj-merck-idUSnBw135772a+100+BSW20150313
20150318†5:36AM UTC,Merck KGaA places $4 bln bond to fund Sigma-Aldrich deal,http://www.reuters.com/article/2015/03/17/merck-bond-idUSL6N0WJ1PL20150317
20150319†4:19PM UTC,New Data Investigating Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015,http://www.reuters.com/article/2015/03/18/nj-merck-idUSnBw186515a+100+BSW20150318
20150319†5:00AM UTC,80 Years of Innovation Drives Continued Success at Merck‚Äôs Consumer Health Business,http://www.reuters.com/article/2015/03/18/merck-idUSnBw185008a+100+BSW20150318
20150321†10:03AM UTC,Award-Winning Actress S. Epatha Merkerson and Merck Challenge African Americans with Type 2 Diabetes to Get to Their Goals,http://www.reuters.com/article/2015/03/20/merck-type2diabetes-idUSnPn8fPYyQ+8d+PRN20150320
20150321†7:51AM UTC,Merck KGaA's deputy chief Oschmann set to become CEO: Manager Magazin,http://www.reuters.com/article/2015/03/20/us-merck-board-idUSKBN0MG1AO20150320
20150321†7:11AM UTC,Merck KGaA's deputy chief Oschmann set to become CEO - Manager Magazin,http://www.reuters.com/article/2015/03/20/merck-board-idUSL6N0WM21D20150320
20150325†11:01AM UTC,Guinea starts testing Merck vaccine in Ebola hotspots,http://www.reuters.com/article/2015/03/25/us-health-ebola-vaccine-idUSKBN0ML1QT20150325
20150325†10:57AM UTC,Guinea starts testing Merck vaccine in Ebola hotspots,http://www.reuters.com/article/2015/03/25/health-ebola-vaccine-idUSL6N0WR3T020150325
20150325†8:00AM UTC,Lycera Announces Milestone in Merck Collaboration,http://www.reuters.com/article/2015/03/25/lycera-merck-collabo-idUSnPn9BP9BB+9b+PRN20150325
20150326†11:01AM UTC,Guinea starts testing Merck vaccine in Ebola hotspots,http://www.reuters.com/article/2015/03/25/us-health-ebola-vaccine-idUSKBN0ML1QT20150325
20150326†10:57AM UTC,Guinea starts testing Merck vaccine in Ebola hotspots,http://www.reuters.com/article/2015/03/25/health-ebola-vaccine-idUSL6N0WR3T020150325
20150326†8:00AM UTC,Lycera Announces Milestone in Merck Collaboration,http://www.reuters.com/article/2015/03/25/lycera-merck-collabo-idUSnPn9BP9BB+9b+PRN20150325
20150327†8:30AM UTC,Merck Announces Collaboration with the American Diabetes Association to Educate Adults with Diabetes About Increased Risk for Serious Diseases like Pneumococcal Pneumonia,http://www.reuters.com/article/2015/03/26/nj-merck-idUSnBw265083a+100+BSW20150326
20150327†2:06AM UTC,BRIEF-Ablynx extends ion channel research collaboration with Merck,http://www.reuters.com/article/2015/03/26/idUSFWN0WR02020150326
20150328†8:00AM UTC,Merck to Hold First-Quarter 2015 Sales and Earnings Conference Call on April 28,http://www.reuters.com/article/2015/03/27/nj-merck-idUSnBw275001a+100+BSW20150327
20150401†8:00AM UTC,Syndax and Merck to Collaborate on Immuno-Oncology Study Evaluating Entinostat in Combination with KEYTRUDA¬Æ (pembrolizumab) in Lung Cancer and Melanoma,http://www.reuters.com/article/2015/03/31/nj-merck-keytruda-idUSnBw315038a+100+BSW20150331
20150402†5:00PM UTC,"Merck, NewLink Ebola vaccine appears safe, effective in new studies",http://www.reuters.com/article/2015/04/01/us-health-ebola-vaccine-idUSKBN0MS5DN20150401
20150402†5:00PM UTC,"Merck, NewLink Ebola vaccine appears safe, effective in new studies",http://www.reuters.com/article/2015/04/01/health-ebola-vaccine-idUSL2N0WY1N020150401
20150407†8:00AM UTC,Merck Receives 2015 ENERGY STAR Sustained Excellence Award from U.S. Environmental Protection Agency,http://www.reuters.com/article/2015/04/06/nj-merck-idUSnBw065015a+100+BSW20150406
20150408†8:00AM UTC,"Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Finalize Agreement to Co-Promote XALKORI¬Æ (crizotinib)",http://www.reuters.com/article/2015/04/07/pfizer-idUSnBw075267a+100+BSW20150407
20150408†6:30AM UTC,Arvinas Announces Strategic R&D; Collaboration with Merck to Study Novel Protein Degradation Technology,http://www.reuters.com/article/2015/04/07/arvinas-rd-merck-idUSnPn7C4b5Y+91+PRN20150407
20150409†7:30AM UTC,"Advaxis and Merck Announce Initiation of Enrollment in the Phase 1/2 Study of ADXS-PSA in Combination With Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab), for the Treatment of Advanced Prostate Cancer",http://www.reuters.com/article/2015/04/08/idUSnGNX3mdPYv+1c6+GNW20150408
20150409†7:00AM UTC,"Event Alert: Kinaxis Customer, Merck, to Present at LogiPharma Europe",http://www.reuters.com/article/2015/04/08/kinaxis-merck-present-idUSnPn7t8Pf7+84+PRN20150408
20150409†7:00AM UTC,"Grazoprevir/Elbasvir, Merck‚Äôs Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations; New Phase 2 and 3 Data in Multiple HCV Patient Types to be Presented at The International Liver Cong",http://www.reuters.com/article/2015/04/08/nj-merck-idUSnBw085119a+100+BSW20150408
20150414†12:30PM UTC,Fitch Downgrades Merck's L-T IDR to 'A'; Outlook Revised to Stable,http://www.reuters.com/article/ny-fitch-ratings-merck-idUSnBw136287a+100+BSW20150413
20150414†12:21PM UTC,Fitch Downgrades Merck's L-T IDR to 'A'; Outlook Revised to Stable,http://www.reuters.com/article/idUSFit91948120150413
20150414†9:24AM UTC,"BRIEF-Merck names Udit Batra leader of combined Merck Millipore, Sigma-Aldrich business",http://www.reuters.com/article/merck-batra-idUSFWN0X80TM20150413
20150415†1:30PM UTC,Phase III Trial of the Merck and NewLink Genetics Investigational Ebola Vaccine Initiated in Sierra Leone,http://www.reuters.com/article/2015/04/14/nj-merck-idUSnBw146514a+100+BSW20150414
20150415†7:00AM UTC,NewLink Genetics and Merck & Co Receives Vaccine Industry Excellence Awards at World Vaccine Congress 2015,http://www.reuters.com/article/2015/04/14/idUSnGNX1zms9q+1c0+GNW20150414
20150417†4:28PM UTC,Merck Chairman and CEO Kenneth C. Frazier Becomes PhRMA Board Chairman,http://www.reuters.com/article/2015/04/16/phrma-board-changes-idUSnPn1nDDFT+8f+PRN20150416
20150417†8:00AM UTC,"Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development",http://www.reuters.com/article/2015/04/16/emd-serono-elect-idUSnPn9MvTff+94+PRN20150416
20150419†11:27AM UTC,Merck aims to quickly repay up to $5 billion in loans: CFO in Boersen-Zeitung,http://www.reuters.com/article/2015/04/18/us-merck-debt-idUSKBN0N90J320150418
20150419†11:18AM UTC,Merck aims to quickly repay up to $5 bln in loans -CFO in Boersen-Zeitung,http://www.reuters.com/article/2015/04/18/merck-debt-idUSL5N0XF0AL20150418
20150420†12:45PM UTC,"Early Findings with KEYTRUDA¬Æ (pembrolizumab), Merck‚Äôs Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting",http://www.reuters.com/article/2015/04/19/pa-merck-idUSnBw195023a+100+BSW20150419
20150420†12:28PM UTC,"Merck's Keytruda shrinks lung cancer tumors, FDA approval sought",http://www.reuters.com/article/2015/04/19/us-merck-co-cancer-lung-idUSKBN0NA0JS20150419
20150420†12:26PM UTC,"CORRECTED-Merck's Keytruda shrinks lung cancer tumors, FDA approval sought",http://www.reuters.com/article/2015/04/19/merck-co-cancer-lung-idUSL2N0XE15R20150419
20150420†8:30AM UTC,"KEYTRUDA¬Æ (pembrolizumab), Merck‚Äôs Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy...",http://www.reuters.com/article/2015/04/19/pa-merck-idUSnBw195027a+100+BSW20150419
20150420†8:02AM UTC,Merck files for FDA approval of Keytruda in lung cancer,http://www.reuters.com/article/2015/04/19/us-merck-fda-lungcancer-idUSKBN0NA0HI20150419
20150420†8:00AM UTC,Merck Announces Submission of Supplemental Biologics License Application (sBLA) to U.S. FDA for KEYTRUDA¬Æ (pembrolizumab) in Advanced Non-Small Cell Lung Cancer,http://www.reuters.com/article/2015/04/19/nj-merck-idUSnBw195022a+100+BSW20150419
20150420†8:00AM UTC,Merck files for FDA approval of Keytruda in lung cancer,http://www.reuters.com/article/2015/04/19/merck-fda-lungcancer-idUSL2N0XG00Y20150419
20150421†8:00AM UTC,TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination With KEYTRUDA(R) (pembrolizumab) in Solid Tumors,http://www.reuters.com/article/idUSnGNXbZC1qh+1d8+GNW20150420
20150421†8:00AM UTC,TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA¬Æ (pembrolizumab) in Solid Tumors,http://www.reuters.com/article/nj-merck-idUSnBw205234a+100+BSW20150420
20150421†8:00AM UTC,"Global Strategic Partners Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Phase III Study with Avelumab* in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer",http://www.reuters.com/article/pfizer-idUSnBw205369a+100+BSW20150420
20150422†8:30AM UTC,Merck Reaffirms Continued Commitment to Developing Innovative Medicines for the Treatment of Infectious Diseases at 25th Annual ECCMID Congress,http://www.reuters.com/article/2015/04/21/nj-merck-idUSnBw215125a+100+BSW20150421
20150423†8:00AM UTC,"Healthcare's Health Scanner: Complementary Research on Pfizer, Mylan, Teva Pharmaceutical, Bristol-Myers Squibb, and Merck & Company",http://www.reuters.com/article/2015/04/22/bc-analysts-review-idUSnPnb6WtKw+8a+PRN20150422
20150423†8:00AM UTC,"Tim McGraw, Merck and the American Diabetes Association Challenge Americans with Type 2 Diabetes to Get to Their A1C Goal",http://www.reuters.com/article/2015/04/22/merckdiabeteschallnge-idUSnPnTWGD2+5e+PRN20150422
20150424†3:30AM UTC,Merck Announces Results from Phase 2/3 Study of Investigational Chronic Hepatitis C Therapy Grazoprevir/Elbasvir in Patients with Advanced Chronic Kidney Disease,http://www.reuters.com/article/2015/04/23/merck-idUSnBw235068a+100+BSW20150423
20150425†1:00AM UTC,Merck oral hepatitis C regimen shows 95 pct cure rate,http://www.reuters.com/article/2015/04/24/merck-hepatitis-c-idUSL1N0XK23A20150424
20150425†1:00AM UTC,Merck‚Äôs Pivotal Phase 3 C-EDGE Program Evaluating Grazoprevir/Elbasvir Shows High Sustained Virologic Responses Across Broad Range of Patients with Chronic Hepatitis C Virus Infection,http://www.reuters.com/article/2015/04/24/merck-idUSnBw236879a+100+BSW20150424
20150428†6:48PM UTC,UPDATE 2-Merck diabetes drug Januvia meets heart safety target,http://www.reuters.com/article/merck-co-diabetes-idUSL1N0XO2M520150427
20150428†6:30PM UTC,Merck Announces Publication of Pivotal Data from Phase 3 Clinical Studies of ZERBAXA‚Ñ¢ (Ceftolozane/Tazobactam) in The Lancet and Clinical Infectious Diseases,http://www.reuters.com/article/nj-merck-idUSnBw275051a+100+BSW20150427
20150428†6:13PM UTC,Merck's diabetes drug Januvia succeeds in heart safety trial,http://www.reuters.com/article/us-merck-co-diabetes-idUSKBN0NI29820150427
20150428†5:29PM UTC,Merck's diabetes drug Januvia succeeds in heart safety trial,http://www.reuters.com/article/merck-co-diabetes-idUSL1N0XO2KK20150427
20150428†5:00PM UTC,Merck Announces the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) Met Primary Endpoint,http://www.reuters.com/article/nj-merck-idUSnBw276374a+100+BSW20150427
20150429†6:49PM UTC,Strong Merck cancer drug sales upstage rival Bristol-Myers,http://www.reuters.com/article/2015/04/28/bristolmyers-merck-cancer-idUSL1N0XP34H20150428
20150429†6:43PM UTC,Strong Merck cancer drug sales upstage rival Bristol-Myers,http://www.reuters.com/article/2015/04/28/us-bristolmyers-merck-cancer-idUSKBN0NJ2PG20150428
20150429†4:34PM UTC,"Dow, S&P; 500 end up with Merck, IBM; Nasdaq slips with Apple",http://www.reuters.com/article/2015/04/28/us-markets-stocks-idUSKBN0NJ18T20150428
20150429†4:33PM UTC,"US STOCKS-Dow, S&P; 500 end up with Merck, IBM; Nasdaq slips with Apple",http://www.reuters.com/article/2015/04/28/markets-stocks-usa-idUSL1N0XP33N20150428
20150429†3:03PM UTC,"US STOCKS-Wall St edges up with Merck, IBM; Nasdaq slips with Apple",http://www.reuters.com/article/2015/04/28/markets-stocks-usa-idUSL1N0XP2F820150428
20150429†12:30PM UTC,"Merck shares jump on strong earnings, Januvia safety data",http://www.reuters.com/article/2015/04/28/us-merck-results-idUSKBN0NJ18220150428
20150429†9:31AM UTC,"Merck says FDA again declines to approve Bridion, needs more data",http://www.reuters.com/article/2015/04/28/us-merck-bridion-merck-co-idUSKBN0NJ1K520150428
20150429†9:25AM UTC,"Merck says FDA again declines to approve Bridion, needs more data",http://www.reuters.com/article/2015/04/28/merck-bridion-merck-co-idUSL1N0XP10U20150428
20150429†8:58AM UTC,"UPDATE 1-Merck shares jump on strong earnings, Januvia safety data",http://www.reuters.com/article/2015/04/28/merck-results-idUSL1N0XP0NG20150428
20150429†7:17AM UTC,"Merck beats Q1 forecasts, helped by Januvia, animal health brands",http://www.reuters.com/article/2015/04/28/merck-results-idUSL1N0XP0N620150428
20150429†7:00AM UTC,Merck Announces First-Quarter 2015 Financial Results,http://www.reuters.com/article/2015/04/28/nj-merck-idUSnBw285615a+100+BSW20150428
20150429†11:11AM UTC,"Merck earnings beat estimates, raises full year guidance",http://www.reuters.com/news/video/videoStory?storyID=107349009
20150430†7:00AM UTC,RPT-Strong Merck cancer drug sales upstage rival Bristol-Myers,http://www.reuters.com/article/2015/04/29/bristolmyers-merck-cancer-idUSL1N0XP3O820150429
20150502†3:59AM UTC,"PeptiDream Announces Peptide Discovery Collaboration Agreement with Merck & Co., Inc<4587.T>",http://www.reuters.com/article/2015/05/01/peptidream-idUSnBw015167a+100+BSW20150501
20150507†1:03PM UTC,"American Express Global Business Travel and American Express Company Partner to Provide End-to-End Travel, Payments, and Meetings & Events Solution to Merck",http://www.reuters.com/article/2015/05/06/ny-american-express-idUSnBw065123a+100+BSW20150506
20150508†8:30AM UTC,Plexxikon and Merck to Collaborate on Combination Study Evaluating Investigational Immuno-oncology Regimen,http://www.reuters.com/article/2015/05/07/ca-plexxikon-idUSnBw075269a+100+BSW20150507
20150513†6:30AM UTC,"Merck KGaA, Threshold win fast track for pancreatic cancer drug",http://www.reuters.com/article/2015/05/12/us-merck-threshold-pharma-fda-idUSKBN0NX13R20150512
20150513†6:27AM UTC,"Merck KGaA, Threshold win fast track for pancreatic cancer drug",http://www.reuters.com/article/2015/05/12/merck-threshold-pharma-fda-idUSFWN0Y302E20150512
20150513†6:25AM UTC,"Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer",http://www.reuters.com/article/2015/05/12/bc-emd-serono-idUSnPn7cmdrx+80+PRN20150512
20150513†6:00AM UTC,"Threshold Pharmaceuticals' Partner Merck KGaA, Darmstadt, Germany, Receives FDA Fast Track Designation for Evofosfamide for the Treatment of Patients Living With Advanced Pancreatic Cancer",http://www.reuters.com/article/2015/05/12/idUSnMKWnB0GPa+1d6+MKW20150512
20150514†8:23PM UTC,Merck loses bid to escape investor lawsuit over Vioxx,http://www.reuters.com/article/2015/05/14/health-vioxx-securities-idUSL1N0Y500W20150514
20150514†5:01PM UTC,"Merck KGaA, Darmstadt, Germany, and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody",http://www.reuters.com/article/2015/05/13/pfizer-idUSnBw136632a+100+BSW20150513
20150514†5:00PM UTC,2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck‚Äôs Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA¬Æ (pembrolizumab) to be Presented,http://www.reuters.com/article/2015/05/13/nj-merck-idUSnBw136540a+100+BSW20150513
20150516†8:40AM UTC,Indian court bars Glenmark from selling Merck drug copies,http://www.reuters.com/article/2015/05/15/us-glenmark-phrm-merck-co-lawsuit-idUSKBN0O011S20150515
20150516†8:36AM UTC,UPDATE 1-Indian court bars Glenmark from selling Merck drug copies,http://www.reuters.com/article/2015/05/15/glenmark-phrm-merck-co-lawsuit-idUSL3N0Y65JM20150515
20150516†6:48AM UTC,India's Supreme Court bars Glenmark from selling copies of Merck diabetes drugs-sources,http://www.reuters.com/article/2015/05/15/glenmark-phrm-merck-co-lawsuit-idUSI8N0WQ00120150515
20150516†3:25AM UTC,"Merck KGaA, Darmstadt, Germany to Present Data at ASCO That Illustrate How the Company is Tackling Difficult-to-Treat Cancers",http://www.reuters.com/article/2015/05/15/bc-emd-serono-idUSnPn1bK5Qv+8a+PRN20150515
20150519†8:00AM UTC,Merck to Present at the UBS Global Healthcare Conference,http://www.reuters.com/article/2015/05/18/nj-merck-idUSnBw185424a+100+BSW20150518
20150520†10:16AM UTC,"Research and Markets: Global Osteoporosis Drugs Market 2015-2019: Key Vendors are Amgen, Eli Lilly, Merck & Novartis",http://www.reuters.com/article/2015/05/19/research-and-markets-idUSnBw196440a+100+BSW20150519
20150520†7:20AM UTC,UPDATE 2-Merck KGaA sees AZ deal and forex countering weak drug sales,http://www.reuters.com/article/2015/05/19/merck-kgaa-results-idUSL5N0YA0DE20150519
20150520†5:32AM UTC,RPT-Merck KGaA says to overcome EU concerns on Sigma-Aldrich deal,http://www.reuters.com/article/2015/05/19/merck-kgaa-results-regulator-idUSL5N0YA28R20150519
20150520†5:04AM UTC,Merck KGaA says to overcome EU concerns on Sigma-Aldrich deal,http://www.reuters.com/article/2015/05/19/merck-kgaa-results-regulator-idUSL5N0YA1R420150519
20150520†1:21AM UTC,Merck sees up to 4.8 pct gain in 2015 adj EBITDA on weak euro,http://www.reuters.com/article/2015/05/19/merck-kgaa-results-idUSFWN0Y906220150519
20150521†9:00AM UTC,Merck Sharp & Dohme Federal Credit Union Significantly Expands Relationship with Fiserv,http://www.reuters.com/article/2015/05/20/wi-fiserv-idUSnBw205203a+100+BSW20150520
20150523†7:28AM UTC,Merck follows Bristol with EU green light for immune cancer drug,http://www.reuters.com/article/2015/05/22/us-health-cancer-merck-co-idUSKBN0O71AL20150522
20150523†7:22AM UTC,Merck follows Bristol with EU green light for immune cancer drug,http://www.reuters.com/article/2015/05/22/health-cancer-merck-co-idUSL3N0YD3VV20150522
20150523†7:12AM UTC,Merck Receives Positive CHMP Opinion for KEYTRUDA¬Æ (pembrolizumab) for the Treatment of Advanced Melanoma,http://www.reuters.com/article/2015/05/22/nj-merck-idUSnBw225286a+100+BSW20150522
20150527†1:31PM UTC,Merck Announces Third-Quarter 2015 Dividend,http://www.reuters.com/article/2015/05/26/nj-merck-idUSnBw266058a+100+BSW20150526
20150528†7:51AM UTC,Merck offers EU concessions over $17 bln Sigma-Aldrich buy,http://www.reuters.com/article/2015/05/27/sigmaaldrich-ma-merck-eu-idUSL5N0YI2NZ20150527
20150529†4:30PM UTC,"Merck Submits U.S. New Drug Application for Grazoprevir/Elbasvir, an Investigational Once-Daily, Single Tablet Combination Therapy, for Treatment of Chronic Hepatitis C Genotypes 1, 4, and 6 Infection",http://www.reuters.com/article/2015/05/28/nj-merck-idUSnBw286341a+100+BSW20150528
20150529†11:46AM UTC,"Merck KGaA, Darmstadt, Germany, as Pioneer in Assisted Reproductive Treatments, Takes Leading Role in Fertility Technologies, Announces a Global Collaboration Agreement with Genea Biomedx",http://www.reuters.com/article/2015/05/28/ma-emd-serono-merck-idUSnPn4LzhH2+92+PRN20150528
20150529†8:30AM UTC,Merck and NanoString Announce Clinical Research Collaboration to Develop an Immune-Related Gene Expression Assay for Use in the Development Program for KEYTRUDA¬Æ (pembrolizumab),http://www.reuters.com/article/2015/05/28/nj-merck-idUSnBw285740a+100+BSW20150528
20150529†7:16AM UTC,"New drugs from Bristol, Merck at forefront of cancer meeting",http://www.reuters.com/article/2015/05/28/us-cancer-asco-immunotherapies-idUSKBN0OD18L20150528
20150529†7:00AM UTC,Merck Serono as Pioneer in Assisted Reproductive Treatments Takes Leading Role in Fertility Technologies Signing a Global Collaboration Agreement with Genea Biomedx,http://www.reuters.com/article/2015/05/28/bc-merck-serono-fertilit-idUSnPn3D0fg1+90+PRN20150528
20150530†2:36PM UTC,Merck immunotherapy appears effective in head and neck cancer-study,http://www.reuters.com/article/2015/05/29/us-cancer-asco-merck-headandneck-idUSKBN0OE2AY20150529
20150530†2:35PM UTC,UPDATE 1-Merck immunotherapy appears effective in head and neck cancer-study,http://www.reuters.com/article/2015/05/29/cancer-asco-merck-headandneck-idUSL1N0YK1SP20150529
20150530†2:06PM UTC,"New Findings Show Durable Anti-Tumor Activity with KEYTRUDA¬Æ (pembrolizumab), Merck‚Äôs Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status",http://www.reuters.com/article/2015/05/29/il-merck-idUSnBw295966a+100+BSW20150529
20150530†2:05PM UTC,First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine,http://www.reuters.com/article/2015/05/29/nj-merck-idUSnBw295964a+100+BSW20150529
20150530†2:00PM UTC,Merck immunotherapy appears effective in head and neck cancer-study,http://www.reuters.com/article/2015/05/29/cancer-asco-merck-headandneck-idUSL1N0YI2V420150529
20150530†8:30AM UTC,Amgen And Merck Announce Expansion Of Collaboration To Support Studies Of Talimogene Laherparepvec In Combination With KEYTRUDA¬Æ (Pembrolizumab) In Patients With Head And Neck Cancer,http://www.reuters.com/article/2015/05/29/amgen-merck-collab-idUSnPn4pVdqC+89+PRN20150529
20150531†9:55PM UTC,Merck immunotherapy appears effective in head and neck cancer: study,http://www.reuters.com/article/2015/05/31/us-cancer-asco-merck-headandneck-idUSKBN0OE2AY20150531
20150531†2:00PM UTC,TESARO and Merck to Collaborate on a Combination Study of Niraparib and KEYTRUDA(R) (Pembrolizumab),http://www.reuters.com/article/2015/05/30/idUSnGNX8FzCN8+1d6+GNW20150530
20150602†5:19PM UTC,Merck KGaA sees immunotherapy drug holding its own in cancer race,http://www.reuters.com/article/us-merck-kgaa-cancer-idUSKBN0OH3EK20150601
20150602†5:12PM UTC,Merck KGaA sees immunotherapy drug holding its own in cancer race,http://www.reuters.com/article/merck-kgaa-cancer-idUSL5N0YN3XW20150601
20150602†4:34PM UTC,"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA¬Æ (pembrolizumab), Merck‚Äôs Anti-PD-1 Therapy, in Advanced Non-Small Cell Lung Cancer, and Grants Priority Review",http://www.reuters.com/article/nj-merck-idUSnBw016690a+100+BSW20150601
20150602†8:30AM UTC,Merck and Dynavax Announce New Collaboration Investigating the Combination of Immuno-Oncology Therapies,http://www.reuters.com/article/nj-merck-idUSnBw015806a+100+BSW20150601
20150603†11:47AM UTC,"Research and Markets: Global Neurodegenerative Diseases Market 2015-2019: Key Vendors are Biogen Idec, Merck Serono, Novartis, Pfizer, Teva Pharmaceutical Industries & UCB",http://www.reuters.com/article/2015/06/02/research-and-markets-idUSnBw026573a+100+BSW20150602
20150604†2:54PM UTC,"CORRECTING and REPLACING CAPTION Merck KGaA, Darmstadt, Germany Celebrates 125 Years in the U.S. with Launch of ‚ÄúSmarter, Together‚Äù Initiative",http://www.reuters.com/article/2015/06/03/cqn-ma-merck-kgaa-idUSnBw036204a+100+BSW20150603
20150604†7:00AM UTC,Merck Extends Immuno-Oncology Collaboration with Agenus,http://www.reuters.com/article/2015/06/03/ma-agenus-idUSnBw035412a+100+BSW20150603
20150605†10:06AM UTC,Merck accused of stonewalling in mumps vaccine antitrust lawsuit,http://www.reuters.com/article/2015/06/04/health-vaccine-idUSL1N0YQ0W820150604
20150605†10:00AM UTC,"Merck Animal Health Urges Owners Don't Skip the Chip""""",http://www.reuters.com/article/2015/06/04/nj-merck-pet-chip-idUSnPn9Ywl0z+90+PRN20150604
20150609†4:37PM UTC,No heart safety issues seen with Merck Januvia diabetes drug: study,http://www.reuters.com/article/us-diabetes-merck-idUSKBN0OO2EF20150608
20150609†4:30PM UTC,"TECOS, Merck‚Äôs Cardiovascular Safety Trial of JANUVIA (sitagliptin), Met Primary Endpoint in Patients with Type 2 Diabetes",http://www.reuters.com/article/nj-merck-idUSnBw086550a+100+BSW20150608
20150609†4:30PM UTC,No heart safety issues seen with Merck Januvia diabetes drug -study,http://www.reuters.com/article/diabetes-merck-idUSL1N0YU1NT20150608
20150609†7:00AM UTC,"Illumina, Merck KGaA, Darmstadt, Germany, and Genea Form the Global Fertility Alliance for Excellence in Assisted Reproductive Treatment",http://www.reuters.com/article/ca-illumina-inc-idUSnBw085387a+100+BSW20150608
20150610†4:00AM UTC,Consumerization Drives Growth at Merck Consumer Health,http://www.reuters.com/article/2015/06/09/merck-idUSnBw095051a+100+BSW20150609
20150612†9:00AM UTC,Liaison Technologies and Merck Cut the Ribbon for a Collaborative Innovation Center on NC State's Centennial Campus,http://www.reuters.com/article/2015/06/11/liaison-technologies-idUSnPncfC6nK+89+PRN20150611
20150612†8:00AM UTC,"Merck Launches New Program That Encourages Women to Rule the Real Talk"" and Prioritize Their Sexual Health""",http://www.reuters.com/article/2015/06/11/merck-sexual-health-idUSnPn230bw1+80+PRN20150611
20150613†7:02AM UTC,BRIEF-Rovi signs deal with Merck to market Orvatez in Spain,http://www.reuters.com/article/2015/06/12/idUSFWN0YX04C20150612
20150615†3:15AM UTC,"Merck KGaA, Darmstadt, Germany: Innovative Fertility Technologies Gavi and Geri of Partner Genea Biomedx Receive CE Mark",http://www.reuters.com/article/2015/06/14/bc-merck-kgaa-idUSnPn7fqfwr+80+PRN20150614
20150616†2:13PM UTC,BRIEF-Merck aims for swift action to comply with EU agreements on Sigma-Aldrich deal,http://www.reuters.com/article/idUSFWN0Z104320150615
20150616†1:52PM UTC,European Commission approves Merck's $17 billion Sigma-Aldrich buy,http://www.reuters.com/article/us-sigma-aldrich-merck-m-a-eu-idUSKBN0OV2G820150615
20150616†1:40PM UTC,European Commission approves Merck's $17 bln Sigma-Aldrich buy,http://www.reuters.com/article/sigma-aldrich-merck-ma-eu-idUSL5N0Z14D820150615
20150616†10:02AM UTC,"Research and Markets: Infectious Diseases Market in US 2015-2019: with GlaxoSmithKline, Merck and Pfizer",http://www.reuters.com/article/research-and-markets-idUSnBw155885a+100+BSW20150615
20150617†5:58PM UTC,"Merck Manuals health guides go digital, and free, in global push",http://www.reuters.com/article/2015/06/16/us-health-merck-co-idUSKBN0OW2RW20150616
20150617†5:52PM UTC,"Merck Manuals health guides go digital, and free, in global push",http://www.reuters.com/article/2015/06/16/health-merck-co-idUSL1N0Z123920150616
20150618†6:10PM UTC,Merck to pay $5.9 million for misleading marketing of pink eye drug: U.S,http://www.reuters.com/article/2015/06/17/us-merck-lawsuit-settlement-idUSKBN0OX2SQ20150617
20150618†6:09PM UTC,Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,http://www.reuters.com/article/2015/06/17/merck-lawsuit-settlement-idUSL1N0Z32Z820150617
20150618†6:06PM UTC,UPDATE 1-Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,http://www.reuters.com/article/2015/06/17/merck-lawsuit-settlement-idUSL1N0Z32WR20150617
20150618†5:40PM UTC,CORRECTED-Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,http://www.reuters.com/article/2015/06/17/merck-lawsuit-settlement-idUSL1N0Z32U820150617
20150618†5:36PM UTC,"Research and Markets: Global Animal Antimicrobials and Antibiotics Market 2015 Report - Bayer, Elanco, Merck Animal Health, Merial, Zoetis Dominate the Market",http://www.reuters.com/article/2015/06/17/research-and-markets-idUSnBw176460a+100+BSW20150617
20150618†4:29PM UTC,Merck to pay $5.9 mln for misleading marketing of pink eye drug: U.S.,http://www.reuters.com/article/2015/06/17/merck-lawsuit-settlement-idUSL1N0Z32I320150617
20150618†9:00AM UTC,Merck Manuals Launches Global Medical Knowledge 2020 to Provide Free Access to Credible Medical Information on Every Continent by 2020,http://www.reuters.com/article/2015/06/17/merck-manuals-idUSnPn47rc9D+81+PRN20150617
20150620†6:03AM UTC,UPDATE 1-Merck aims to be leader in OLED materials by 2018,http://www.reuters.com/article/2015/06/19/merck-oleds-idUSL5N0Z51J720150619
20150620†5:15AM UTC,Merck aims to be leader in OLED materials by 2018,http://www.reuters.com/article/2015/06/19/merck-oleds-idUSF9N0YA00520150619
20150623†2:40PM UTC,"Research and Markets: Global Pneumonia Vaccine Market Outlook 2020 with GlaxoSmithKline, Pfizer and Merck Dominating",http://www.reuters.com/article/2015/06/22/research-and-markets-idUSnBw226250a+100+BSW20150622
20150624†10:32AM UTC,"Merck KGaA, Darmstadt, Germany, Launches More than a Mother"" Campaign Aiming to Reduce Social Suffering of Infertile Women in Africa""",http://www.reuters.com/article/2015/06/23/bc-merck-kgaa-darmstadt-idUSnPnmfVBH+47+PRN20150623
20150626†4:25PM UTC,"Research and Markets: United States Human Growth Hormone Market Study 2015-2019 Features Merck Serono, Pfizer and Novo Nordisk",http://www.reuters.com/article/2015/06/25/research-and-markets-idUSnBw256336a+100+BSW20150625
20150627†9:07AM UTC,"Research and Markets: United States Asthma Drugs Market 2015-2019 - Popularity of Combination Therapies with AstraZeneca, F. Hoffmann-La Roche, GlaxoSmithKline & Merck Dominating",http://www.reuters.com/article/2015/06/26/research-and-markets-idUSnBw265379a+100+BSW20150626
20150627†8:00AM UTC,Merck to Hold Second-Quarter 2015 Sales and Earnings Conference Call on July 28,http://www.reuters.com/article/2015/06/26/nj-merck-idUSnBw265028a+100+BSW20150626
20150630†11:11AM UTC,German Merck expanding presence in Israel with acquisitions,http://www.reuters.com/article/2015/06/29/merck-israel-idUSL5N0ZF3GF20150629
20150630†8:30AM UTC,Merck Announces Phase 3 Study of Single-Dose EMEND¬Æ (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogeni,http://www.reuters.com/article/2015/06/29/nj-merck-idUSnBw295560a+100+BSW20150629
20150630†2:31AM UTC,BRIEF-German Merck to buy remaining stake in Qlight Nanotech,http://www.reuters.com/article/2015/06/29/idUSFWN0ZD00C20150629
20150701†6:03AM UTC,"Research and Markets: Global Cancer Vaccines Market 2015-2019 With Dendreon, GSK & Merck Dominating",http://www.reuters.com/article/2015/06/30/research-and-markets-idUSnBw305590a+100+BSW20150630
20150708†7:00AM UTC,Allergan Enters Into Licensing Agreement with Merck to Obtain Exclusive Worldwide Rights to CGRP Migraine Development Program,http://www.reuters.com/article/nj-allergan-merck-idUSnPnbsghyW+81+PRN20150707
20150715†9:04AM UTC,OpGen Closes $6 Million Financing With Merck GHI to Expand Infectious Disease Diagnostic Testing Capabilities,http://www.reuters.com/article/idUSnGNX8FNN2Q+1dd+GNW20150714
20150716†5:31PM UTC,PADF and Merck Launch Digital Data Platform on Maternal Mortality,http://www.reuters.com/article/padf-maternal-mortality-idUSnBw156632a+100+BSW20150715
20150716†3:28PM UTC,"PA Physician General, Merck officials meet to discuss childhood immunization rates",http://www.reuters.com/article/pahealth-immunization-idUSnPn7RDMPG+9f+PRN20150715
20150716†9:54AM UTC,"Harris & Harris Group Portfolio Company, OpGen, Gains $6 Million Investment From Merck GHI in Addition to New Acquisition",http://www.reuters.com/article/idUSnGNX7hrCQK+1c7+GNW20150715
20150716†8:00AM UTC,"Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal",http://www.reuters.com/article/merck-ada-challenge-idUSnPn30QSp8+8c+PRN20150715
20150722†8:00AM UTC,Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS,http://www.reuters.com/article/nj-merck-idUSnBw215554a+100+BSW20150721
20150723†1:28PM UTC,Merck Announces Fourth-Quarter 2015 Dividend,http://www.reuters.com/article/nj-merck-idUSnBw226186a+100+BSW20150722
20150723†7:00AM UTC,"European Commission Approves Merck‚Äôs Anti-PD-1 Therapy, KEYTRUDA¬Æ (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma",http://www.reuters.com/article/nj-merck-idUSnBw225153a+100+BSW20150722
20150723†1:49AM UTC,Belgium's Ablynx triples cooperation deal with Merck & Co,http://www.reuters.com/article/ablynx-merck-co-idUSL5N1020DB20150722
20150723†1:18AM UTC,BRIEF-Ablynx expands its immuno-oncology collaboration with Merck & Co,http://www.reuters.com/article/idUSFWN10101R20150722
20150724†11:03AM UTC,"Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection",http://www.reuters.com/article/nj-merck-idUSnBw236000a+100+BSW20150723
20150724†7:51AM UTC,Merck Serono and BioMed X Extend Collaboration,http://www.reuters.com/article/bc-merck-and-biomed-x-idUSnPntFbpC+49+PRN20150723
20150728†8:30AM UTC,Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA‚Ñ¢ (Ceftolozane and Tazobactam),http://www.reuters.com/article/nj-merck-idUSnBw275117a+100+BSW20150727
20150729†4:15PM UTC,Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors,http://www.reuters.com/article/nj-merck-idUSnBw285126a+100+BSW20150728
20150729†8:01AM UTC,"Merck raises forecast on strong sales of diabetes, cancer drugs",http://www.reuters.com/article/us-merck-co-results-idUSKCN0Q217420150728
20150729†8:00AM UTC,"UPDATE 1-Merck raises forecast on strong sales of diabetes, cancer drugs",http://www.reuters.com/article/merck-co-results-idUSL3N10840E20150728
20150729†7:16AM UTC,Strong dollar weighs on Merck revenue,http://www.reuters.com/article/merck-co-results-idUSL3N1083U920150728
20150729†7:00AM UTC,Merck Announces Second-Quarter 2015 Financial Results,http://www.reuters.com/article/nj-merck-idUSnBw285827a+100+BSW20150728
20150729†6:45AM UTC,Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics,http://www.reuters.com/article/nj-merck-idUSnBw285731a+100+BSW20150728
20150729†6:30AM UTC,"Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection",http://www.reuters.com/article/nj-merck-idUSnBw285530a+100+BSW20150728
20150731†8:00AM UTC,"Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal",http://www.reuters.com/article/il-merck-diabetes-idUSnPn5jk9vV+81+PRN20150730
20150801†11:29AM UTC,"After Merck success, work goes on with other Ebola vaccines",http://www.reuters.com/article/health-ebola-vaccine-alternatives-idUSL5N10B3IW20150731
20150801†8:10AM UTC,"In Interim Results from Phase 3 Study, Merck‚Äôs Investigational Ebola Vaccine Efficacious; Study is Continuing",http://www.reuters.com/article/nj-merck-idUSnBw315308a+100+BSW20150731
20150801†8:00AM UTC,Merck's Ebola vaccine proves fully effective in Guinea trial,http://www.reuters.com/article/health-ebola-vaccine-idUSL5N10B1QM20150731
20150801†6:06AM UTC,"Research and Markets: Global Statin Market 2015-2019 with AstraZeneca, Merck, Novartis & Pfizer Dominating",http://www.reuters.com/article/research-and-markets-idUSnBw315250a+100+BSW20150731
20150806†2:42PM UTC,"Research and Markets: PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2023 Featuring Bristol-Myers Squibb, Novartis, Roche & Merck",http://www.reuters.com/article/research-and-markets-idUSnBw056450a+100+BSW20150805
20150807†2:28PM UTC,Merck KGaA books $1.1 billion hedging gain from Sigma-Aldrich deal,http://www.reuters.com/article/us-merck-kgaa-results-hedging-idUSKCN0QB1K820150806
20150807†6:17AM UTC,Merck KGaA books 1 bln eur hedging gain from Sigma-Aldrich deal,http://www.reuters.com/article/merck-kgaa-results-hedging-idUSL5N10H1Q720150806
20150811†8:01AM UTC,Immune Design and Merck to Collaborate on Combination Trials of Two Immune Design Immunotherapies With Merck's KEYTRUDA for Non-Hodgkin's Lymphoma and Melanoma,http://www.reuters.com/article/idUSnGNX5pVzYt+1ca+GNW20150810
20150812†7:30AM UTC,"Sigma-Aldrich and Merck KGaA, Darmstadt, Germany, Obtain Antitrust Approval in Brazil for Planned Acquisition",http://www.reuters.com/article/sigma-aldrich-merck-idUSnPnbpZCyF+8d+PRN20150811
20150812†3:11AM UTC,BRIEF-Merck says has all approvals for Sigma-Aldrich takeover now,http://www.reuters.com/article/idUSFWN10M00020150811
20150813†10:18AM UTC,BRIEF-Merck Ltd says June quarter net income 168.6 mln rupees,http://www.reuters.com/article/idUSI8N0X700420150812
20150814†8:00AM UTC,Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors,http://www.reuters.com/article/nj-merck-idUSnBw135036a+100+BSW20150813
20150815†8:00AM UTC,"Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal",http://www.reuters.com/article/ny-merck-diabetes-a1c-idUSnPn2NRkdv+98+PRN20150814
20150819†1:17PM UTC,Merck Recalls TEMODAR¬Æ and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child‚ÄìResistant Closure Requirement,http://www.reuters.com/article/nj-merck-idUSnBw186351a+100+BSW20150818
20150819†12:10PM UTC,Merck Recalls Temodar and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child-Resistant Closure Requirement,http://www.reuters.com/article/cpsc-brokencapsrecall-idUSnPnc63gtC+81+PRN20150818
20150819†8:00AM UTC,"FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA¬Æ (pembrolizumab), Merck‚Äôs Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review",http://www.reuters.com/article/nj-merck-idUSnBw185715a+100+BSW20150818
20150820†7:28AM UTC,"Research and Markets: Global Contraceptive Devices Market 2015-2019 with Ansell, Actavis, Bayer, Church & Dwight & Merck & Co Dominating",http://www.reuters.com/article/research-and-markets-idUSnBw195572a+100+BSW20150819
20150828†12:46PM UTC,BRIEF-German Merck places 2.1 bln eur bond for Sigma-Aldrich buy,http://www.reuters.com/article/idUSFWN11206R20150827
20150901†12:46PM UTC,Daktari Enters Collaboration Agreement with Merck to Develop Test for Hepatitis C Virus,http://www.reuters.com/article/daktari-merck-partner-idUSnPn8lN0JW+8b+PRN20150831
20150908†6:00AM UTC,UK backs use of Merck cancer immunotherapy after price discount,http://www.reuters.com/article/us-merck-co-cancer-britain-idUSKCN0R710I20150907
20150908†5:55AM UTC,UK backs use of Merck cancer immunotherapy after price discount,http://www.reuters.com/article/merck-co-cancer-britain-idUSL5N11D1HY20150907
20150911†9:00AM UTC,Merck Publishes 2014 Global Corporate Responsibility Report,http://www.reuters.com/article/nj-merck-idUSnBw105344a+100+BSW20150910
20150912†5:21AM UTC,Merck KGaA to try again to get approval for MS pill cladribine,http://www.reuters.com/article/us-merck-cladribine-idUSKCN0RB0HF20150911
20150912†5:20AM UTC,UPDATE 1-Merck KGaA to try again to get approval for MS pill cladribine,http://www.reuters.com/article/merck-cladribine-idUSL5N11H0Q720150911
20150912†4:00AM UTC,"Merck KGaA, Darmstadt, Germany and Pfizer to Present Updates for Avelumab at the European Cancer Congress 2015",http://www.reuters.com/article/pfizer-idUSnBw115109a+100+BSW20150911
20150912†2:33AM UTC,Merck KGaA tries to revive multiple sclerosis pill cladribine,http://www.reuters.com/article/merck-cladribine-idUSFWN11G01W20150911
20150916†10:00AM UTC,Merck Animal Health Announces HomeAgain¬Æ Helps Campaign Finalists,http://www.reuters.com/article/merck-animal-health-idUSnPn61YjFy+8a+PRN20150915
20150916†9:10AM UTC,An Update on Quarterly Results - Report on Merck,http://www.reuters.com/article/bc-aci-association-idUSnPnHkfxj+50+PRN20150915
20150917†10:53AM UTC,Merck's once-weekly diabetes drug found effective in study,http://www.reuters.com/article/us-merck-co-study-idUSKCN0RG21320150916
20150917†10:48AM UTC,Merck's once-weekly diabetes drug found effective in study,http://www.reuters.com/article/merck-co-study-idUSL4N11M4BJ20150916
20150917†10:16AM UTC,"Merck‚Äôs Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor, Achieved Similar A1C Reductions to JANUVIA¬Æ (sitagliptin) in Patients with Type 2 Diabetes Inadequately Controlled on Metformin Monotherapy",http://www.reuters.com/article/nj-merck-idUSnBw165979a+100+BSW20150916
20150917†7:30AM UTC,Merck Highlights Its Commitment to Infectious Disease with 40 Presentations of Data at ICAAC/ICC 2015,http://www.reuters.com/article/nj-merck-idUSnBw165385a+100+BSW20150916
20150918†8:38AM UTC,"Research and Markets: Bayer, Elanco, Merck, Merial, Zoetis Dominate the Global Animal Health Market, 2015 Report Says",http://www.reuters.com/article/research-and-markets-idUSnBw175712a+100+BSW20150917
20150918†8:30AM UTC,"Merck Provides Diabetes Portfolio Update and Underscores Comprehensive, Long-Term Commitment to Patients with Diabetes",http://www.reuters.com/article/nj-merck-idUSnBw175317a+100+BSW20150917
20150919†3:00PM UTC,Results of Phase 2 Study of Merck‚Äôs Investigational Beta-Lactamase Inhibitor Relebactam Presented at ICAAC/ICC 2015,http://www.reuters.com/article/nj-merck-idUSnBw185023a+100+BSW20150918
20150921†12:51PM UTC,Merck antibody reduces risk of Clostridium difficile recurrence: study,http://www.reuters.com/article/us-health-merck-c-dif-idUSKCN0RK0TC20150920
20150921†12:30PM UTC,"Pivotal Phase 3 Studies of Bezlotoxumab, Merck‚Äôs Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint",http://www.reuters.com/article/nj-merck-idUSnBw205053a+100+BSW20150920
20150921†12:30PM UTC,Merck antibody reduces risk of C. difficile recurrence - study,http://www.reuters.com/article/health-merck-c-dif-idUSL1N11O1NR20150920
20150922†9:03AM UTC,"Equities Coverage on the Financial and Healthcare Sector - American International Group, Strategic Hotels & Resorts, Can-Fite Biopharma, Pfizer and Merck & Company",http://www.reuters.com/article/bc-aci-association-idUSnPn8vnKyG+85+PRN20150921
20150922†8:00AM UTC,ANI Pharmaceuticals to Acquire Two NDAs from Merck for $75 Million,http://www.reuters.com/article/ani-pharma-acquirenda-idUSnPn5vSKnQ+8d+PRN20150921
20150922†8:00AM UTC,"Data in Nine Difficult-to-Treat Cancers from Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) Development Program to be Presented at European Cancer Congress 2015, Including Data in Four New Cancer Types: ...",http://www.reuters.com/article/nj-merck-idUSnBw215390a+100+BSW20150921
20150923†12:42PM UTC,"Research and Markets: Global Asthma & COPD Market Report: 2015 Edition Featuring Leading Market Players, AstraZeneca, Merck and Co., Roche, Sanofi and Novartis",http://www.reuters.com/article/research-and-markets-idUSnBw226239a+100+BSW20150922
20150925†5:00PM UTC,"Merck KGaA, Darmstadt, Germany, and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab",http://www.reuters.com/article/pfizer-idUSnBw246481a+100+BSW20150924
20150925†5:00PM UTC,"Merck and Pfizer Collaborate with Dako, an Agilent Technologies Company, on Development of Companion Diagnostic for Investigational anti-PD-L1 Antibody, Avelumab",http://www.reuters.com/article/pfizer-idUSnBw246460a+100+BSW20150924
20150926†8:00AM UTC,Merck to Hold Third-Quarter 2015 Sales and Earnings Conference Call on October 27,http://www.reuters.com/article/nj-merck-idUSnBw255002a+100+BSW20150925
20150926†7:00AM UTC,Merck and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma,http://www.reuters.com/article/pfizer-idUSnBw255228a+100+BSW20150925
20150926†7:00AM UTC,"Merck KGaA, Darmstadt, Germany, and Pfizer Announce FDA Orphan Drug Designation for Investigational Immunotherapy Avelumab in Merkel Cell Carcinoma",http://www.reuters.com/article/pfizer-idUSnBw255223a+100+BSW20150925
20150928†7:00AM UTC,"New Data from KEYNOTE-028, Merck‚Äôs Trial Evaluating KEYTRUDA¬Æ (pembrolizumab) Across a Range of Cancer Types, Presented at 2015 European Cancer Congress",http://www.reuters.com/article/nj-merck-idUSnBw275081a+100+BSW20150927
20150929†10:00AM UTC,"Merck Animal Health, Afya Project and Mission Rabies: Working Toward a World Free of Rabies",http://www.reuters.com/article/nj-merck-animalrabies-idUSnPn5tdPS2+86+PRN20150928
20150929†8:19AM UTC,Merck's once-weekly diabetes drug approved in Japan,http://www.reuters.com/article/us-merck-co-diabetesdrug-idUSKCN0RS1E320150928
20150929†8:17AM UTC,Merck's once-weekly diabetes drug approved in Japan,http://www.reuters.com/article/merck-co-diabetesdrug-idUSL3N11Y3M220150928
20150929†8:00AM UTC,Syndax And Merck Announce First Patients Dosed In Phase 1b/2 Clinical Trial Of Entinostat And KEYTRUDA¬Æ,http://www.reuters.com/article/syndax-keytruda-trial-idUSnPn6CXZ2B+9d+PRN20150928
20150929†7:30AM UTC,"MARIZEV¬Æ (Omarigliptin), Merck‚Äôs Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes, Approved in Japan",http://www.reuters.com/article/nj-merck-idUSnBw285491a+100+BSW20150928
20150929†7:00AM UTC,"Sigma-Aldrich and Merck KGaA, Darmstadt, Germany, Making Progress Toward Completion of Planned Acquisition",http://www.reuters.com/article/sigma-aldrich-merck-idUSnPn5nfsW2+82+PRN20150928
20150929†2:13AM UTC,BRIEF-Merck KGaA says closing of Sigma-Aldrich takeover expected soon,http://www.reuters.com/article/idUSFWN11V01720150928
20151001†4:00AM UTC,Merck‚Äôs Consumer Health Business Counts on Latin America for Growth,http://www.reuters.com/article/merck-idUSnBw305042a+100+BSW20150930
20151002†9:20AM UTC,Corrected-Merck KGaA says avelumab alliance with Pfizer on track,http://www.reuters.com/article/idUSL5N1212WZ20151001
20151002†8:00AM UTC,Merck and DNAtrix Announce Phase 2 Immuno-Oncology Collaboration in Patients with Aggressive Form of Brain Cancer,http://www.reuters.com/article/nj-merck-idUSnBw015478a+100+BSW20151001
20151002†5:12AM UTC,BRIEF-Merck KGaA says avelumab alliance with Pfizer on track,http://www.reuters.com/article/idUSFWN12007I20151001
20151002†4:12AM UTC,Germany's Merck sells rights to Kuvan back to BioMarin Pharma,http://www.reuters.com/article/us-merck-biomarin-pharma-reversal-idUSKCN0RV3SY20151001
20151002†4:03AM UTC,Germany's Merck sells rights to Kuvan back to BioMarin Pharma,http://www.reuters.com/article/merck-biomarin-pharma-reversal-idUSFWN12007920151001
20151002†3:30AM UTC,BioMarin to Acquire Rights to Phenylketonuria (PKU) Franchise From Merck Serono,http://www.reuters.com/article/idUSnGNXbmmNC8+1c6+GNW20151001
20151003†4:21PM UTC,FDA expands approval of Merck's Keytruda to lung cancer,http://www.reuters.com/article/us-merck-co-fda-idUSKCN0RW20W20151002
20151003†4:19PM UTC,UPDATE 3-U.S. FDA expands approval of Merck's Keytruda to lung cancer,http://www.reuters.com/article/merck-co-fda-idUSL3N12235920151002
20151003†3:55PM UTC,LabCorp to Follow Pivotal Role in Clinical Trial of Merck‚Äôs Keytruda¬Æ by Offering PD-L1 Companion Diagnostic,http://www.reuters.com/article/nc-labcorp-idUSnBw025746a+100+BSW20151002
20151003†3:39PM UTC,"Quest Diagnostics Introduces Dako's PD-L1 Companion Diagnostic for KEYTRUDA¬Æ, Merck's Anti-PD-1 Therapy for Metastatic Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 with Disease Progression On or After Platinum-Cont",http://www.reuters.com/article/quest-diagnostics-idUSnPn3PY2Bz+9a+PRN20151002
20151003†2:01PM UTC,FDA approves Merck's Keytruda for use in lung cancer,http://www.reuters.com/article/merck-co-fda-idUSL3N12234H20151002
20151006†7:01PM UTC,Results from Merck‚Äôs Phase 3 Study of Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir in Patients with Advanced Chronic Kidney Disease Published in The Lancet,http://www.reuters.com/article/nj-merck-idUSnBw056479a+100+BSW20151005
20151006†5:15PM UTC,Merck Congratulates Awardees of 2015 Nobel Prize in Physiology or Medicine for Discovery Leading to River Blindness Treatment,http://www.reuters.com/article/nj-merck-idUSnBw056695a+100+BSW20151005
20151008†9:04PM UTC,"REFILE-BRIEF-Bionomics announces extension of strategic collaboration with Merck & Co., Inc",http://www.reuters.com/article/bionomics-brief-idUSWNBS01FQZ20151008
20151008†8:11AM UTC,"Research and Markets: Global Glioblastoma Multiforme Therapeutics Market 2015-2019 - Key Vendors are Arbor Pharmaceuticals, Bristol-Myers Squibb, Eisai, F. Hoffmann-La Roche & Merck",http://www.reuters.com/article/research-and-markets-idUSnBw075734a+100+BSW20151007
20151008†7:00AM UTC,"Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma",http://www.reuters.com/article/pfizer-idUSnBw075668a+100+BSW20151007
20151009†7:00AM UTC,"Dynavax Initiates Immuno-Oncology Clinical Trial Evaluating SD-101 in Combination With Merck's Anti-PD-1 Therapy, KEYTRUDA(R) (pembrolizumab)",http://www.reuters.com/article/idUSnMKWBd4Gwa+1e4+MKW20151008
20151009†6:00AM UTC,"Bionomics Announces Extension of Strategic Collaboration with Merck & Co., Inc. for the Discovery and Development of Novel Pain Medications",http://www.reuters.com/article/bionomics-merck-pain-idUSnPn54hVRP+87+PRN20151008
20151010†8:00AM UTC,"Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal",http://www.reuters.com/article/la-merck-diabetes-idUSnPn2Y59SY+93+PRN20151009
20151013†8:09PM UTC,Merck cholesterol drug's odds dim after Lilly failure,http://www.reuters.com/article/us-merck-cholesterol-idUSKCN0S700K20151013
20151013†8:06PM UTC,Merck cholesterol drug's odds dim after Lilly failure,http://www.reuters.com/article/merck-cholesterol-idUSL1N12C1GN20151013
20151013†6:10AM UTC,Merck KGaA bets on cancer drugs to revitalize German firm,http://www.reuters.com/article/us-merck-pfizer-cancer-idUSKCN0S60YH20151012
20151013†5:47AM UTC,Merck KGaA bets on cancer drugs to revitalise German firm,http://www.reuters.com/article/merck-pfizer-cancer-idUSL8N12A0MB20151012
20151014†8:33PM UTC,Ex-Merck employees gets 3 years in prison for insider trading,http://www.reuters.com/article/merck-insidertrading-idUSL1N12E00X20151014
20151014†8:32PM UTC,Ex-Merck employees gets three years in prison for insider trading,http://www.reuters.com/article/us-merck-insidertrading-idUSKCN0S801720151014
20151014†8:29PM UTC,Ex-Merck employees gets 3 years in prison for insider trading,http://www.reuters.com/article/merck-insidertrading-idUSL1N11M2AE20151014
20151014†4:28PM UTC,Society for Clinical Research Sites Announces Winning Sponsor and CRO of 2015 Eagle Award - Merck & Co. and Quintiles,http://www.reuters.com/article/assocclinresearch-idUSnPn82PBTb+8e+PRN20151013
20151014†7:48AM UTC,Merck KGaA appoints Oschmann as CEO to replace Kley,http://www.reuters.com/article/merck-ceo-idUSFWN12C01V20151013
20151014†7:30AM UTC,Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda¬Æ (pembrolizumab) as First-line Treatment for Advanced Melanoma,http://www.reuters.com/article/de-incyte-merck-idUSnBw135622a+100+BSW20151013
20151016†7:00AM UTC,Codexis Earns First Technology Transfer Milestone Payment From Merck,http://www.reuters.com/article/idUSnGNXbqQYwf+1cc+GNW20151015
20151016†1:18AM UTC,BRIEF-Ablynx gets first milestone in immuno-oncology deal with Merck & Co.,http://www.reuters.com/article/idUSFWN12E02F20151015
20151017†2:58PM UTC,"Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal",http://www.reuters.com/article/nj-merck-diabetes-idUSnPn2025Ld+82+PRN20151016
20151021†10:35AM UTC,"Merck to Present New Data on Investigational Chronic Hepatitis C Treatment Elbasvir/Grazoprevir at The Liver Meeting¬Æ 2015, Including Phase 3 Results in Selected Difficult-to-Treat Populations",http://www.reuters.com/article/nj-merck-idUSnBw206240a+100+BSW20151020
20151021†6:57AM UTC,Merck clears major hurdle to Sigma-Aldrich takeover,http://www.reuters.com/article/us-sigma-aldrich-m-a-merck-honeywell-int-idUSKCN0SE18F20151020
20151021†6:55AM UTC,Merck clears major hurdle to Sigma-Aldrich takeover,http://www.reuters.com/article/sigma-aldrich-ma-merck-honeywell-intl-idUSL8N12K2C820151020
20151021†6:05AM UTC,BRIEF-Merck's Sigma-Aldrich sells some assets to Honeywell,http://www.reuters.com/article/idUSFWN12K03520151020
20151022†10:04PM UTC,"/C O R R E C T I O N -- Merck KGaA, Darmstadt, Germany/",http://www.reuters.com/article/merck-curiosity-index-idUSnPn2KqvMH+93+PRN20151022
20151022†9:10AM UTC,"/C O R R E C T I O N -- Merck KGaA, Darmstadt, Germany/",http://www.reuters.com/article/merck-curiosity-index-idUSnPn9rwvnk+80+PRN20151021
20151022†8:00AM UTC,"Merck KGaA, Darmstadt, Germany Presents First Curiosity Report in the U.S. to Help Drive Innovation",http://www.reuters.com/article/merck-curiosity-index-idUSnPn25FHCT+8f+PRN20151021
20151023†7:31AM UTC,MacroGenics and Merck to Collaborate on Immuno-Oncology Study Evaluating Margetuximab in Combination with KEYTRUDA(R) (pembrolizumab) for Advanced Gastric Cancer,http://www.reuters.com/article/idUSnGNX81h0YG+1c3+GNW20151022
20151024†4:32AM UTC,"Research and Markets: Global Female Contraceptives Market 2015-2019 with Allergan, Merck, Pfizer & Teva Pharmaceutical Dominating",http://www.reuters.com/article/research-and-markets-idUSnBw235209a+100+BSW20151023
20151027†11:03AM UTC,Merck's Keytruda extends survival in lung cancer study,http://www.reuters.com/article/us-merck-keytruda-lung-idUSKCN0SK1VB20151026
20151027†10:58AM UTC,Merck's Keytruda extends survival in lung cancer study,http://www.reuters.com/article/merck-keytruda-lung-idUSL1N12Q16O20151026
20151027†9:00AM UTC,Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) Shows Superior Overall Survival Compared to Chemotherapy in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer Whose Tumors Express PD-L1,http://www.reuters.com/article/nj-merck-idUSnBw265735a+100+BSW20151026
20151027†8:00AM UTC,Merck and the National Sleep Foundation Urge Insomnia Sufferers to Prioritize Sleep and Move Beyond Tired,http://www.reuters.com/article/merck-beyond-tired-idUSnPn6NZ9Rs+9a+PRN20151026
20151028†10:57AM UTC,"Merck profit tops estimates on strong diabetes, cancer drug sales",http://www.reuters.com/article/us-merck-co-results-idUSKCN0SL18P20151027
20151028†10:55AM UTC,"UPDATE 3-Merck profit tops estimates on strong diabetes, cancer drug sales",http://www.reuters.com/article/merck-co-results-idUSL3N12R3TU20151027
20151028†9:30AM UTC,BRIEF-Merck says expects januvia to retain strong position as add-on diabetes therapy despite favorable data seen with lilly's rival jardiance,http://www.reuters.com/article/idUSL1N12R0WP20151027
20151028†8:38AM UTC,Exostar Receives Additional $10 Million Investment from Merck Global Health Innovation Fund,http://www.reuters.com/article/va-exostar-idUSnBw275046a+100+BSW20151027
20151028†6:56AM UTC,"Merck revenue down 5 pct, hurt by strong dollar",http://www.reuters.com/article/merck-co-results-idUSL3N12R3SR20151027
20151028†6:45AM UTC,Merck Announces Third-Quarter 2015 Financial Results,http://www.reuters.com/article/nj-merck-idUSnBw275850a+100+BSW20151027
20151029†1:54PM UTC,"Research and Markets: Global HIV Drugs Market 2015-2019 - Key Vendors are Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Johnson & Johnson & Merck",http://www.reuters.com/article/research-and-markets-idUSnBw286395a+100+BSW20151028
20151029†8:00AM UTC,Synthace Announces Collaboration With Merck to Develop Biomanufacturing Platform,http://www.reuters.com/article/bc-synthace-idUSnPnbF5v1S+91+PRN20151028
20151029†8:00AM UTC,KEYTRUDA¬Æ (pembrolizumab) from Merck Awarded Prix Galien USA 2015 Best Biotechnology Product Award,http://www.reuters.com/article/nj-merck-idUSnBw285722a+100+BSW20151028
20151031†10:39AM UTC,BRIEF-Merck India Sept-qtr net profit falls 29 pct,http://www.reuters.com/article/idUSS8N12S00320151030
20151103†9:00AM UTC,"Merck KGaA, Darmstadt, Germany, Appoints Laszlo Radvanyi as Head of Global Immuno-Oncology Research",http://www.reuters.com/article/emd-elect-radvanyi-idUSnPn5PF6yP+99+PRN20151102
20151103†8:00AM UTC,Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA¬Æ (pembrolizumab) in Advanced Colorectal Cancer,http://www.reuters.com/article/nj-merck-idUSnBw025577a+100+BSW20151102
20151103†4:00AM UTC,BRIEF-Selvita signs deal for R&D; financing and cooperation with Merck,http://www.reuters.com/article/idUSFWN12X01120151102
20151104†4:43PM UTC,"Merck KGaA, Darmstadt, Germany, Named as Top Employer by Science Magazine",http://www.reuters.com/article/merck-kgaa-scimag-awd-idUSnPnbQq1Km+92+PRN20151103
20151104†6:58AM UTC,GSK and Merck to Study Immunotherapy Combination as Potential Cancer Treatment,http://www.reuters.com/article/nj-merck-idUSnBw035502a+100+BSW20151103
20151105†8:42AM UTC,"Merck KGaA, Pfizer widen development of cancer immunology drug",http://www.reuters.com/article/us-merck-kgaa-pfizer-immunotherapy-idUSKCN0ST1TW20151104
20151105†8:31AM UTC,"Merck KGaA, Pfizer widen development of cancer immunology drug",http://www.reuters.com/article/merck-kgaa-pfizer-immunotherapy-idUSFWN12Z05020151104
20151105†8:00AM UTC,Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer,http://www.reuters.com/article/pfizer-idUSnBw045146a+100+BSW20151104
20151105†8:00AM UTC,"Merck KGaA, Darmstadt, Germany, and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer",http://www.reuters.com/article/pfizer-idUSnBw045123a+100+BSW20151104
20151106†2:31PM UTC,"Research and Markets: North America Animal Health Market 2015-2019 with Bayer, Elanco, Merck, Merial & Zoetis Dominating",http://www.reuters.com/article/research-and-markets-idUSnBw056609a+100+BSW20151105
20151106†1:00PM UTC,Chairman of the Executive Board and CEO of Merck KGaA Karl-Ludwig Kley elected to Verizon Board of Directors,http://www.reuters.com/article/verizon-elects-bod-idUSnPn9hxJNg+86+PRN20151105
20151106†10:37AM UTC,"EU regulator finds no safety issues with GSK, Merck HPV vaccines",http://www.reuters.com/article/us-health-vaccines-hpv-idUSKCN0SU2CK20151105
20151106†10:30AM UTC,"EU regulator finds no safety issues with GSK, Merck HPV vaccines",http://www.reuters.com/article/health-vaccines-hpv-idUSL8N1304Z920151105
20151106†8:43AM UTC,Merck Announces Samsung Bioepis Will Present New Biosimilars Data at the 2015 ACR/ARHP Annual Meeting,http://www.reuters.com/article/nj-merck-idUSnBw055905a+100+BSW20151105
20151106†8:30AM UTC,First Patient Dosed in Clinical Trial of Halozyme Investigational Drug PEGPH20 in Combination With Merck Immuno-oncology Drug KEYTRUDA,http://www.reuters.com/article/halozyme-clintrial-idUSnPnbzvSwG+85+PRN20151105
20151107†8:22PM UTC,"U.S. federal agencies investigate Merck, Lilly drug pricing",http://www.reuters.com/article/us-merck-co-pricing-idUSKCN0SV2C120151107
20151107†3:18PM UTC,FDA panel backs Merck & Co drug to reverse muscle relaxant effect,http://www.reuters.com/article/us-merck-co-fda-idUSKCN0SV2O020151106
20151107†3:12PM UTC,"U.S. agencies investigate Merck, Lilly drug pricing",http://www.reuters.com/article/merck-co-pricing-idUSL1N1311PH20151106
20151107†3:10PM UTC,UPDATE 2-FDA panel backs Merck & Co drug to reverse muscle relaxant effect,http://www.reuters.com/article/merck-co-fda-idUSL3N13160120151106
20151107†3:09PM UTC,"UPDATE 1-U.S. agencies investigate Merck, Lilly drug pricing",http://www.reuters.com/article/merck-co-pricing-idUSL1N13120V20151106
20151107†2:13PM UTC,"Merck Statement on FDA Advisory Committee Meeting for BRIDION¬Æ (sugammadex), Investigational Agent for the Reversal of Neuromuscular Blockade (NMB) Induced by Rocuronium or Vecuronium",http://www.reuters.com/article/nj-merck-idUSnBw065937a+100+BSW20151106
20151107†2:03PM UTC,FDA panel votes unanimously in favor of Merck & Co's Sugammadex,http://www.reuters.com/article/merck-co-fda-idUSL3N1315ZR20151106
20151107†12:20PM UTC,"U.S. federal agencies investigate Merck, Lilly drug pricing",http://www.reuters.com/article/us-merck-co-pricing-idUSKCN0SV2C120151106
20151107†12:19PM UTC,"UPDATE 1-U.S. federal agencies investigate Merck, Lilly drug pricing",http://www.reuters.com/article/merck-co-pricing-idUSL3N1315R920151106
20151107†11:56AM UTC,Merck & Co under Pennsylvania Attorney's Office probe over pricing,http://www.reuters.com/article/merck-co-pricing-idUSL3N1315PX20151106
20151107†11:30AM UTC,Merck's Patrick Magri Elected National Pharmaceutical Council's Chairman of the Board,http://www.reuters.com/article/npc-board-chairman-idUSnPn2wW0hd+88+PRN20151106
20151107†6:00AM UTC,"Viralytics and Merck & Co., Inc., Kenilworth, New Jersey, U.S.A. to Collaborate on Combination Clinical Trial of CAVATAK(TM) and KEYTRUDA(R) in Lung and Bladder Cancer",http://www.reuters.com/article/vla-kenilworth-trial-idUSnPn8SBrXN+9b+PRN20151106
20151111†11:52AM UTC,"Sigma-Aldrich and Merck KGaA, Darmstadt, Germany, Obtain EC Antitrust Approval and Work Toward Closing Planned Acquisition",http://www.reuters.com/article/sigma-aldrich-merck-idUSnPncpXmj+44+PRN20151110
20151111†11:39AM UTC,BRIEF-Merck set to complete $17 bln buy of Sigma-Aldrich on Nov. 18,http://www.reuters.com/article/idUSFWN13506320151110
20151113†7:55PM UTC,Merck to buy Harrisvaccines to boost livestock vaccine portfolio,http://www.reuters.com/article/us-harrisvaccines-m-a-merck-co-idUSKCN0T202O20151113
20151113†7:46PM UTC,Merck to buy Harrisvaccines to boost livestock vaccine portfolio,http://www.reuters.com/article/harrisvaccines-ma-merck-co-idUSL1N1373UE20151113
20151113†5:00PM UTC,Merck Animal Health to Acquire Harrisvaccines,http://www.reuters.com/article/nj-merck-animal-health-idUSnBw126639a+100+BSW20151112
20151113†1:13PM UTC,U.S. appeals court invalidates four Merck Cubicin patents,http://www.reuters.com/article/merck-co-patent-idUSL1N1372A620151112
20151113†1:03PM UTC,U.S. appeals court invalidates four Merck Cubicin patents,http://www.reuters.com/article/merck-co-patent-idUSL3N13759T20151112
20151113†11:49AM UTC,Merck Statement Regarding CUBICIN¬Æ (daptomycin for injection) Patent Litigation,http://www.reuters.com/article/nj-merck-idUSnBw126167a+100+BSW20151112
20151113†6:52AM UTC,Merck KGaA ups earnings outlook on strong biotech labs demand,http://www.reuters.com/article/us-merck-kgaa-results-idUSKCN0T11BM20151112
20151113†6:50AM UTC,UPDATE 2-Merck KGaA ups earnings outlook on strong biotech labs demand,http://www.reuters.com/article/merck-kgaa-results-idUSL8N1370S320151112
20151113†1:19AM UTC,Merck KGaA lifts 2015 guidance on Sigma-Aldrich takeover,http://www.reuters.com/article/merck-kgaa-results-idUSFWN13605T20151112
20151114†8:35AM UTC,Panel recommends Merck & Co continue cholesterol drug study,http://www.reuters.com/article/us-merck-co-study-idUSKCN0T21J020151113
20151114†8:34AM UTC,UPDATE 1-Panel recommends Merck & Co continue cholesterol drug study,http://www.reuters.com/article/merck-co-study-idUSL3N1384HP20151113
20151114†8:12AM UTC,Panel recommends Merck continue cholesterol drug study,http://www.reuters.com/article/merck-co-study-idUSL3N1384GI20151113
20151114†8:00AM UTC,Merck Provides Update on REVEAL Outcomes Study,http://www.reuters.com/article/nj-merck-idUSnBw135119a+100+BSW20151113
20151115†7:00PM UTC,"Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrho",http://www.reuters.com/article/nj-merck-idUSnBw145028a+100+BSW20151115
20151115†7:00PM UTC,"Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy",http://www.reuters.com/article/nj-merck-idUSnBw145005a+100+BSW20151115
20151117†8:30AM UTC,Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting¬Æ,http://www.reuters.com/article/nj-merck-idUSnBw165459a+100+BSW20151116
20151119†8:20AM UTC,BRIEF-Merck KGAA says closes takeover of Sigma-Aldrich,http://www.reuters.com/article/idUSFWN13D03M20151118
20151119†7:08AM UTC,BRIEF-Merck KGAA and Pfizer receive FDA breakthrough status for Avelumab,http://www.reuters.com/article/idUSFWN13D02720151118
20151119†7:00AM UTC,"Threshold Pharmaceuticals Enters Into Definitive Co-Promotion Agreement for Evofosfamide With Merck KGaA, Darmstadt, Germany",http://www.reuters.com/article/idUSnMKWpj5rfa+1c0+MKW20151118
20151119†7:00AM UTC,"Merck KGaA, Darmstadt, Germany, and Pfizer Receive FDA Breakthrough Therapy Designation for Avelumab in Metastatic Merkel Cell Carcinoma",http://www.reuters.com/article/pfizer-idUSnBw185702a+100+BSW20151118
20151121†4:01PM UTC,Merck Animal Health Pioneers H3N2 Canine Influenza Vaccine,http://www.reuters.com/article/merck-h3n2-vaccine-idUSnPn1lqrcY+81+PRN20151120
20151121†8:47AM UTC,BRIEF-Merck plans to more than double Africa sales by 2020,http://www.reuters.com/article/idUSL8N13F2PM20151120
20151122†4:30PM UTC,Merck Announces Initial Results for KEYTRUDA¬Æ (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress,http://www.reuters.com/article/nj-merck-idUSnBw215022a+100+BSW20151121
20151125†12:35PM UTC,Merck Announces Increased Quarterly Dividend,http://www.reuters.com/article/nj-merck-idUSnBw245963a+100+BSW20151124
20151126†4:00AM UTC,"Merck KGaA, Darmstadt, Germany, and Pfizer Receive Positive Opinion for Orphan Drug Designation for Avelumab in Merkel Cell Carcinoma from EMA Committee for Orphan Medicinal Products",http://www.reuters.com/article/pfizer-idUSnBw255077a+100+BSW20151125
20151127†5:32PM UTC,Merck plans to sell its allergy business unit to cut debt: Bloomberg,http://www.reuters.com/article/us-merck-allergopharma-sale-idUSKBN0TF2HI20151126
20151127†5:24PM UTC,Merck plans to sell its allergy business unit to cut debt -Bloomberg,http://www.reuters.com/article/merck-allergopharma-sale-idUSL1N13L1DQ20151126
20151127†8:07AM UTC,MEDIA-Merck KGaA aims to put out a new drug every year -WirtschaftsWoche,http://www.reuters.com/article/idUSL8N13L2OW20151126
20151205†8:01AM UTC,Amgen And Merck Announce Cancer Immunotherapy Collaboration For Patients With Non-Hodgkin Lymphoma,http://www.reuters.com/article/amgen-merck-idUSnPnRMrsN+59+PRN20151204
20151210†11:00AM UTC,"Merck KGaA, Darmstadt, Germany, and Pfizer Initiate Two Phase III Studies of Investigational Immunotherapy Avelumab in Advanced Gastric and Gastro-esophageal Junction Cancers",http://www.reuters.com/article/pfizer-idUSnBw095944a+100+BSW20151209
20151211†9:00AM UTC,Biothera Announces Clinical Study to Evaluate Combination Therapy of Imprime PGG and Merck's Checkpoint Inhibitor Keytruda in Patients with Non-Small Cell Lung Cancer,http://www.reuters.com/article/mn-biothera-pharmaceutic-idUSnBw105181a+100+BSW20151210
20151211†6:30AM UTC,Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA¬Æ Combination Trial,http://www.reuters.com/article/eli-lilly-merck-trial-idUSnPn5Cl7Gx+92+PRN20151210
20151211†4:09AM UTC,BRIEF-Merck KGaA to invest extra 250 mln eur in pharma pipeline,http://www.reuters.com/article/idUSFWN13Y04K20151210
20151215†9:47PM UTC,Merck fails to win FDA panel backing for Vytorin heart claim,http://www.reuters.com/article/us-merck-zetia-fda-idUSKBN0TX2IL20151215
20151215†6:17PM UTC,Merck fails to win FDA panel backing for Vytorin heart claim,http://www.reuters.com/article/us-merck-zetia-fda-idUSKBN0TX2IL20151214
20151215†6:12PM UTC,UPDATE 3-Merck fails to win FDA panel backing for Vytorin heart claim,http://www.reuters.com/article/merck-co-zetia-fda-idUSL1N14325420151214
20151215†4:28PM UTC,FDA panel rejects Merck claim Zetia/Vytorin cut heart risk,http://www.reuters.com/article/merck-zetia-fda-idUSL1N14323L20151214
20151215†4:09AM UTC,"BRIEF-Merck says acquires Ormet Circuits, no purchase price disclosed",http://www.reuters.com/article/idUSFWN14005920151214
20151216†9:25PM UTC,FDA approves Merck drug to reverse effects of muscle relaxants,http://www.reuters.com/article/us-merck-co-fda-bridion-idUSKBN0TY2TK20151216
20151216†4:04PM UTC,FDA approves Merck drug to reverse effects of muscle relaxants,http://www.reuters.com/article/us-merck-co-fda-bridion-idUSKBN0TY2TK20151215
20151216†4:01PM UTC,FDA approves Merck drug to reverse effects of muscle relaxants,http://www.reuters.com/article/merck-co-fda-bridion-idUSL1N1442FA20151215
20151217†6:12AM UTC,Bayer consumer health still looking to bulk up after Merck deal,http://www.reuters.com/article/us-bayer-consumerhealth-idUSKBN0TZ1E720151216
20151217†6:00AM UTC,Bayer consumer health still looking to bulk up after Merck deal,http://www.reuters.com/article/bayer-consumerhealth-idUSF9N0NT00Q20151216
20151217†3:00AM UTC,PsiOxus Therapeutics Initiates Combination Study of Merck‚Äôs Keytruda with Oncolytic Virus Enadenotucirev,http://www.reuters.com/article/psioxus-therapeutics-idUSnBw165119a+100+BSW20151216
20151217†2:00AM UTC,Merck Honored by R&D; Magazine for Innovation,http://www.reuters.com/article/merck-idUSnBw156682a+100+BSW20151216
20151218†8:00AM UTC,"WellDoc¬Æ Raises $22 Million in Series B Funding From Samsung Ventures, Merck Global Health Innovation Fund and Other Leading Venture Groups",http://www.reuters.com/article/idUSnGNX7Sr8BM+1d3+GNW20151217
20151219†4:05PM UTC,FDA Approves Expanded Indication for Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) for the Treatment of Patients with Advanced Melanoma,http://www.reuters.com/article/nj-merck-idUSnBw185982a+100+BSW20151218
20151219†8:00AM UTC,Merck Provides Update on European Medicines Agency Marketing Authorization Application for Investigational Chronic Hepatitis C Therapy Elbasvir/Grazoprevir,http://www.reuters.com/article/nj-merck-idUSnBw185008a+100+BSW20151218
20151219†7:00AM UTC,Codexis Signs Multi-year Extension of Contract with Merck to Supply Enzyme Used in Manufacture of Sitagliptin,http://www.reuters.com/article/idUSnGNX26vP7H+1c5+GNW20151218
20151220†10:55AM UTC,Merck‚Äôs KEYTRUDA¬Æ (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1,http://www.reuters.com/article/nj-merck-idUSnBw195003a+100+BSW20151219
20151223†9:50AM UTC,BRIEF-Selvita signs deal with Merck for commercialization of oncological terapeutical molecules ,http://www.reuters.com/article/idUSFWN14B03720151222
20160108†2:09AM UTC,BRIEF-Biocartis Group announces collaboration with Merck,http://www.reuters.com/article/idUSFWN14P02R20160107
20160108†2:06AM UTC,"BRIEF-Merck KGaA, Biocartis to collaborate on new liquid biopsy technology for ras biomarker testing",http://www.reuters.com/article/idUSFWN14P05820160107
20160113†8:36AM UTC,"Merck, BioLineRX to study drug combo to fight pancreatic cancer",http://www.reuters.com/article/us-bioline-rx-merck-co-idUSKCN0UQ1ND20160112
20160113†8:18AM UTC,"Merck, BioLineRX to study drug combo to fight pancreatic cancer",http://www.reuters.com/article/bioline-rx-merck-co-idUSL8N14W30O20160112
20160113†7:16AM UTC,BRIEF-Sanochemia Pharmazeutika says Franco Merckling to become new CEO,http://www.reuters.com/article/idUSFWN14V04Z20160112
20160116†12:15PM UTC,Fight over Merck name sees German firm win in British court,http://www.reuters.com/article/us-merckkgaa-name-idUSKCN0UT239
20160116†12:11PM UTC,Fight over Merck name sees German firm win in British court,http://www.reuters.com/article/merckkgaa-name-idUSL8N14Z3KJ
20160116†10:05AM UTC,Merck agrees to pay $830 mln to settle Vioxx securities lawsuit,http://www.reuters.com/article/merck-vioxx-settlement-idUSL2N14Z1F6
20160116†9:38AM UTC,Merck agrees to pay $830 million to settle Vioxx securities lawsuit,http://www.reuters.com/article/us-merck-vioxx-settlement-idUSKCN0UT1PX
20160116†9:36AM UTC,Merck agrees to pay $830 mln to settle Vioxx securities lawsuit,http://www.reuters.com/article/merck-vioxx-settlement-idUSL2N14Z13C
20160116†8:52AM UTC,BRIEF-Germany's Merck says wins UK court ruling in dispute over name,http://www.reuters.com/article/idUSFWN14Y07B
20160120†2:05AM UTC,BRIEF-Germany's Merck appoints new executive board members,http://www.reuters.com/article/idUSFWN153005
20160121†5:48AM UTC,Vaccines alliance signs $5 million advance deal for Merck's Ebola shot,http://www.reuters.com/article/us-health-ebola-vaccine-idUSKCN0UY0OT
20160121†3:30AM UTC,Vaccines alliance signs $5 mln advance deal for Merck's Ebola shot,http://www.reuters.com/article/health-ebola-vaccine-idUSL8N1533S6
20160123†11:14AM UTC,Merck sees deal opportunities as biotech funding gets tighter,http://www.reuters.com/article/us-merck-co-m-a-ceo-idUSKCN0V0205
20160129†7:50PM UTC,FDA approves Merck's new hepatitis C pill,http://www.reuters.com/article/us-merck-co-hepatitis-fda-idUSKCN0V631S
20160129†7:48PM UTC,UPDATE 1-U.S. FDA approves Merck's new hepatitis C pill,http://www.reuters.com/article/merck-co-hepatitis-fda-idUSL2N15C3PV
20160129†6:10PM UTC,U.S. FDA approves Merck's new hepatitis C pill,http://www.reuters.com/article/merck-co-hepatitis-fda-idUSL2N15C2EO
20160130†4:02PM UTC,Payers see price leverage with entry of Merck hepatitis C drug,http://www.reuters.com/article/us-merck-co-gilead-sciences-hepatitis-idUSKCN0V72BT
20160130†3:57PM UTC,UPDATE 1-Payers see price leverage with entry of Merck hepatitis C drug,http://www.reuters.com/article/merck-co-gilead-sciences-hepatitis-idUSL2N15D2AM
20160130†1:40PM UTC,Payers see price leverage with entry of Merck hepatitis C drug,http://www.reuters.com/article/merck-co-gilead-sciences-hepatitis-idUSL2N15D1MX
20160204†12:56PM UTC,Merck gives cautious 2016 outlook as sales of top medicines lag,http://www.reuters.com/article/us-merck-co-results-idUSKCN0VC1AX
20160204†12:38PM UTC,UPDATE 3-Merck gives cautious 2016 outlook as sales of top medicines lag,http://www.reuters.com/article/merck-co-results-idUSL3N15I48X
20160204†9:14AM UTC,"BRIEF-Merck sees accelerating declines for Remicade, due to biosimilars",http://www.reuters.com/article/idUSL2N15I11D
20160204†8:54AM UTC,"Pfizer, J&J;, Merck evaluating technologies for Zika vaccine",http://www.reuters.com/article/us-health-zika-big-pharma-idUSKCN0VC1EB
20160204†7:27AM UTC,"Pfizer, J&J;, Merck evaluating technologies for Zika vaccine",http://www.reuters.com/article/health-zika-big-pharma-idUSL3N15I45M
20160204†6:57AM UTC,Merck revenue falls as dollar strengthens,http://www.reuters.com/article/merck-co-results-idUSL3N15I47Z
20160216†7:53PM UTC,Merck says U.S. FDA reject its claim that Zetia and Vytorin cut heart risk,http://www.reuters.com/article/merck-co-zetia-fda-idUSL3N15U435
20160224†4:18AM UTC,Merck KGaA says consumer health saw 'nice' growth in 2015,http://www.reuters.com/article/merck-kgaa-consumer-health-idUSF9N10H01N
20160308†2:11AM UTC,BRIEF-Neuron Bio designated as reference laboratory for Merck Millipore,http://www.reuters.com/article/idUSFWN16F00G
20160309†8:47AM UTC,Sanofi and Merck pull the plug on European vaccines venture,http://www.reuters.com/article/us-sanofi-merck-idUSKCN0WA1MP
20160309†8:41AM UTC,UPDATE 1-Sanofi and Merck pull the plug on European vaccines venture,http://www.reuters.com/article/sanofi-merck-idUSL5N16G39K
20160309†8:13AM UTC,Sanofi Pasteur and Merck end European vaccines venture,http://www.reuters.com/article/sanofi-merck-idUSFWN16G019
20160309†6:04AM UTC,Merck KGaA sees adj EBITDA growth of up to 20 pct in 2016,http://www.reuters.com/article/merck-kgaa-results-target-idUSL5N16G1YG
20160309†2:57AM UTC,BRIEF-Merck says China to be one of the major growth drivers -CNBC,http://www.reuters.com/article/idUSL5N16G166
20160309†2:12AM UTC,UPDATE 1-Merck KGaA aims for 2016 earnings growth thanks to takeover,http://www.reuters.com/article/merck-kgaa-results-idUSL5N16G0IZ
20160309†1:11AM UTC,Merck KGaA aims for 2016 earnings growth thanks to takeover,http://www.reuters.com/article/merck-kgaa-results-idUSF9N0NT00T
20160310†4:00AM UTC,E.ON to name Merck KGaA CEO Kley as supervisory board chairman,http://www.reuters.com/article/us-e-on-chairman-idUSKCN0WB0W2
20160310†3:55AM UTC,E.ON to name Merck KGaA CEO Kley as supervisory board chairman,http://www.reuters.com/article/e-on-chairman-idUSFWN16H00C
20160323†8:48PM UTC,UPDATE 3-Merck patents on Hepatitis C treatment found valid in Gilead dispute,http://www.reuters.com/article/gilead-sciences-merck-co-verdict-idUSL2N16U28H
20160323†5:46PM UTC,Merck patents on Hepatitis C treatment found valid in Gilead dispute,http://www.reuters.com/article/gilead-sciences-merck-co-verdict-idUSL2N16U2A5
20160323†5:27PM UTC,Merck patents on Hepatitis C treatment found valid in dispute with Gilead,http://www.reuters.com/article/gilead-sciences-merck-co-verdict-idUSL2N16U26U
20160324†4:41AM UTC,Merck patents on Hepatitis C treatment found valid in Gilead dispute,http://www.reuters.com/article/us-gilead-sciences-merck-co-verdict-idUSKCN0WO353
20160325†10:51PM UTC,Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,http://www.reuters.com/article/gilead-sciences-merck-co-damages-idUSL2N16X011
20160325†9:58PM UTC,Gilead ordered to pay Merck $200 million in hepatitis C drug patent dispute,http://www.reuters.com/article/us-gilead-sciences-merck-co-damages-idUSKCN0WR00V
20160325†9:55PM UTC,UPDATE 3-Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,http://www.reuters.com/article/gilead-sciences-merck-co-damages-idUSL2N16X009
20160325†7:59PM UTC,Gilead ordered to pay Merck $200 mln in hepatitis C drug patent dispute,http://www.reuters.com/article/gilead-sciences-merck-co-damages-idUSL2N16W1AM
20160330†7:06AM UTC,Gilead says Merck 'deceitful' in hepatitis C drug patent fight,http://www.reuters.com/article/ip-gilead-hearing-idUSL2N1710BZ
20160401†7:51AM UTC,BRIEF-Selvita signs another deal with Merck KGaA,http://www.reuters.com/article/idUSFWN1730J2
20160412†6:38PM UTC,BRIEF-Merck & Co says CEO Kenneth C. Frazier's total compensation for 2015 was $24.2 MLN,http://www.reuters.com/article/idUSFWN17E0OO
20160414†7:11AM UTC,BRIEF-Merck says FDA has accepted for review supplemental biologics license application for Keytruda,http://www.reuters.com/article/idUSASC08KW1
20160415†8:21AM UTC,BRIEF-Merck KGaA files answer to trademark right violation claims made by MSD,http://www.reuters.com/article/idUSFWN17H0D0
20160415†5:41AM UTC,BRIEF-Merck KgaA appoints Maya Martinez-Davis as global head of oncology,http://www.reuters.com/article/idUSFWN17H0BZ
20160415†3:50AM UTC,BRIEF-Merck launches Merck for Health project in partnership with H-farm,http://www.reuters.com/article/idUSFWN17H0E8
20160419†8:16AM UTC,BRIEF-Merck receives breakthrough therapy designation from FDA for use of Keytruda in classical hodgkin lymphoma,http://www.reuters.com/article/idUSASC08LFM
20160420†5:20PM UTC,BRIEF-Merck Animal Health to buy worldwide rights to Whisper Veterinary Stethoscope System,http://www.reuters.com/article/idUSASD08E6S
20160426†2:11AM UTC,BRIEF-Merck KGaA publishes Chinese Phase III study for Erbitux,http://www.reuters.com/article/idUSFWN17P14N
20160427†8:39AM UTC,BRIEF-Merck KGaA selects Unisys to deliver global end-user IT services,http://www.reuters.com/article/idUSFWN17T05E
20160428†9:17PM UTC,Merck sex discrimination case could be collective action: judge,http://www.reuters.com/article/us-usa-merck-co-discrimination-idUSKCN0XO2RI
20160428†7:38PM UTC,UPDATE 1-Merck sex discrimination case could be collective action -judge,http://www.reuters.com/article/usa-merck-co-discrimination-idUSL2N17U2SD
20160428†6:07PM UTC,Merck sex discrimination case could be collective action -judge,http://www.reuters.com/article/usa-merck-co-discrimination-idUSL2N17U2MZ
20160428†6:04PM UTC,Merck sex discrimination case could be collective action -judge,http://www.reuters.com/article/usa-merck-co-discrimination-idUSL2N17U2H3
20160430†4:20AM UTC,BRIEF-Merck sees negative FX effects for 2016,http://www.reuters.com/article/idUSF9N17F00G
20160506†9:41AM UTC,BRIEF-Merck says EU Zepatier launch may be delayed,http://www.reuters.com/article/idUSL2N1820O2
20160506†9:10AM UTC,BRIEF-Merck says EU manufacturer of Zepatier cited for recordkeeping lapses,http://www.reuters.com/article/idUSL2N1820JP
20160506†8:52AM UTC,"RPT-UPDATE 2-Merck sales disappoint as Januvia, Remicade fall short",http://www.reuters.com/article/merck-co-results-idUSL2N1820K0
20160506†8:49AM UTC,"Merck sales disappoint as Januvia, Remicade fall short",http://www.reuters.com/article/us-merck-co-results-idUSKCN0XW0YK
20160506†6:57AM UTC,BRIEF-Merck Q1 earnings per share $0.40,http://www.reuters.com/article/idUSASC08N4X
20160513†8:38AM UTC,BRIEF-Merck to present Phase 3 data on Ertugliflozin and MK-1293,http://www.reuters.com/article/idUSASC08P7D
20160514†10:21AM UTC,Germany's Merck says gene editing to help it outperform,http://www.reuters.com/article/us-merckkgaa-lifescience-idUSKCN0Y41TK
20160517†7:05AM UTC,Merck B vitamin formula patent invalid due to on-sale bar - Federal Circuit,http://www.reuters.com/article/health-merck-idUSL2N18D0A2
20160519†6:25PM UTC,"German Merck, Pfizer immunotherapy shows promise in rare skin cancer",http://www.reuters.com/article/us-health-cancer-merck-idUSKCN0Y92X1
20160519†5:19PM UTC,"Merck, Bristol drugs show longer survival for deadly cancers",http://www.reuters.com/article/us-health-cancer-immunotherapies-idUSKCN0Y92WD
20160519†5:04PM UTC,Pfizer cancer drug shows promise in combo with Merck's Keytruda,http://www.reuters.com/article/us-health-cancer-pfizer-immunotherapy-idUSKCN0Y92W2
20160519†5:00PM UTC,"German Merck, Pfizer immunotherapy shows promise in rare skin cancer",http://www.reuters.com/article/health-cancer-merck-idUSL2N18F1ZY
20160519†5:00PM UTC,"Merck, Bristol drugs show longer survival for deadly cancers",http://www.reuters.com/article/health-cancer-immunotherapies-idUSL2N18E1K0
20160519†5:00PM UTC,Pfizer cancer drug shows promise in combo with Merck's Keytruda,http://www.reuters.com/article/health-cancer-pfizer-immunotherapy-idUSL2N18F0Z4
20160520†4:11AM UTC,BRIEF-Merck KGaA expects to file for first approval of Avelumab in H2,http://www.reuters.com/article/idUSL5N18G1TR
20160520†1:21AM UTC,Merck KGaA sees gain in adj EBITDA of up to 18.5 pct,http://www.reuters.com/article/merck-kgaa-results-idUSFWN18G01O
20160525†2:36PM UTC,BRIEF-Merck sets quarterly dividend of 46 cents per share,http://www.reuters.com/article/idUSFWN18L0JL
20160227†6:22PM UTC,Judge trims antitrust case against Merck over potassium drug,http://www.reuters.com/article/health-merck-idUSL2N1652GT
20160614†11:02AM UTC,BRIEF-Merck investigational insulin glargine met primary endpoint in two Phase 3 studies,http://www.reuters.com/article/idUSASC08TTD
20160702†1:38PM UTC,BRIEF-Merck Animal Health to buy controlling interest in Vall√©e S.A,http://www.reuters.com/article/idUSFWN19N0FH
20160825†11:26AM UTC,BRIEF-Biothera Pharmaceuticals expands relationship with Merck,http://www.reuters.com/article/idUSFWN1B50GT
20161018†6:08AM UTC,BRIEF-Merck KGaA announces cooperation agreement with durXtreme GmbH,http://www.reuters.com/article/idUSFWN1CN048
20161105†1:56AM UTC,BRIEF-Merck KGaA says invests 250 mln eur in production value chain in China,http://www.reuters.com/article/idUSFWN1D41NY
20161123†1:25PM UTC,BRIEF-Merck raises quarterly dividend to $0.47/share from $0.46/share,http://www.reuters.com/article/idUSFWN1DN0RJ
20161123†8:07AM UTC,"BRIEF-QuintilesIMS forms new Collaboration with Bristol-Myers Squibb, Lilly, Merck KGaA, Darmstadt, Germany, and Pfizer to generate real world insights on usage of anti-cancer therapies across Europe",http://www.reuters.com/article/idUSFWN1DN0L3
20160528†4:19PM UTC,BRIEF-Merck Global Health Innovation Fund hikes stake in OpGen to 37.5 pct from 11.8 pct,http://www.reuters.com/article/idUSFWN18O0DB
20160528†2:01PM UTC,BRIEF-Merck shareholder proposal for report on disposal of unused or expired drugs defeated,http://www.reuters.com/article/idUSFWN18O0D3
20160528†7:59AM UTC,BRIEF-Merck receives positive CHMP opinion for Zepatier in the EU,http://www.reuters.com/article/idUSFWN18O09U
20160601†5:14AM UTC,Eddy Merckx may face trial in Belgian cycle kickback probe: newspaper,http://www.reuters.com/article/us-belgium-merckx-idUSKCN0YM0W4
20160605†9:23AM UTC,"BRIEF-Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial",http://www.reuters.com/article/idUSFWN18W002
20160607†9:56PM UTC,UPDATE 2-Gilead escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com/article/gilead-sciences-merck-co-ruling-idUSL1N18Z00Z
20160607†8:32PM UTC,Gileads escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com/article/gilead-sciences-merck-co-ruling-idUSL1N18Z009
20160607†11:40AM UTC,"CORRECTED-BRIEF-Merck KGaA, Pfizer present positive mid-stage data on merkel cell carcinoma drug at ASCO",http://www.reuters.com/article/idUSFWN18Y0H6
20160607†8:22AM UTC,"BRIEF-Merck says updated Keytruda findings show response rates benefit in head, neck cancer patients",http://www.reuters.com/article/idUSFWN18Y0E2
20160608†9:57AM UTC,FDA staff question efficacy of Merck's drug for infectious diarrhea,http://www.reuters.com/article/us-health-merck-cdifficile-idUSKCN0YT1I6
20160608†9:55AM UTC,UPDATE 2-FDA staff question efficacy of Merck's drug for infectious diarrhea,http://www.reuters.com/article/health-merck-cdifficile-idUSL1N18Z0I9
20160608†8:54AM UTC,FDA staff review questions efficacy of Merck's C. difficile drug,http://www.reuters.com/article/health-merck-cdifficile-idUSL1N18Z0H0
20160608†6:57AM UTC,Gilead escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com/article/gilead-sciences-merck-co-ruling-idUSL1N18Z01W
20160608†6:06AM UTC,Gilead escapes liability in hepatitis C patent fight with Merck,http://www.reuters.com/article/us-gilead-sciences-merck-co-ruling-idUSKCN0YT01A
20160610†6:07PM UTC,U.S. panel backs approval for Merck infectious diarrhea drug,http://www.reuters.com/article/us-merck-co-fda-idUSKCN0YV2ER
20160610†5:57PM UTC,UPDATE 2-U.S. panel backs approval for Merck infectious diarrhea drug,http://www.reuters.com/article/merck-co-fda-idUSL1N191247
20160610†5:35PM UTC,BRIEF-Merck to acquire Afferent Pharmaceuticals,http://www.reuters.com/article/idUSASC08TJF
20160610†3:57PM UTC,U.S. regulatory panel backs approval for Merck C. difficile drug,http://www.reuters.com/article/merck-co-fda-idUSL1N19120O
20160610†9:16AM UTC,BRIEF-Agenus announces lead product candidate selection in Merck collaboration,http://www.reuters.com/article/idUSFWN1910JN
20160617†1:54PM UTC,Merck's Keytruda prolongs life in big lung-cancer study,http://www.reuters.com/article/us-merck-keytruda-lung-idUSKCN0Z21OQ
20160617†1:38PM UTC,UPDATE 1-Merck's Keytruda prolongs life in big lung-cancer study,http://www.reuters.com/article/merck-co-keytruda-lung-idUSL1N1981CJ
20160617†9:36AM UTC,Merck's Keytruda prolongs life in big lung-cancer study,http://www.reuters.com/article/merck-keytruda-lung-idUSL1N1980OY
20160617†6:50AM UTC,"BRIEF-Merck's Keytruda shows superior progression-free, overall survival in lung cancer patients",http://www.reuters.com/article/idUSFWN198090
20160621†12:50PM UTC,"BRIEF-Merck announces results of study of Relebactam, in combination with Imipenem/Cilastatin",http://www.reuters.com/article/idUSB8N19C02S
20160621†6:16AM UTC,BRIEF-Merck KGaA says plans to apply for authorization for Avelumab in H2,http://www.reuters.com/article/idUSL8N19C1MN
20160628†6:25AM UTC,BRIEF-Merck receives CHMP positive opinion for Keytruda in advanced non-small cell lung cancer,http://www.reuters.com/article/idUSASC08VBB
20160630†7:32AM UTC,BRIEF-Merck and Moderna announce strategic collaboration,http://www.reuters.com/article/idUSFWN19L09Z
20160630†7:17AM UTC,"After hepatitis C patent win over Merck, Gilead faces other foes",http://www.reuters.com/article/ip-gilead-lawsuits-idUSL1N19L0B3
20160701†9:28AM UTC,"BRIEF-Merck, Premier Inc collaborate to improve care for osteoporosis patients",http://www.reuters.com/article/idUSFWN19M0P5
20160701†7:14AM UTC,3rd Circuit to weigh Fosamax warning lawsuits against Merck,http://www.reuters.com/article/merck-labeling-case-idUSL1N19M0B8
20160701†3:20AM UTC,"BRIEF-Merck KGaA says Zeiss, Hamilton Thorne to join global fertility alliance",http://www.reuters.com/article/idUSFWN19L11Z
20160707†4:41PM UTC,"Pfizer, Germany's Merck begin large ovarian cancer trial",http://www.reuters.com/article/us-cancer-ovarian-pfizer-idUSKCN0ZM2DV
20160707†4:37PM UTC,"Pfizer, Germany's Merck begin large ovarian cancer trial",http://www.reuters.com/article/cancer-ovarian-pfizer-idUSL1N19S1YN
20160708†11:56AM UTC,REFILE-BRIEF-Pfizer and Germany's Merck KGaA initiate phase III trial,http://www.reuters.com/article/idUSFWN19S06Y
20160708†7:06AM UTC,Merck appeals order reversing its $200 mln verdict against Gilead,http://www.reuters.com/article/health-merck-idUSL1N19T0BF
20160712†7:26AM UTC,BRIEF- Merck's Healthcare invests majority stake in Staywell,http://www.reuters.com/article/idUSFWN19X0H7
20160715†7:24PM UTC,UK charity pockets $150 million from Merck cancer immunotherapy drug,http://www.reuters.com/article/us-merck-britain-charity-idUSKCN0ZU2RD
20160715†7:01PM UTC,UK charity pockets $150 mln from Merck cancer immunotherapy drug,http://www.reuters.com/article/merck-britain-charity-idUSL8N1A03PM
20160719†8:42AM UTC,CORRECTED-BRIEF-Merck KGaA gets EMA acceptance for review of marketing application,http://www.reuters.com/article/idUSFWN1A40DN
20160719†2:30AM UTC,BRIEF-Merck says EMA accepts cladribine for review marketing authorisation application,http://www.reuters.com/article/idUSFWN1A10GI
20160722†4:50PM UTC,Ruling invalidating Merck patent over on-sale bar stayed,http://www.reuters.com/article/health-beyaz-idUSL1N1A725M
20160722†4:46PM UTC,BRIEF-Merck provides regulatory update on Biologics application,http://www.reuters.com/article/idUSASC08XTD
20160723†7:41AM UTC,BRIEF-Merck says EMA has accepted file for formulation of Isentress for review,http://www.reuters.com/article/idUSFWN1A80KD
20160726†5:28PM UTC,BRIEF-Enigma biomedical announces research collaboration agreement with Biogen Inc and Merck,http://www.reuters.com/article/idUSFWN1AB0S6
20160726†9:18AM UTC,BRIEF-Merck designated breakthrough therapy by FDA and gets prime status from EMA for ebola vaccine,http://www.reuters.com/article/idUSASC08Y0D
20160727†2:18PM UTC,BRIEF-Merck sets quarterly dividend of $0.46 per share,http://www.reuters.com/article/idUSFWN1AC0Z4
20160728†1:25AM UTC,BRIEF-Merck plans to end partnership agreement with Alk Abello,http://www.reuters.com/article/idUSL8N1AD0KM
20160729†11:31AM UTC,"BRIEF-Germany's Merck KGaA, AmoyDx collaborate to bring liquid biopsy RAS biomarker testing to China",http://www.reuters.com/article/idUSL8N1AE8II
20160729†6:55AM UTC,Roberts lifts stay of ruling invalidating Merck patent,http://www.reuters.com/article/health-beyaz-idUSL1N1AE0D1
20160729†6:53AM UTC,"Gilead, Merck lock horns on legal fees in hepatitis C patent fight",http://www.reuters.com/article/ip-gilead-fees-idUSL1N1AE0CY
20160729†6:52AM UTC,Merck seeks to curb plaintiff firm's 'misleading' communications,http://www.reuters.com/article/health-merck-idUSL1N1AE0CU
20160730†9:16AM UTC,"Merck quarterly results beat forecasts, shares rise",http://www.reuters.com/article/us-merck-co-results-idUSKCN10917E
20160730†9:15AM UTC,"UPDATE 2-Merck quarterly results beat forecasts, shares rise",http://www.reuters.com/article/merck-co-results-idUSL4N1AF4EM
20160730†6:54AM UTC,Merck & Co reports 1 pct rise in quarterly revenue,http://www.reuters.com/article/merck-co-results-idUSL4N1AF4DW
20160730†6:50AM UTC,BRIEF-Merck Q2 adjusted earnings per share $0.93,http://www.reuters.com/article/idUSASC08ZGX
20160802†5:44PM UTC,Merck motion to bar plaintiff firm's communications denied as moot,http://www.reuters.com/article/health-merck-idUSL1N1AI1QX
20160802†3:31AM UTC,Nanoco signs deal with Merck for use of quantum dot technology,http://www.reuters.com/article/nanoco-group-deals-merck-idUSL3N1AI2RN
20160803†6:13PM UTC,"Biogen draws takeover interest from Merck, Allergan: WSJ",http://www.reuters.com/article/us-biogen-m-a-idUSKCN10D25T
20160803†6:10PM UTC,"UPDATE 4-Biogen draws takeover interest from Merck, Allergan-WSJ",http://www.reuters.com/article/biogen-ma-idUSL3N1AJ554
20160803†5:54PM UTC,BRIEF-European Commission approves Merck's anti-PD-1 therapy KEYTRUDA,http://www.reuters.com/article/idUSFWN1AJ0VR
20160803†5:10PM UTC,"UPDATE 3-Biogen draws takeover interest from Merck, Allergan -WSJ",http://www.reuters.com/article/biogen-ma-idUSL3N1AJ4NN
20160803†2:58PM UTC,"REFILE-Biogen draws takeover interest from Merck, Allergan - WSJ",http://www.reuters.com/article/biogen-ma-idUSL3N1AJ4MM
20160803†2:47PM UTC,BRIEF-Biogen has drawn takeover interest from drug companies including Merck & Co and Allergan - WSJ,http://www.reuters.com/article/idUSFWN1AJ0U4
20160805†4:48AM UTC,BRIEF-Merck KGaA says fertility unit benefiting from production problems at 2 U.S. rivals,http://www.reuters.com/article/idUSL8N1AL21T
20160805†3:27AM UTC,UPDATE 2-Merck KGaA lifts profit forecast on fertility treatment,http://www.reuters.com/article/merck-kgaa-results-idUSL8N1AL0O8
20160805†1:18AM UTC,Merck KGaA lifts FY profit forecast on strong lab supplies,http://www.reuters.com/article/merck-kgaa-results-idUSFWN1AK1AL
20160806†8:15AM UTC,BRIEF-Merck announces U.S. FDA filing acceptance of new drug application (NDA) for mk-1293,http://www.reuters.com/article/idUSASC09177
20160809†11:43AM UTC,CORRECTED-BRIEF-Merck & Co says FDA approves Keytruda for a type of head and neck cancer (Aug 5),http://www.reuters.com/article/idUSFWN1AM1FK
20160812†8:46PM UTC,Gilead to get attorney fees in hepatitis C patent fight with Merck,http://www.reuters.com/article/gilead-sciences-merck-co-ruling-idUSL1N1AT01I
20160812†8:43PM UTC,Gilead to get attorney fees in hepatitis C patent fight with Merck,http://www.reuters.com/article/us-gilead-sciences-merck-co-ruling-idUSKCN10N02Y
20160812†8:38PM UTC,Gilead to get attorney fees in hepatitis C patent fight with Merck,http://www.reuters.com/article/gilead-sciences-merck-co-ruling-idUSL3N1AT05H
20160818†2:07PM UTC,Exclusive: Merck enters race for cancer drugmaker Medivation - sources,http://www.reuters.com/article/us-medivation-m-a-exclusive-idUSKCN10S1SW
20160818†1:51PM UTC,Exclusive: Merck enters race for cancer drugmaker Medivation - sources,http://www.reuters.com/article/uk-medivation-m-a-exclusive-idUSKCN10S1WW
20160818†1:48PM UTC,EXCLUSIVE-Merck enters race for cancer drugmaker Medivation -sources,http://www.reuters.com/article/medivation-ma-idUSL1N1AY153
20160826†6:41PM UTC,Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo,http://www.reuters.com/article/us-cancer-bristol-myers-merck-co-idUSKCN1102N6
20160826†6:08PM UTC,Lung cancer doctors eye Merck's Keytruda over Bristol's Opdivo,http://www.reuters.com/article/cancer-bristol-myers-merck-co-idUSL1N1B6175
20160830†8:20PM UTC,Judge invalidates Merck's NuvaRing patent claims,http://www.reuters.com/article/ip-merck-nuvaring-idUSL1N1BB00E
20160831†12:20PM UTC,BRIEF-Moody's changes outlook on Merck KGAA's ratings to stable from negative; affirms ratings,http://www.reuters.com/article/idUSFWN1BB0JP
20160903†7:52AM UTC,Merck scraps development of osteoporosis drug due to stroke risk,http://www.reuters.com/article/us-merck-co-study-idUSKCN1181E6
20160903†7:51AM UTC,UPDATE 1-Merck scraps development of osteoporosis drug due to stroke risk,http://www.reuters.com/article/merck-co-study-idUSL3N1BE3OV
20160903†7:36AM UTC,BRIEF-Merck provides update on odanacatib development program,http://www.reuters.com/article/idUSASC09587
20160903†7:20AM UTC,REFILE-Merck aborts development of osteoporosis drug due to stroke risk,http://www.reuters.com/article/merck-co-study-idUSL3N1BE3N4
20160908†8:52AM UTC,"BRIEF-Aralez acquires U.S., Canadian rights to Zontivity from Merck",http://www.reuters.com/article/idUSFWN1BJ0C5
20160908†8:39AM UTC,BRIEF-Merck says FDA grants breakthrough therapy designation to Keytruda,http://www.reuters.com/article/idUSASC095IT
20160913†8:18AM UTC,BRIEF-Merck Canada says BRENZYS approved in Canada,http://www.reuters.com/article/idUSFWN1BO076
20160915†3:44AM UTC,Roche says new MS drug works better than Merck's Rebif,http://www.reuters.com/article/us-roche-ocrevus-idUSKCN11K0NH
20160915†3:41AM UTC,Roche says new MS drug works better than Merck's Rebif,http://www.reuters.com/article/roche-ocrevus-idUSL8N1BQ0ZB
20160916†8:58AM UTC,"BRIEF-Merck, Pfizer say investigational Ertugliflozin met primary endpoint",http://www.reuters.com/article/idUSFWN1BR05I
20160917†6:43AM UTC,BRIEF-Merck presents new data examining durable efficacy with investigational cladribine tablets in multiple sclerosis,http://www.reuters.com/article/idUSFWN1BS06D
20160921†2:02AM UTC,BRIEF-Bayer says Merck & Co integration disrupts business more than expected,http://www.reuters.com/article/idUSL8N1BW0JG
20160924†10:03AM UTC,BRIEF-Merck KGaA announces Isabel de Paoli new chief strategy officer,http://www.reuters.com/article/idUSFWN1BZ0HY
20161007†9:48AM UTC,BRIEF-Vaccinex announces clinical collaboration with Merck Kgaa,http://www.reuters.com/article/idUSFWN1CC0GA
20161008†6:51AM UTC,Merck asks justices to change how Federal Circuit reviews PTO trials,http://www.reuters.com/article/ip-merck-gnosis-idUSL2N1CD0B8
20161009†2:23AM UTC,Merck's Keytruda achieves 24 percent response in bladder cancer study,http://www.reuters.com/article/us-health-cancer-merck-bladder-idUSKCN128082
20161009†2:15AM UTC,Merck's Keytruda achieves 24 pct response in bladder cancer study,http://www.reuters.com/article/health-cancer-merck-bladder-idUSL2N1CB2B3
20161010†10:21AM UTC,"Anuncian nuevo d√≠a"" en lucha contra c√°ncer de pulm√≥n tras exitosas pruebas de f√°rmaco de Merck""",http://www.reuters.com/article/salud-cancer-merck-co-idUSL1N1CF06R
20161010†5:18AM UTC,"'New day' in lung cancer as Merck drug shines, works with chemo",http://www.reuters.com/article/us-health-cancer-merck-co-idUSKCN12904Q
20161010†5:15AM UTC,"UPDATE 1-'New day' in lung cancer as Merck drug shines, works with chemo",http://www.reuters.com/article/health-cancer-merck-co-idUSL8N1CF05C
20161010†2:15AM UTC,Merck drug shines in lung cancer and also works with chemo,http://www.reuters.com/article/health-cancer-merck-co-idUSL5N1CE0J7
20161011†6:02PM UTC,Judge upholds Merck antibiotic patents against Hospira challenge,http://www.reuters.com/article/health-invanz-idUSL1N1CG1M9
20161011†2:15PM UTC,UPDATE 1-Bristol lung-cancer setback puts rival Merck drug in driver seat,http://www.reuters.com/article/bristolmyers-merck-stocks-idUSL1N1CG0XE
20161012†12:09PM UTC,"BRIEF-Transgene announces collaboration with Merck KGaA, Darmstadt, Germany and Pfizer to evaluate the combination of TG4001 with Avelumab",http://www.reuters.com/article/idUSASC09ATC
20161012†9:50AM UTC,BRIEF-Aetna and Merck sign a contract for Januvia and Janumet,http://www.reuters.com/article/idUSFWN1CH0RR
20161012†1:29AM UTC,Bristol lung-cancer setback puts rival Merck drug in driver seat,http://www.reuters.com/article/us-bristolmyers-merck-stocks-idUSKCN12A1V6
20161013†1:05AM UTC,BRIEF-Ablynx extends research collaboration with Merck & Co,http://www.reuters.com/article/idUSFWN1CH12H
20161014†5:58AM UTC,BRIEF-Merck KGaA says still plan to apply for avelumab approval this year,http://www.reuters.com/article/idUSL8N1CJ24Q
20161014†5:49AM UTC,Germany's Merck expects extra benefits from Sigma-Aldrich deal,http://www.reuters.com/article/merck-kgaa-synergies-idUSL8N1CJ1TH
20161020†7:50AM UTC,Merck's antiviral drug meets main goal in late-stage trial,http://www.reuters.com/article/us-merck-co-trial-idUSKCN12J1CB
20161020†7:48AM UTC,UPDATE 1-Merck's antiviral drug meets main goal in late-stage trial,http://www.reuters.com/article/merck-co-trial-idUSL4N1CP3O6
20161020†7:19AM UTC,BRIEF-Merck says phase 3 study with Letermovir meets its primary endpoint,http://www.reuters.com/article/idUSASC09BQU
20161020†7:18AM UTC,Merck's antiviral drug meets main goal in late-stage trial,http://www.reuters.com/article/merck-co-trial-idUSL4N1CP3MU
20161021†8:29AM UTC,BRIEF-Debiopharm reports clinical collaboration with Merck KGaA and Pfizer,http://www.reuters.com/article/idUSASC09C2M
20161021†7:47AM UTC,BRIEF-Advaxis initiates combination portion of phase 1/2 study with Merck,http://www.reuters.com/article/idUSFWN1CQ0KB
20161022†7:48AM UTC,Merck's Keytruda succeeds in key bladder cancer trial,http://www.reuters.com/article/us-merck-co-study-idUSKCN12L1BX
20161022†7:43AM UTC,UPDATE 1-Merck's Keytruda succeeds in key bladder cancer trial,http://www.reuters.com/article/merck-co-study-idUSL4N1CR3JS
20161022†7:32AM UTC,BRIEF-Merck's bladder cancer drug meets primary endpoint and stops early,http://www.reuters.com/article/idUSASC09CAC
20161022†7:04AM UTC,Merck's immunotherapy drug succeeds in key bladder cancer trial,http://www.reuters.com/article/merck-co-study-idUSL4N1CR3IL
20161025†10:20PM UTC,U.S. FDA approves Merck's lung cancer drug as first-line treatment,http://www.reuters.com/article/merck-co-fda-idUSL1N1CU20V
20161025†6:14PM UTC,BRIEF-Merck & Co says FDA also approves a labeling update for Keytruda for treatment of patients with metastatic NSCLC,http://www.reuters.com/article/idUSASC09CNH
20161026†12:11PM UTC,UPDATE 3-Merck predicts lung cancer dominance for Keytruda immunotherapy,http://www.reuters.com/article/merck-co-results-idUSL4N1CV3WV
20161026†9:08AM UTC,BRIEF-Merck says aims to be leader in second-line lung cancer,http://www.reuters.com/article/idUSL1N1CV0II
20161026†8:36AM UTC,"Merck quarterly revenue beats, raises full-year forecast",http://www.reuters.com/article/us-merck-co-results-idUSKCN12P1BO
20161026†7:48AM UTC,Merck wins early U.S. approval for Keytruda in untreated lung cancer,http://www.reuters.com/article/us-merck-co-fda-idUSKCN12P06Q
20161026†7:24AM UTC,BRIEF-Merck & Co Q3 non-gaap EPS $1.07,http://www.reuters.com/article/idUSASC09CRZ
20161026†7:03AM UTC,UPDATE 1-Merck wins early U.S. approval for Keytruda in untreated lung cancer,http://www.reuters.com/article/merck-co-fda-idUSL1N1CV09T
20161026†6:54AM UTC,Merck reports 19.6 pct jump in quarterly profit,http://www.reuters.com/article/merck-co-results-idUSL4N1CV3W6
20161027†1:34PM UTC,BRIEF-Merck prices EUR 1 bln debt offering,http://www.reuters.com/article/idUSASC09DAM
20161028†5:19PM UTC,Correction: Fitch Rates Merck's Euro Notes Offering 'A',http://www.reuters.com/article/idUSFit978493
20161028†1:34PM UTC,Fitch Rates Merck's Euro Notes Offering 'A',http://www.reuters.com/article/idUSFit978416
20161108†9:56AM UTC,BRIEF-Merck and Idemitsu sign collaboration agreement in the OLED material business,http://www.reuters.com/article/idUSFWN1D80UT
20161112†8:16AM UTC,BRIEF-Merck Sept quarter net profit 275.4 million rupees,http://www.reuters.com/article/idUSFWN1DC13I
20161115†9:26AM UTC,BRIEF-Merck KGaA says primary endpoint was not met in study population,http://www.reuters.com/article/idUSFWN1DF0Z9
20161115†7:20AM UTC,BRIEF-OpGen collaborates with Merck to develop rapid diagnostics and informatics tools to help combat antimicrobial resistance,http://www.reuters.com/article/idUSFWN1DF0RO
20161116†5:01AM UTC,BRIEF-Merck sees continued price pressure for Erbitux in the EU,http://www.reuters.com/article/idUSF9N1D403X
20161116†2:09AM UTC,UPDATE 1-Merck KGaA expects profit gain from lower development costs,http://www.reuters.com/article/merck-results-idUSL8N1DG0XA
20161116†1:14AM UTC,Merck KGaA lifts profit guidance on lower development costs,http://www.reuters.com/article/merck-results-idUSFWN1DG00W
20161117†8:35AM UTC,BRIEF-Genexine entered into a clinical research collaboration with Merck & Co,http://www.reuters.com/article/idUSFWN1DH0HD
20161118†5:06PM UTC,Gilead loses bid to invalidate two Merck hepatitis C patents ahead of trial,http://www.reuters.com/article/health-gilead-idUSL1N1DI2FM
20161126†7:43AM UTC,BRIEF-Opexa Therapeutics receives notice from Ares Trading S.A. Unit of Merck Serono,http://www.reuters.com/article/idUSFWN1DQ0EP
20161129†7:41AM UTC,BRIEF-FDA grants priority review to Merck's supplemental biologics license application (SBLA) for Keytruda,http://www.reuters.com/article/idUSFWN1DT0EG
20161129†7:19AM UTC,"Gilead, Merck to face off before jury over hepatitis C drug patents",http://www.reuters.com/article/health-idenix-idUSL1N1DT0DD
20161130†8:09AM UTC,"German Merck, Pfizer get FDA priority review for cancer drug",http://www.reuters.com/article/us-merck-kgaa-priorityreview-idUSKBN13O1KL
20161130†8:06AM UTC,"German Merck, Pfizer get FDA priority review for cancer drug",http://www.reuters.com/article/merck-kgaa-priorityreview-idUSF9N1D405H
20161201†11:12AM UTC,BRIEF-Natrix Separations announces collaboration agreements with Merck and Sanofi,http://www.reuters.com/article/idUSASC09L75
20161201†1:54AM UTC,"BRIEF-Evotec, Merck to collaborate on target discovery technologies",http://www.reuters.com/article/idUSL8N1DV0QQ
20161202†7:13PM UTC,Merck wins UK okay for Keytruda in lung cancer after price cut,http://www.reuters.com/article/us-merck-britain-cancer-idUSKBN13R009
20161202†7:01PM UTC,Merck wins UK okay for Keytruda in lung cancer after price cut,http://www.reuters.com/article/merck-britain-cancer-idUSL8N1DW5BU
20161202†11:18AM UTC,BRIEF-Merck CEO says importing drugs from outside U.S. not possible,http://www.reuters.com/article/idUSL1N1DW15K
20161202†11:06AM UTC,BRIEF-Merck CEO Kenneth Frazier on CNBC - We continue to have great hopes for our Alzheimer's drug,http://www.reuters.com/article/idUSFWN1DW0GC
20161202†7:19AM UTC,BRIEF-FDA grants priority review to Merck's application to expand use of Keytruda in hodgkin lymphoma,http://www.reuters.com/article/idUSFWN1DW07Z
20161203†7:56AM UTC,Merck: Gilead should pay for infringing hep C drug patents,http://www.reuters.com/article/usa-ip-idUSL1N1DX0KL
20161206†10:54AM UTC,BRIEF-Merck presents updated findings from Keytruda,http://www.reuters.com/article/idUSFWN1E00LK
20161206†9:35AM UTC,BRIEF-Biothera Pharmaceuticals and Merck further expand research collaboration,http://www.reuters.com/article/idUSFWN1E00KF
20161207†9:03AM UTC,BRIEF-Merck presents updated Keytruda data in small cell lung cancer and mesothelioma,http://www.reuters.com/article/idUSFWN1E10HW
20161208†3:04PM UTC,BRIEF-Merck Canada says Zostavax II showed vaccine effectiveness against shingles in observational effectiveness study,http://www.reuters.com/article/idUSFWN1E210A
20161208†1:19AM UTC,BRIEF-Biocartis launches second liquid biopsy assay co-developed with Merck,http://www.reuters.com/article/idUSFWN1E10TL
20161216†6:22PM UTC,Merck wins $2.54 bln in hepatitis C drug trial against Gilead,http://www.reuters.com/article/gilead-sciences-merck-co-verdict-idUSL1N1EA2CY
20161216†6:01PM UTC,Merck wins $2.54 billion in hepatitis C drug trial against Gilead,http://www.reuters.com/article/us-gilead-sciences-merck-co-verdict-idUSKBN1442U9
20161216†5:59PM UTC,UPDATE 2-Merck wins $2.54 bln in hepatitis C drug trial against Gilead,http://www.reuters.com/article/gilead-sciences-merck-co-verdict-idUSL1N1EA29Q
20161216†4:54PM UTC,Gilead sciences to pay Merck $2.54 bln in hepatitis c royalties -court verdict,http://www.reuters.com/article/gilead-sciences-merck-co-verdict-idUSL1N1EA28S
20161217†7:34AM UTC,BRIEF-Europea's CHMP recommends Merck's Keytruda for lung cancer treatment,http://www.reuters.com/article/idUSFWN1EB0EQ
20161223†1:01AM UTC,BRIEF-Advanced Nano Technologies signs revised supply agreement with Merck KGaA,http://www.reuters.com/article/idUSFWN1EG0Y1
20161231†7:38AM UTC,BRIEF-Merck Ltd says received demand notice from NPPA,http://www.reuters.com/article/idUSFWN1EP064
20170106†4:37PM UTC,BRIEF-Cerveau Technologies signs license agreement with Merck for novel investigational Tau imaging agent,http://www.reuters.com/article/idUSFWN1EV0S8
20170110†8:26AM UTC,BRIEF-Incyte and Merck to advance clinical development program investigating the combination of Epacadostat with Keytruda,http://www.reuters.com/article/idUSFWN1EZ0PC
20170111†6:11PM UTC,FDA accepts Merck application for lung cancer combo therapy,http://www.reuters.com/article/merck-co-cancer-idUSL1N1F0224
20170111†4:19PM UTC,BRIEF-Merck & Co Inc gets FDA acceptance of supplemental biologics license application for Keytruda in combination with chemotherapy,http://www.reuters.com/article/idUSASC09QDC
20170111†4:28AM UTC,BRIEF-Merck and CLEARink Displays sign development agreement,http://www.reuters.com/article/idUSFWN1F007J
20170112†9:56AM UTC,Merck leapfrogs rivals in lung cancer drug combination race,http://www.reuters.com/article/us-merck-co-cancer-idUSKBN14U2T5
20170112†9:52AM UTC,UPDATE 2-Merck leapfrogs rivals in lung cancer drug combination race,http://www.reuters.com/article/merck-co-cancer-idUSL1N1F10AF
20170112†9:50AM UTC,"US STOCKS-Merck lifts Dow; S&P;, Nasdaq flat ahead of Trump speech",http://www.reuters.com/article/usa-stocks-idUSL4N1F13WO
20170112†9:38AM UTC,"BRIEF-Merck KGaA, Darmstadt, Germany licenses four oncology research and development programs from Vertex",http://www.reuters.com/article/idUSFWN1F10L7
20170112†6:54AM UTC,BRIEF-Eli Lilly and Merck expand immuno-oncology collaboration,http://www.reuters.com/article/idUSFWN1F10JX
20170113†5:46PM UTC,"BRIEF-Merck Kgaa, Darmstadt, Germany, Palantir launch new healthcare partnership",http://www.reuters.com/article/idUSFWN1F20V6
20170120†4:08PM UTC,Merck CEO sees Keytruda in pole position in cancer race,http://www.reuters.com/article/us-davos-meeting-merck-co-idUSKBN1532GU
20170121†5:31PM UTC,"Merck, Bristol-Myers agree to settle Keytruda patent suit",http://www.reuters.com/article/merck-settlement-bristolmyers-idUSL1N1FA20V
20170121†5:22PM UTC,"Merck, Bristol-Myers agree to settle Keytruda patent suit",http://www.reuters.com/article/us-merck-settlement-bristolmyers-idUSKBN1542VO
20170121†5:20PM UTC,"UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit",http://www.reuters.com/article/merck-settlement-bristolmyers-idUSL4N1FA5DA
20170121†4:53PM UTC,"Bristol-Myers lung cancer delay slams shares, keeps Merck in lead",http://www.reuters.com/article/us-bristol-myers-cancer-idUSKBN1542CR
20170121†4:52PM UTC,"UPDATE 1-Bristol-Myers lung cancer delay slams shares, keeps Merck in lead",http://www.reuters.com/article/bristol-myers-cancer-idUSL1N1FA1R9
20170121†4:23PM UTC,"Merck, Bristol-Myers agree to settle Keytruda patent suit",http://www.reuters.com/article/merck-settlement-bristolmyers-idUSL4N1FA5BU
20170121†4:11PM UTC,BRIEF-Bristol-Myers squibb and Ono pharmaceutical enters license agreement with Merck,http://www.reuters.com/article/idUSFWN1FA0SV
20170121†4:06PM UTC,BRIEF-Merck announces license agreement resolving Keytruda patent litigation,http://www.reuters.com/article/idUSFWN1FA0PO
20170124†8:46AM UTC,"BRIEF-Merck KGaA, Darmstadt, Germany, announces research collaboration with Domain Therapeutics in immuno-oncology",http://www.reuters.com/article/idUSFWN1FD0IT
20170124†5:40AM UTC,BRIEF-Ono Pharmaceutical reaches settlement with Merck and signs license agreement,http://www.reuters.com/article/idUSL4N1FD3NV
20170128†2:08PM UTC,Merck reveals seven years of its U.S. drug price increase history,http://www.reuters.com/article/us-merck-co-drugpricing-idUSKBN15B24D
20170128†2:05PM UTC,Merck reveals 7 years of its U.S. drug price increase history,http://www.reuters.com/article/merck-co-drugpricing-idUSL1N1FH142
20170203†12:20PM UTC,Merck 2017 forecast reassuring; full-speed ahead with Keytruda,http://www.reuters.com/article/us-merck-co-results-idUSKBN15H19N
20170203†12:18PM UTC,UPDATE 3-Merck 2017 forecast reassuring; full-speed ahead with Keytruda,http://www.reuters.com/article/merck-co-results-idUSL4N1FN2MW
20170203†9:11AM UTC,BRIEF-Merck CEO says business development a priority,http://www.reuters.com/article/idUSL1N1FN0LT
20170203†6:56AM UTC,Merck's quarterly sales slip 1 pct,http://www.reuters.com/article/merck-co-results-idUSL4N1FN2M7
20170203†6:53AM UTC,BRIEF-Merck Q4 adjusted earnings per share $0.89,http://www.reuters.com/article/idUSASB0AY60
20170203†10:01AM UTC,Merck's profit soars,http://www.reuters.com/news/video/videoStory?storyID=125910178
20170204†6:49AM UTC,BRIEF-Merck says FDA accepts two SBLAs for Keytruda,http://www.reuters.com/article/idUSASB0AYFF
20170207†7:58AM UTC,"BRIEF-Immunovaccine says Princess Margaret Cancer Centre to conduct Phase 2 clinical trial to evaluate use of co, Merck's combination of immunotherapies",http://www.reuters.com/article/idUSL5N1FR31A
20170208†9:40PM UTC,BRIEF-Merck announces stoppage of work by a section of workers at Goa,http://www.reuters.com/article/idUSFWN1FS114
20170214†5:14PM UTC,BRIEF-Capital World Investors reports 5.1 pct passive stake in Merck & Co as on Dec 30 - SEC Filing,http://www.reuters.com/article/idUSFWN1FY10Z
20170215†6:48PM UTC,Merck stopping late stage study as another Alzheimer's drug fails,http://www.reuters.com/article/us-health-alzheimers-merck-co-idUSKBN15T31M
20170215†6:46PM UTC,UPDATE 1-Merck stopping late stage study as another Alzheimer's drug fails,http://www.reuters.com/article/health-alzheimers-merck-co-idUSL4N1FZ6LQ
20170215†6:04PM UTC,Merck to halt study of mild to moderate Alzheimer's drug,http://www.reuters.com/article/health-alzheimers-merck-co-idUSL4N1FZ6GZ
20170215†5:26PM UTC,BRIEF-Merck announces Epoch study of Verubecestat,http://www.reuters.com/article/idUSFWN1FZ1A5
20170215†4:41PM UTC,BRIEF-Merck's doravirine meets primary efficacy endpoint in pivotal phase 3 trial,http://www.reuters.com/article/idUSASB0B08O
20170224†5:53PM UTC,BRIEF-Merck to record $2.9 bln impairment charge related to uprifosbuvir program - SEC filing,http://www.reuters.com/article/brief-merck-to-record-29-bln-impairment-idUSFWN1G819H
20170224†1:53PM UTC,Merck drug prevents serious infection after marrow transplant: study,http://www.reuters.com/article/us-merck-co-pharmaceuticals-antiviral-idUSKBN1622C9
20170224†1:51PM UTC,Merck drug prevents serious infection after marrow transplant -study,http://www.reuters.com/article/merck-co-pharmaceuticals-antiviral-idUSL1N1G81KQ
20170224†9:20AM UTC,"BRIEF-Biothera Pharmaceuticals initiates patient dosing in phase 2 trial investigating Imprime PGG, Merck's Keytruda",http://www.reuters.com/article/brief-biothera-pharmaceuticals-initiates-idUSASB0B1YA
20170225†4:04PM UTC,BRIEF-In first phase 3 trial Merck's virus vaccine (V2120 reduced the incidence of confirmed herpes zoster cases,http://www.reuters.com/article/brief-in-first-phase-3-trial-mercks-viru-idUSASB0B2AK
20170228†6:58AM UTC,BRIEF-Merck Dec-qtr profit rises about 25 pct,http://www.reuters.com/article/brief-merck-dec-qtr-profit-rises-about-idUSFWN1GC0GN
20170301†1:48PM UTC,BRIEF-Merck sets quarterly dividend of $0.47/share,http://www.reuters.com/article/brief-merck-sets-quarterly-dividend-of-idUSFWN1GD15R
20170301†11:51AM UTC,UK rejects Merck's Keytruda as initial treatment for lung cancer,http://www.reuters.com/article/us-merck-britain-cancer-idUSKBN167228
20170301†11:40AM UTC,UK rejects Merck's Keytruda as initial treatment for lung cancer,http://www.reuters.com/article/merck-britain-cancer-idUSL5N1GD6T2
20170301†7:42AM UTC,"Merck KGaA, Pfizer get priority review for bladder cancer drug",http://www.reuters.com/article/us-merck-pharmaceuticals-pfizer-idUSKBN1671F6
20170301†7:38AM UTC,"Merck KGaA, Pfizer get priority review for bladder cancer drug",http://www.reuters.com/article/merck-pharmaceuticals-pfizer-idUSFWN1GD0J5
20170303†9:19AM UTC,BRIEF-Beigene says expects decision in Q1 of 2017 from partner Merck KGaA on BGB-283,http://www.reuters.com/article/brief-beigene-says-expects-decision-in-q-idUSFWN1GF0M6
20170303†2:04AM UTC,BRIEF-Merck says NICE expands a positive recommendation for Erbitux,http://www.reuters.com/article/brief-merck-says-nice-expands-a-positive-idUSFWN1GE1DZ
20170307†8:31AM UTC,BRIEF-Merck and pfizer announce U.S. Fda and EMA filing acceptances,http://www.reuters.com/article/brief-merck-and-pfizer-announce-us-fda-a-idUSFWN1GJ0FX
20170310†9:22AM UTC,Development costs to keep Merck KGaA profit flat this year,http://www.reuters.com/article/us-merck-results-idUSKBN16G0IS
20170310†9:20AM UTC,UPDATE 2-Development costs to keep Merck KGaA profit flat this year,http://www.reuters.com/article/merck-results-idUSL5N1GM0S1
20170310†6:12AM UTC,Germany's Merck well advanced in talks to sell biosimilars unit,http://www.reuters.com/article/us-merck-results-biosimilars-idUSKBN16G1E6
20170310†6:04AM UTC,Germany's Merck well advanced in talks to sell biosimilars unit,http://www.reuters.com/article/merck-results-biosimilars-idUSF9N1GF008
20170310†1:17AM UTC,Merck KGaA predicts stable adj EBITDA in 2017,http://www.reuters.com/article/merck-results-idUSFWN1GL0U6
20170311†10:36AM UTC,BRIEF-Merck KGaA announces release of two fertility technologies products,http://www.reuters.com/article/brief-merck-kgaa-announces-release-of-tw-idUSFWN1GN088
20170223†12:46PM UTC,"BRIEF-Merck canada says effective Feb 28, Ontario to reimburse Zepatier, will be followed by British Columbia on March 21",http://www.reuters.com/article/brief-merck-canada-says-effective-feb-idUSFWN1G70YN
20170418†4:28PM UTC,BRIEF-Aurinia completes licensing deal with Merck Animal Health,http://www.reuters.com/article/brief-aurinia-completes-licensing-deal-w/brief-aurinia-completes-licensing-deal-with-merck-animal-health-idUSFWN1HP09S
20170524†6:16PM UTC,"FDA clears Merck's Keytruda based on cancer genetics, not location",http://www.reuters.com/article/us-merck-co-fda/fda-clears-mercks-keytruda-based-on-cancer-genetics-not-location-idUSKBN18J2T9
20170524†6:01PM UTC,"UPDATE 2-FDA clears Merck's Keytruda based on cancer genetics, not location",http://www.reuters.com/article/merck-co-fda/update-2-fda-clears-mercks-keytruda-based-on-cancer-genetics-not-location-idUSL4N1IP541
20170524†4:52PM UTC,FDA clears Merck's Keytruda for cancer patients with certain biomarkers,http://www.reuters.com/article/merck-co-fda/fda-clears-mercks-keytruda-for-cancer-patients-with-certain-biomarkers-idUSL1N1IP263
20170524†4:45PM UTC,UK competition watchdog accuses Merck of obstructing biosimilars,http://www.reuters.com/article/merck-co-britain-remicade/uk-competition-watchdog-accuses-merck-of-obstructing-biosimilars-idUSL1N1IP25B
20170524†3:33PM UTC,FDA clears Merck's Keytruda for cancer patients with certain biomarkers,http://www.reuters.com/article/merck-co-fda/fda-clears-mercks-keytruda-for-cancer-patients-with-certain-biomarkers-idUSL4N1IP538
20170524†1:56PM UTC,BRIEF-Merck sets quarterly dividend of $0.47 per share,http://www.reuters.com/article/brief-merck-sets-quarterly-dividend-of-0/brief-merck-sets-quarterly-dividend-of-0-47-per-share-idUSFWN1IP0OP
20170524†8:14AM UTC,UK competition watchdog accuses Merck of obstructing biosimilars,http://www.reuters.com/article/us-merck-co-britain-remicade/uk-competition-watchdog-accuses-merck-of-obstructing-biosimilars-idUSKBN18J12Z
20170524†8:13AM UTC,UPDATE 2-UK competition watchdog accuses Merck of obstructing biosimilars,http://www.reuters.com/article/merck-co-britain-remicade/update-2-uk-competition-watchdog-accuses-merck-of-obstructing-biosimilars-idUSL8N1IP2I8
20170524†7:17AM UTC,BRIEF-FDA grants priority review to Merck's supplemental marketing application for Keytruda,http://www.reuters.com/article/brief-fda-grants-priority-review-to-merc/brief-fda-grants-priority-review-to-mercks-supplemental-marketing-application-for-keytruda-idUSASA09QWM
20170524†5:01AM UTC,UK competition watchdog accuses Merck of obstructing biosimilars,http://www.reuters.com/article/merck-co-britain-remicade/uk-competition-watchdog-accuses-merck-of-obstructing-biosimilars-idUSL8N1IP2GD
20170524†4:56AM UTC,BRIEF-Merck unit says confident it complied with UK competition law,http://www.reuters.com/article/brief-merck-unit-says-confident-it-compl/brief-merck-unit-says-confident-it-complied-with-uk-competition-law-idUSL8N1IP2FA
20170524†4:43AM UTC,BRIEF-UK's CMA issues statement of objections to Merck's unit,http://www.reuters.com/article/brief-uks-cma-issues-statement-of-object/brief-uks-cma-issues-statement-of-objections-to-mercks-unit-idUSFWN1IP078
20170804†5:28AM UTC,UPDATE 1-Germany's Merck reshuffles board to tackle chemicals competition,http://www.reuters.com/article/merckkgaa-results/update-1-germanys-merck-reshuffles-board-to-tackle-chemicals-competition-idUSL5N1KP1IV
20170804†4:30AM UTC,BRIEF-Merck KGaA to decide over next few mths over U.S. filing of cladribine,http://www.reuters.com/article/brief-merck-kgaa-to-decide-over-next-few/brief-merck-kgaa-to-decide-over-next-few-mths-over-u-s-filing-of-cladribine-idUSL5N1KP2D7
20170804†4:27AM UTC,BRIEF-Merck KGaA says patent office to grant patent application for Crispr,http://www.reuters.com/article/brief-merck-kgaa-says-patent-office-to-g/brief-merck-kgaa-says-patent-office-to-grant-patent-application-for-crispr-idUSFWN1KP0EE
20170804†1:25AM UTC,Merck KGaA's adj profit lower on competition in liquid crystals,http://www.reuters.com/article/merckkgaa-results/merck-kgaas-adj-profit-lower-on-competition-in-liquid-crystals-idUSFWN1KP05T
20170909†5:27PM UTC,Germany's Merck hires JP Morgan to sell consumer health,http://www.reuters.com/article/us-merckkgaa-jpmorgan-consumerhealth/germanys-merck-hires-jp-morgan-to-sell-consumer-health-idUSKCN1BJ2BU
20170909†4:34PM UTC,Germany's Merck hires JP Morgan to sell consumer health,http://www.reuters.com/article/us-health-cancer-merck-co/germanys-merck-hires-jp-morgan-to-sell-consumer-health-idUSKCN1BI30D
20170909†4:31PM UTC,UPDATE 1-Germany's Merck hires JP Morgan to sell consumer health,http://www.reuters.com/article/merckkgaa-jpmorgan-consumerhealth/update-1-germanys-merck-hires-jp-morgan-to-sell-consumer-health-idUSL8N1LP4ZC
20170909†2:06PM UTC,Germany's Merck hires JP Morgan to advise on consumer health review,http://www.reuters.com/article/merckkgaa-jpmorgan-consumerhealth/germanys-merck-hires-jp-morgan-to-advise-on-consumer-health-review-idUSL8N1LP4WY
20170909†6:18AM UTC,"UPDATE 1-Merck's immunotherapy, chemo mix shows extended lung cancer gains",http://www.reuters.com/article/health-cancer-merck-co/update-1-mercks-immunotherapy-chemo-mix-shows-extended-lung-cancer-gains-idUSL8N1LP275
20170315†6:26PM UTC,Merck's Keytruda wins FDA nod for treating blood cancer,http://www.reuters.com/article/us-merck-co-fda-idUSKBN16L2QZ
20170315†6:22PM UTC,Merck's Keytruda wins FDA nod for treating blood cancer,http://www.reuters.com/article/merck-co-fda-idUSL3N1GR5C9
20170315†5:18PM UTC,BRIEF-Merck says FDA approves keytruda for treatment of patients with refractory classical hodgkin lymphoma,http://www.reuters.com/article/brief-merck-says-fda-approves-keytruda-f-idUSASB0B5I0
20170315†4:47PM UTC,BRIEF-Merck provides update on supplemental biologics license application (sbla) for KEYTRUDA¬Æ (pembrolizumab),http://www.reuters.com/article/brief-merck-provides-update-on-supplemen-idUSASB0B5HQ
20170323†4:35PM UTC,U.S. appeals court revives Fosamax warning claims against Merck,http://www.reuters.com/article/merck-fosamax-idUSL2N1GZ1UU
20170323†12:27PM UTC,Merck must face renewed Fosamax warning claims: U.S. appeals court,http://www.reuters.com/article/us-merck-fosamax-idUSKBN16T1JT
20170323†12:24PM UTC,UPDATE 3-Merck must face renewed Fosamax warning claims -U.S. appeals court,http://www.reuters.com/article/merck-fosamax-idUSL2N1GZ0FW
20170323†8:48AM UTC,U.S. appeals court revives Fosamax warning claims against Merck,http://www.reuters.com/article/merck-fosamax-idUSL2N1GZ0FE
20170323†8:33AM UTC,BRIEF-U.S. appeals court revives claims against Merck over Fosamax,http://www.reuters.com/article/brief-us-appeals-court-revives-claims-ag-idUSFWN1GZ0I1
20170324†5:23PM UTC,Merck employee's relative settles SEC insider trading case,http://www.reuters.com/article/securities-insidertrading-idUSL2N1H025H
20170324†3:11PM UTC,"FDA approves Pfizer, German Merck immunotherapy for skin cancer",http://www.reuters.com/article/us-pfizer-merck-fda-idUSKBN16U2PG
20170324†3:10PM UTC,"FDA approves Pfizer, German Merck immunotherapy for skin cancer",http://www.reuters.com/article/pfizer-merck-fda-idUSL2N1H01KV
20170325†9:14AM UTC,BRIEF-European Medicines Agency's CHMP recommends approval of Merck's keytruda,http://www.reuters.com/article/brief-european-medicines-agencys-chmp-re-idUSFWN1H10AO
20170401†7:11AM UTC,BRIEF-Incyte and Merck provide additional details on previously announced collaboration,http://www.reuters.com/article/brief-incyte-and-merck-provide-additiona-idUSFWN1H80IK
20170407†5:16PM UTC,Merck seeks to reverse ruling reviving Fosamax injury lawsuits,http://www.reuters.com/article/product-merck/merck-seeks-to-reverse-ruling-reviving-fosamax-injury-lawsuits-idUSL2N1HE26W
20170408†9:28AM UTC,UPDATE 2-FDA rejects Merck's bid to add heart data on diabetes drug labels,http://www.reuters.com/article/merck-co-fda/update-2-fda-rejects-mercks-bid-to-add-heart-data-on-diabetes-drug-labels-idUSL3N1HF47U
20170408†8:26AM UTC,FDA rejects Merck's application to add heart data on diabetes drug labels,http://www.reuters.com/article/us-merck-co-fda/fda-rejects-mercks-application-to-add-heart-data-on-diabetes-drug-labels-idUSKBN1791TG
20170408†7:55AM UTC,FDA rejects Merck's application to add heart safety data on diabetes drug labels,http://www.reuters.com/article/merck-co-fda/fda-rejects-mercks-application-to-add-heart-safety-data-on-diabetes-drug-labels-idUSL3N1HF45M
20170408†7:43AM UTC,BRIEF-Merck receives complete response letter from the FDA for Tecos study with sitagliptin,http://www.reuters.com/article/brief-merck-receives-complete-response-l/brief-merck-receives-complete-response-letter-from-the-fda-for-tecos-study-with-sitagliptin-idUSASB0B8YT
20170411†5:01PM UTC,BRIEF-Merck & Co Inc's CEO's 2016 total compensation was $21.8 mln,http://www.reuters.com/article/brief-merck-co-incs-ceos-2016-total-comp/brief-merck-co-incs-ceos-2016-total-compensation-was-21-8-mln-idUSFWN1HI0K9
20170411†4:57PM UTC,BRIEF-Merck says board of directors to have 13 members,http://www.reuters.com/article/brief-merck-says-board-of-directors-to-h/brief-merck-says-board-of-directors-to-have-13-members-idUSFWN1HI0K6
20170412†1:54AM UTC,BRIEF-KYORIN Holdings unit gets license from Merck for drug KRP-114V,http://www.reuters.com/article/idUSL3N1HJ27Z
20170419†5:29AM UTC,German Merck aims to role out child formula for schistosomiasis drug,http://www.reuters.com/article/us-health-tropical-merck/german-merck-aims-to-role-out-child-formula-for-schistosomiasis-drug-idUSKBN17K0X2
20170419†5:21AM UTC,German Merck aims to role out child formula for schistosomiasis drug,http://www.reuters.com/article/health-tropical-merck/german-merck-aims-to-role-out-child-formula-for-schistosomiasis-drug-idUSL8N1HQ1F1
20170422†10:36AM UTC,BRIEF-Merck reports results from real-world observational study in U.S. Veterans Affairs System evaluating use of ZEPATIER,http://www.reuters.com/article/brief-merck-reports-results-from-real-wo/brief-merck-reports-results-from-real-world-observational-study-in-u-s-veterans-affairs-system-evaluating-use-of-zepatier-idUSFWN1HT0K1
20170422†8:31AM UTC,BRIEF-Atara bio announces collaboration with Merck,http://www.reuters.com/article/brief-atara-bio-announces-collaboration/brief-atara-bio-announces-collaboration-with-merck-idUSFWN1HT07P
20170425†5:37PM UTC,Merck to pay PDL BioPharma $19.5 million to settle patent lawsuit,http://www.reuters.com/article/ip-merck/merck-to-pay-pdl-biopharma-19-5-million-to-settle-patent-lawsuit-idUSL1N1HW1N0
20170425†5:18PM UTC,"Fresenius snaps up Akorn, Merck KGaA's biosimilars in separate deals",http://www.reuters.com/article/akorn-ma-fresenius/fresenius-snaps-up-akorn-merck-kgaas-biosimilars-in-separate-deals-idUSF9N0NT01F
20170425†7:14AM UTC,BRIEF-PDL BioPharma announces settlement of Keytruda lawsuit with Merck,http://www.reuters.com/article/brief-pdl-biopharma-announces-settlement/brief-pdl-biopharma-announces-settlement-of-keytruda-lawsuit-with-merck-idUSFWN1HW0C6
20170426†9:22AM UTC,BRIEF-Fresenius sees no change in relationship of Merck KGaA's unit with partner Dr Reddy's,http://www.reuters.com/article/brief-fresenius-sees-no-change-in-relati/brief-fresenius-sees-no-change-in-relationship-of-merck-kgaas-unit-with-partner-dr-reddys-idUSL8N1HX49Z
20170426†4:17AM UTC,"Fresenius picks up M&A; pace with Akorn, Merck KGaA deals",http://www.reuters.com/article/us-akorn-m-a-fresenius/fresenius-picks-up-ma-pace-with-akorn-merck-kgaa-deals-idUSKBN17Q29Q
20170426†4:14AM UTC,"UPDATE 2-Fresenius picks up M&A; pace with Akorn, Merck KGaA deals",http://www.reuters.com/article/akorn-ma-fresenius/update-2-fresenius-picks-up-ma-pace-with-akorn-merck-kgaa-deals-idUSL8N1HW6JK
20170427†5:10PM UTC,"Merck cholesterol drug Vytorin faces competition from Impax, Teva generics",http://www.reuters.com/article/us-u-s-health-merck-vytorin/merck-cholesterol-drug-vytorin-faces-competition-from-impax-teva-generics-idUSKBN17S2RQ
20170427†5:08PM UTC,"UPDATE 1-Merck cholesterol drug Vytorin faces competition from Impax, Teva generics",http://www.reuters.com/article/ushealth-merck-vytorin/update-1-merck-cholesterol-drug-vytorin-faces-competition-from-impax-teva-generics-idUSL4N1HY5Z3
20170427†4:12PM UTC,FDA approves Impax generic of Merck's cholesterol drug Vytorin,http://www.reuters.com/article/ushealth-merck-vytorin/fda-approves-impax-generic-of-mercks-cholesterol-drug-vytorin-idUSL1N1HX1YY
20170428†7:16AM UTC,BRIEF-Syndax Pharmaceuticals announces expansion ongoing phase 2 collaboration with Merck unit,http://www.reuters.com/article/brief-syndax-pharmaceuticals-announces-e/brief-syndax-pharmaceuticals-announces-expansion-ongoing-phase-2-collaboration-with-merck-unit-idUSFWN1HZ0OL
20170429†7:11AM UTC,UPDATE 1-Merck KGaA says dominance in liquid crystals could be at risk,http://www.reuters.com/article/merckkgaa-liquidcrystals/update-1-merck-kgaa-says-dominance-in-liquid-crystals-could-be-at-risk-idUSL8N1I02X3
20170429†4:51AM UTC,Merck KGaA says dominance in liquid crystals could be at risk,http://www.reuters.com/article/merckkgaa-liquidcrystals/merck-kgaa-says-dominance-in-liquid-crystals-could-be-at-risk-idUSF9N0NT01I
20170503†4:11PM UTC,Merck eyes key cancer drug growth as others lose patent protection,http://www.reuters.com/article/merck-co-results/merck-eyes-key-cancer-drug-growth-as-others-lose-patent-protection-idUSL1N1I41Q5
20170503†11:02AM UTC,Merck eyes key cancer drug growth as others lose patent protection,http://www.reuters.com/article/us-merck-co-results/merck-eyes-key-cancer-drug-growth-as-others-lose-patent-protection-idUSKBN17Y15D
20170503†10:57AM UTC,UPDATE 3-Merck eyes key cancer drug growth as others lose patent protection,http://www.reuters.com/article/merck-co-results/update-3-merck-eyes-key-cancer-drug-growth-as-others-lose-patent-protection-idUSL4N1I4301
20170503†9:02AM UTC,BRIEF-Merck expecting somewhat slower animal health growth,http://www.reuters.com/article/brief-merck-expecting-somewhat-slower-an/brief-merck-expecting-somewhat-slower-animal-health-growth-idUSL1N1I40EA
20170503†6:52AM UTC,Merck's revenue rises 1.3 pct,http://www.reuters.com/article/merck-co-results/mercks-revenue-rises-1-3-pct-idUSL4N1I42ZP
20170505†11:41AM UTC,BRIEF-Cerveau Technologies says finalization of a clinical supply agreement with Merck,http://www.reuters.com/article/brief-cerveau-technologies-says-finaliza/brief-cerveau-technologies-says-finalization-of-a-clinical-supply-agreement-with-merck-idUSASA09N3K
20170510†8:05AM UTC,BRIEF-Merck KGaA acquires Grzybowski Scientific Inventions,http://www.reuters.com/article/brief-merck-kgaa-acquires-grzybowski-sci/brief-merck-kgaa-acquires-grzybowski-scientific-inventions-idUSFWN1IB0J8
20170511†6:12PM UTC,UPDATE 2-U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer,http://www.reuters.com/article/merck-co-lungcancer/update-2-u-s-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-idUSL1N1IC28N
20170511†6:05PM UTC,BRIEF-U.S. FDA approves Merck's Keytruda chemo combo for lung cancer,http://www.reuters.com/article/brief-us-fda-approves-mercks-keytruda-ch/brief-u-s-fda-approves-mercks-keytruda-chemo-combo-for-lung-cancer-idUSASA09OWZ
20170511†5:39PM UTC,U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer,http://www.reuters.com/article/merck-co-lungcancer/u-s-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-idUSL1N1IC287
20170511†11:43AM UTC,BRIEF-European Commission grants approval for Merck's new Pergoveris Pen for fertility treatment,http://www.reuters.com/article/brief-european-commission-grants-approva/brief-european-commission-grants-approval-for-mercks-new-pergoveris-pen-for-fertility-treatment-idUSFWN1IC10A
20170511†9:12AM UTC,BRIEF-Merck KGaA's Pergoveris fertility pen gets EU approval,http://www.reuters.com/article/brief-merck-kgaas-pergoveris-fertility-p/brief-merck-kgaas-pergoveris-fertility-pen-gets-eu-approval-idUSL8N1IC5UY
20170511†6:34AM UTC,BRIEF-Oncosec announces clinical collaboration with Merck,http://www.reuters.com/article/brief-oncosec-announces-clinical-collabo/brief-oncosec-announces-clinical-collaboration-with-merck-idUSFWN1IC0H1
20170512†12:13PM UTC,U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer,http://www.reuters.com/article/us-merck-co-lungcancer/u-s-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-idUSKBN1862Y2
20170513†10:21AM UTC,"Vaccine alliance says 300,000 doses of Merck's Ebola shot available for emergencies",http://www.reuters.com/article/us-health-ebola-vaccine/vaccine-alliance-says-300000-doses-of-mercks-ebola-shot-available-for-emergencies-idUSKBN1881ZF
20170513†10:20AM UTC,"Vaccine alliance says 300,000 doses of Merck's Ebola shot available for emergencies",http://www.reuters.com/article/health-ebola-vaccine/vaccine-alliance-says-300000-doses-of-mercks-ebola-shot-available-for-emergencies-idUSL8N1IE5B7
20170517†8:31PM UTC,"Merck, Upsher-Smith to pay $60 mln in 'pay-for-delay' drug case",http://www.reuters.com/article/merck-co-lawsuit/merck-upsher-smith-to-pay-60-mln-in-pay-for-delay-drug-case-idUSL2N1IJ00T
20170517†6:31PM UTC,"Merck, Upsher-Smith to pay $60 million in 'pay-for-delay' drug case",http://www.reuters.com/article/us-merck-co-lawsuit/merck-upsher-smith-to-pay-60-million-in-pay-for-delay-drug-case-idUSKCN18C2RW
20170517†6:22PM UTC,"Merck, Upsher-Smith to pay $60 mln in 'pay-for-delay' drug case",http://www.reuters.com/article/merck-co-lawsuit/merck-upsher-smith-to-pay-60-mln-in-pay-for-delay-drug-case-idUSL2N1II1ZT
20170517†8:40AM UTC,Merck KGaA considers making divisions legally separate subsidiaries,http://www.reuters.com/article/us-merck-restructuring/merck-kgaa-considers-making-divisions-legally-separate-subsidiaries-idUSKCN18C12G
20170517†8:37AM UTC,UPDATE 1-Merck KGaA considers making divisions legally separate subsidiaries,http://www.reuters.com/article/merck-restructuring/update-1-merck-kgaa-considers-making-divisions-legally-separate-subsidiaries-idUSL8N1II31L
20170517†6:05AM UTC,Merck KGaA considers transferring its units into subsidiaries,http://www.reuters.com/article/merck-restructuring/merck-kgaa-considers-transferring-its-units-into-subsidiaries-idUSFWN1II07W
20170518†7:05PM UTC,Merck says test shows Keytruda improves survival for bladder cancer patients,http://www.reuters.com/article/us-health-cancer-bladder/merck-says-test-shows-keytruda-improves-survival-for-bladder-cancer-patients-idUSKCN18D2Q8
20170518†6:55PM UTC,UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients,http://www.reuters.com/article/health-cancer-bladder/update-1-merck-says-test-shows-keytruda-improves-survival-for-bladder-cancer-patients-idUSL2N1IJ24U
20170518†5:24PM UTC,"Merck, Incyte immunotherapy combination effective in lung cancer study",http://www.reuters.com/article/us-health-cancer-merck-incyte/merck-incyte-immunotherapy-combination-effective-in-lung-cancer-study-idUSKCN18D2QI
20170518†5:20PM UTC,"UPDATE 1-Merck, Incyte immunotherapy combination effective in lung cancer study",http://www.reuters.com/article/health-cancer-merck-incyte/update-1-merck-incyte-immunotherapy-combination-effective-in-lung-cancer-study-idUSL2N1IJ1XU
20170518†5:00PM UTC,"Merck, Incyte immunotherapy combination effective in lung cancer study",http://www.reuters.com/article/health-cancer-merck-incyte/merck-incyte-immunotherapy-combination-effective-in-lung-cancer-study-idUSL2N1IJ1QC
20170518†5:00PM UTC,Merck says test shows Keytruda improves survival for bladder cancer patients,http://www.reuters.com/article/health-cancer-bladder/merck-says-test-shows-keytruda-improves-survival-for-bladder-cancer-patients-idUSL1N1IE1ZK
20170518†1:03PM UTC,BRIEF-Merck's Glucophage SR receives label extension for patients at high risk of type 2 diabetes in UK,http://www.reuters.com/article/brief-mercks-glucophage-sr-receives-labe/brief-mercks-glucophage-sr-receives-label-extension-for-patients-at-high-risk-of-type-2-diabetes-in-uk-idUSASM000BI6
20170518†12:36PM UTC,BRIEF-German Merck's Glucophage receives label extension in UK,http://www.reuters.com/article/brief-german-mercks-glucophage-receives/brief-german-mercks-glucophage-receives-label-extension-in-uk-idUSFWN1IJ0J2
20170518†9:12AM UTC,BRIEF-Aduro Biotech announces clinical collaboration with Merck,http://www.reuters.com/article/brief-aduro-biotech-announces-clinical-c/brief-aduro-biotech-announces-clinical-collaboration-with-merck-idUSB8N1HP00J
20170520†8:03AM UTC,BRIEF-Merck receives CHMP positive opinion recommending approval of isentress,http://www.reuters.com/article/brief-merck-receives-chmp-positive-opini/brief-merck-receives-chmp-positive-opinion-recommending-approval-of-isentress-idUSASA09QN9
20170523†11:37AM UTC,BRIEF-Merck announces presentation of phase 2 results for MK-7264,http://www.reuters.com/article/brief-merck-announces-presentation-of-ph/brief-merck-announces-presentation-of-phase-2-results-for-mk-7264-idUSFWN1IO0CW
20170526†2:08PM UTC,BRIEF-Optum and Merck collaborate to advance value-based contracting of pharmaceuticals,http://www.reuters.com/article/brief-optum-and-merck-collaborate-to-adv/brief-optum-and-merck-collaborate-to-advance-value-based-contracting-of-pharmaceuticals-idUSFWN1IR0K5
20170526†8:10AM UTC,BRIEF-Merck enters exclusive worldwide license agreement with Teijin Pharma,http://www.reuters.com/article/brief-merck-enters-exclusive-worldwide-l/brief-merck-enters-exclusive-worldwide-license-agreement-with-teijin-pharma-idUSFWN1IR0AF
20170531†7:01PM UTC,Britain backs first-line use of Merck's Keytruda under cancer fund,http://www.reuters.com/article/merck-co-britain-cancer/britain-backs-first-line-use-of-mercks-keytruda-under-cancer-fund-idUSL8N1IW301
20170531†7:15AM UTC,BRIEF-Merck receives FDA approval of ISENTRESS HD for treatment of HIV-1 infection in appropriate patients,http://www.reuters.com/article/brief-merck-receives-fda-approval-of-ise/brief-merck-receives-fda-approval-of-isentress-hd-for-treatment-of-hiv-1-infection-in-appropriate-patients-idUSASA09RS9
20170603†7:42AM UTC,BRIEF-Merck announces updated longer-term overall survival data from evaluating keytruda,http://www.reuters.com/article/brief-merck-announces-updated-longer-ter/brief-merck-announces-updated-longer-term-overall-survival-data-from-evaluating-keytruda-idUSFWN1IZ0AD
20170605†7:24AM UTC,BRIEF-Merck KGaA enters immuno-oncology collaboration with F-Star,http://www.reuters.com/article/brief-merck-kgaa-enters-immuno-oncology/brief-merck-kgaa-enters-immuno-oncology-collaboration-with-f-star-idUSFWN1IZ0L9
20170606†7:31AM UTC,BRIEF-Merck presents positive mid-stage data from breast cancer combo therapy,http://www.reuters.com/article/brief-merck-presents-positive-mid-stage/brief-merck-presents-positive-mid-stage-data-from-breast-cancer-combo-therapy-idUSASA09SML
20170606†7:09AM UTC,BRIEF-Incyte Corp updates on Echo-202 trial of Incyte‚Äôs Epacadostat in combination with Merck‚Äôs Keytruda,http://www.reuters.com/article/brief-incyte-corp-updates-on-echo-202-tr/brief-incyte-corp-updates-on-echo-202-trial-of-incytes-epacadostat-in-combination-with-mercks-keytruda-idUSASA09SMD
20170613†5:34PM UTC,Merck to pause two late-stage studies testing Keytruda in myeloma,http://www.reuters.com/article/us-merck-keytruda/merck-to-pause-two-late-stage-studies-testing-keytruda-in-myeloma-idUSKBN1932GG
20170613†5:18PM UTC,UPDATE 1-Merck to pause two late-stage studies testing Keytruda in myeloma,http://www.reuters.com/article/merck-keytruda/update-1-merck-to-pause-two-late-stage-studies-testing-keytruda-in-myeloma-idUSL3N1J951E
20170613†4:59PM UTC,CORRECTED-Merck to pause two late-stage studies testing Keytruda in myeloma,http://www.reuters.com/article/merck-keytruda/corrected-merck-to-pause-two-late-stage-studies-testing-keytruda-in-myeloma-idUSL3N1J9506
20170613†4:21PM UTC,BRIEF-Merck provides update on multiple myeloma studies keynote-183 and 185 of keytruda in combination with other therapies,http://www.reuters.com/article/brief-merck-provides-update-on-multiple/brief-merck-provides-update-on-multiple-myeloma-studies-keynote-183-and-185-of-keytruda-in-combination-with-other-therapies-idUSASA09TK8
20170614†2:00AM UTC,"CORRECTED-Merck KGaA: 2 bln eur pipeline potential driven by cancer, MS drugs",http://www.reuters.com/article/merck-development/corrected-merck-kgaa-2-bln-eur-pipeline-potential-driven-by-cancer-ms-drugs-idUSL8N1J94BL
20170615†11:52AM UTC,BRIEF-Merck awarded first CRISPR patent by Australian patent office,http://www.reuters.com/article/brief-merck-awarded-first-crispr-patent/brief-merck-awarded-first-crispr-patent-by-australian-patent-office-idUSL8N1JB53F
20170616†2:49PM UTC,"BRIEF-Human Longevity says agreement with Merck KGaA, Darmstadt, Germany to engage in cancer biomarker discovery in advanced melanoma",http://www.reuters.com/article/brief-human-longevity-says-agreement-wit/brief-human-longevity-says-agreement-with-merck-kgaa-darmstadt-germany-to-engage-in-cancer-biomarker-discovery-in-advanced-melanoma-idUSFWN1JC0L2
20170621†3:45PM UTC,BRIEF-PV Nano Cell says cooperating with Merck for single-crystalline metal particles technology applications,http://www.reuters.com/article/brief-pv-nano-cell-says-cooperating-with/brief-pv-nano-cell-says-cooperating-with-merck-for-single-crystalline-metal-particles-technology-applications-idUSFWN1JH0M7
20170621†1:18PM UTC,"BRIEF-Serimmune announces research, development collaboration agreement with subsidiary of Merck",http://www.reuters.com/article/brief-serimmune-announces-research-devel/brief-serimmune-announces-research-development-collaboration-agreement-with-subsidiary-of-merck-idUSFWN1JH0LP
20170621†8:54AM UTC,BRIEF-Effector Therapeutics to collaborate with Pfizer and Merck to evaluate immuno-oncology combination in microsatellite stable colorectal cancer,http://www.reuters.com/article/brief-effector-therapeutics-to-collabora/brief-effector-therapeutics-to-collaborate-with-pfizer-and-merck-to-evaluate-immuno-oncology-combination-in-microsatellite-stable-colorectal-cancer-idUSFWN1JH0FQ
20170622†6:03PM UTC,Gilead knocks out Merck patent on hepatitis C treatment,http://www.reuters.com/article/gilead-knocks-out-merck-patent-on-hepati/gilead-knocks-out-merck-patent-on-hepatitis-c-treatment-idUSL1N1JI23E
20170622†5:41PM UTC,BRIEF-Leap Therapeutics says Merck will sponsor and fund initial trials of their combo drug study,http://www.reuters.com/article/brief-leap-therapeutics-says-merck-will/brief-leap-therapeutics-says-merck-will-sponsor-and-fund-initial-trials-of-their-combo-drug-study-idUSFWN1JI0S1
20170622†9:17AM UTC,BRIEF-Leap Therapeutics announces collaboration with Merck,http://www.reuters.com/article/brief-leap-therapeutics-announces-collab/brief-leap-therapeutics-announces-collaboration-with-merck-idUSFWN1JI0JD
20170624†7:43AM UTC,BRIEF-EMA recommends approval of Merck's multiple sclerosis drug,http://www.reuters.com/article/brief-ema-recommends-approval-of-mercks/brief-ema-recommends-approval-of-mercks-multiple-sclerosis-drug-idUSFWN1JI0DF
20170625†3:23PM UTC,Germany's Merck gets EU backing for oral MS drug,http://www.reuters.com/article/us-merck-cladribine/germanys-merck-gets-eu-backing-for-oral-ms-drug-idUSKBN19E1BD
20170625†3:20PM UTC,CORRECTED-Germany's Merck gets EU backing for oral MS drug,http://www.reuters.com/article/merck-cladribine/corrected-germanys-merck-gets-eu-backing-for-oral-ms-drug-idUSL8N1JK29M
20170628†12:36PM UTC,Merck heart drug surprises with positive result; questions linger,http://www.reuters.com/article/us-merck-co-study/merck-heart-drug-surprises-with-positive-result-questions-linger-idUSKBN19I1BN
20170628†12:34PM UTC,UPDATE 2-Merck heart drug surprises with positive result; questions linger,http://www.reuters.com/article/merck-co-study/update-2-merck-heart-drug-surprises-with-positive-result-questions-linger-idUSL3N1JO3JT
20170628†11:19AM UTC,BRIEF-Merck says in tweet company's computer network was compromised as part of global hack,http://www.reuters.com/article/brief-merck-says-in-tweet-companys-compu/brief-merck-says-in-tweet-companys-computer-network-was-compromised-as-part-of-global-hack-idUSFWN1JO0CL
20170628†7:26AM UTC,BRIEF-Merck provides update on reveal outcomes study of Anacetrapib,http://www.reuters.com/article/brief-merck-provides-update-on-reveal-ou/brief-merck-provides-update-on-reveal-outcomes-study-of-anacetrapib-idUSASA09V4I
20170628†7:25AM UTC,Merck's cholesterol drug clears main goal in late-stage study,http://www.reuters.com/article/merck-co-study/mercks-cholesterol-drug-clears-main-goal-in-late-stage-study-idUSL3N1JO3J1
20170630†7:24AM UTC,"Sales hopes for new Novartis, Merck heart drugs under microscope",http://www.reuters.com/article/us-novartis-cardiovascular/sales-hopes-for-new-novartis-merck-heart-drugs-under-microscope-idUSKBN19K0QC
20170630†7:22AM UTC,"UPDATE 1-Sales hopes for new Novartis, Merck heart drugs under microscope",http://www.reuters.com/article/novartis-cardiovascular/update-1-sales-hopes-for-new-novartis-merck-heart-drugs-under-microscope-idUSL8N1JQ1EC
20170706†8:54PM UTC,FDA puts hold on Merck multiple myeloma trials after deaths,http://www.reuters.com/article/us-merck-fda/fda-puts-hold-on-merck-multiple-myeloma-trials-after-deaths-idUSKBN19Q2VM
20170706†5:39PM UTC,UPDATE 1-FDA puts hold on Merck multiple myeloma trials after deaths,http://www.reuters.com/article/merck-co-fda/update-1-fda-puts-hold-on-merck-multiple-myeloma-trials-after-deaths-idUSL3N1JW50J
20170706†4:47PM UTC,FDA places clinical hold on Merck's combo therapy for multiple myeloma,http://www.reuters.com/article/fda-places-clinical-hold-on-mercks-combo/fda-places-clinical-hold-on-mercks-combo-therapy-for-multiple-myeloma-idUSL3N1JW4ZS
20170706†4:34PM UTC,"BRIEF-Merck provides further update on 3 multiple myeloma studies evaluating Keytruda in combination with Pomalidomide, Lenalidomide",http://www.reuters.com/article/brief-merck-provides-further-update-on-3/brief-merck-provides-further-update-on-3-multiple-myeloma-studies-evaluating-keytruda-in-combination-with-pomalidomide-lenalidomide-idUSASA09W3X
20170707†11:31AM UTC,"EU charges Merck KGaA, GE, Canon over merger rules",http://www.reuters.com/article/us-eu-merck-ge-canon/eu-charges-merck-kgaa-ge-canon-over-merger-rules-idUSKBN19R10R
20170707†11:24AM UTC,"UPDATE 2-EU charges Merck KGaA, GE, Canon over merger rules",http://www.reuters.com/article/eu-merck-ge-canon/update-2-eu-charges-merck-kgaa-ge-canon-over-merger-rules-idUSL8N1JX2X0
20170707†7:07AM UTC,BRIEF-Merck to present new data from clinical trials at IAS 2017,http://www.reuters.com/article/brief-merck-to-present-new-data-from-cli/brief-merck-to-present-new-data-from-clinical-trials-at-ias-2017-idUSASA09W5W
20170707†5:32AM UTC,"EU charges Merck KGaA, GE, Canon of misleading merger info",http://www.reuters.com/article/eu-merck-ge-canon/eu-charges-merck-kgaa-ge-canon-of-misleading-merger-info-idUSL8N1JX1UI
20170711†7:26AM UTC,BRIEF-PDS Biotechnology enters a clinical trial collaboration agreement with a subsidiary of Merck,http://www.reuters.com/article/brief-pds-biotechnology-enters-a-clinica/brief-pds-biotechnology-enters-a-clinical-trial-collaboration-agreement-with-a-subsidiary-of-merck-idUSFWN1K10BU
20170711†7:04AM UTC,"BRIEF-NetScientific updates on clinical trial collaboration deal between PDS, unit of Merck & Co",http://www.reuters.com/article/brief-netscientific-updates-on-clinical/brief-netscientific-updates-on-clinical-trial-collaboration-deal-between-pds-unit-of-merck-co-idUSFWN1K10AR
20170713†9:43AM UTC,BRIEF-Merck KGaA refines Western European Life Science Production site network,http://www.reuters.com/article/brief-merck-kgaa-refines-western-europea/brief-merck-kgaa-refines-western-european-life-science-production-site-network-idUSFWN1K30B3
20170714†8:27AM UTC,BRIEF-Aduro Biotech reports $2 mln milestone payment under licensing deal with Merck,http://www.reuters.com/article/brief-aduro-biotech-reports-2-mln-milest/brief-aduro-biotech-reports-2-mln-milestone-payment-under-licensing-deal-with-merck-idUSFWN1K40D0
20170718†7:18AM UTC,BRIEF-Merck announces presentations of clinical and real-world data at the Alzheimer‚Äôs Association International Conference,http://www.reuters.com/article/brief-merck-announces-presentations-of-c/brief-merck-announces-presentations-of-clinical-and-real-world-data-at-the-alzheimers-association-international-conference-idUSFWN1K80BN
20170721†1:15PM UTC,FDA tentatively approves Merck's copycat of Sanofi's Lantus,http://www.reuters.com/article/merck-co-fda/fda-tentatively-approves-mercks-copycat-of-sanofis-lantus-idUSL1N1KB1AW
20170721†7:49AM UTC,BRIEF-Merck announces U.S. FDA grants tentative approval for Lusduna‚Ñ¢ Nexvue‚Ñ¢,http://www.reuters.com/article/brief-merck-announces-us-fda-grants-tent/brief-merck-announces-u-s-fda-grants-tentative-approval-for-lusduna-nexvue-idUSASB0B9UH
20170722†7:52AM UTC,BRIEF-European Medicines Agency's CHMP recommends approval for Merck's Keytruda,http://www.reuters.com/article/brief-european-medicines-agencys-chmp-re/brief-european-medicines-agencys-chmp-recommends-approval-for-mercks-keytruda-idUSFWN1KC0AJ
20170722†7:38AM UTC,BRIEF-Merck KGaA and Pfizer: CHMP recommends approval of avelumab,http://www.reuters.com/article/brief-merck-kgaa-and-pfizer-chmp-recomme/brief-merck-kgaa-and-pfizer-chmp-recommends-approval-of-avelumab-idUSFWN1KC0AK
20170722†7:36AM UTC,"Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval",http://www.reuters.com/article/us-pfizer-merck-cancer/pfizer-merck-kgaa-skin-cancer-drug-gets-ema-nod-for-approval-idUSKBN1A61C9
20170722†7:34AM UTC,"Pfizer, Merck KGaA skin cancer drug gets EMA nod for approval",http://www.reuters.com/article/pfizer-merck-cancer/pfizer-merck-kgaa-skin-cancer-drug-gets-ema-nod-for-approval-idUSL3N1KC3E0
20170725†6:08PM UTC,Merck immunotherapy fails to improve survival in head and neck cancer,http://www.reuters.com/article/us-merck-co-keytruda/merck-immunotherapy-fails-to-improve-survival-in-head-and-neck-cancer-idUSKBN1A92OL
20170725†6:05PM UTC,Merck immunotherapy fails to improve survival in head and neck cancer,http://www.reuters.com/article/merck-co-keytruda/merck-immunotherapy-fails-to-improve-survival-in-head-and-neck-cancer-idUSL1N1KF1NU
20170725†5:07PM UTC,BRIEF-Merck provides update on phase 3 study of keytruda,http://www.reuters.com/article/brief-merck-provides-update-on-phase-3-s/brief-merck-provides-update-on-phase-3-study-of-keytruda-idUSASB0BACC
20170725†2:22PM UTC,FDA tentatively approves Merck's copycat of Sanofi's Lantus,http://www.reuters.com/article/us-merck-co-fda/fda-tentatively-approves-mercks-copycat-of-sanofis-lantus-idUSKBN1A52BN
20170725†2:06PM UTC,CORRECTED-FDA tentatively approves Merck's copycat of Sanofi's Lantus (July 20),http://www.reuters.com/article/merck-co-fda/corrected-fda-tentatively-approves-mercks-copycat-of-sanofis-lantus-idUSL3N1KB501
20170725†1:24PM UTC,"Merck, Samsung Bioepis launch discounted U.S. Remicade alternative",http://www.reuters.com/article/samsung-bioepis-johnsonjohnson-remicade/merck-samsung-bioepis-launch-discounted-u-s-remicade-alternative-idUSL1N1KF0YM
20170725†1:03PM UTC,"Merck, Samsung Bioepis launch discounted U.S. Remicade alternative",http://www.reuters.com/article/us-samsung-bioepis-johnson-johnson-remic/merck-samsung-bioepis-launch-discounted-u-s-remicade-alternative-idUSKBN1A91GL
20170725†12:58PM UTC,"UPDATE 1-Merck, Samsung Bioepis launch discounted U.S. Remicade alternative",http://www.reuters.com/article/samsung-bioepis-johnsonjohnson-remicade/update-1-merck-samsung-bioepis-launch-discounted-u-s-remicade-alternative-idUSL3N1KF4OL
20170725†8:18AM UTC,BRIEF-Merck announces U.S. launch of Renflexis,http://www.reuters.com/article/brief-merck-announces-us-launch-of-renfl/brief-merck-announces-u-s-launch-of-renflexis-idUSFWN1KF0D1
20170725†7:12AM UTC,BRIEF-Merck announces week 96 results from Oncemrk,http://www.reuters.com/article/brief-merck-announces-week-96-results-fr/brief-merck-announces-week-96-results-from-oncemrk-idUSFWN1KF0BO
20170726†4:14PM UTC,BRIEF-Merck sets quarterly dividend of $0.47 per share,http://www.reuters.com/article/brief-merck-sets-quarterly-dividend-of-0/brief-merck-sets-quarterly-dividend-of-0-47-per-share-idUSFWN1KG0WR
20170726†8:41AM UTC,"BRIEF-Merck's investigational NNRTI, doravirine, meets primary efficacy endpoint",http://www.reuters.com/article/brief-mercks-investigational-nnrti-dorav/brief-mercks-investigational-nnrti-doravirine-meets-primary-efficacy-endpoint-idUSASB0BAH9
20170728†3:27AM UTC,BRIEF-Astrazeneca says establish strategic oncology collaboration with Merck,http://www.reuters.com/article/brief-astrazeneca-says-establish-strateg/brief-astrazeneca-says-establish-strategic-oncology-collaboration-with-merck-idUSFWN1KI0BF
20170729†12:31PM UTC,"Merck says cyber attack halted production, will hurt profits",http://www.reuters.com/article/us-merck-co-results/merck-says-cyber-attack-halted-production-will-hurt-profits-idUSKBN1AD1AO
20170729†12:17PM UTC,"UPDATE 4-Merck says cyber attack halted production, will hurt profits",http://www.reuters.com/article/merck-co-results/update-4-merck-says-cyber-attack-halted-production-will-hurt-profits-idUSL3N1KJ3S6
20170729†7:05AM UTC,BRIEF-Merck reports Q2 non-GAAP earnings of $1.01/shr,http://www.reuters.com/article/brief-merck-reports-q2-non-gaap-earnings/brief-merck-reports-q2-non-gaap-earnings-of-1-01-shr-idUSASB0BBK7
20170729†6:51AM UTC,Merck profit soars 61.5 pct as Keytruda sales surge,http://www.reuters.com/article/merck-co-results/merck-profit-soars-61-5-pct-as-keytruda-sales-surge-idUSL3N1KJ3RH
20170801†9:37AM UTC,BRIEF-Generex announces collaboration with Merck to evaluate Keytruda in combination with ae37 in patients with triple-negative breast cancer,http://www.reuters.com/article/brief-generex-announces-collaboration-wi/brief-generex-announces-collaboration-with-merck-to-evaluate-keytruda-in-combination-with-ae37-in-patients-with-triple-negative-breast-cancer-idUSFWN1KM0PX
20170808†7:09AM UTC,BRIEF-India's Merck June-qtr profit down about 12 pct,http://www.reuters.com/article/brief-indias-merck-june-qtr-profit-down/brief-indias-merck-june-qtr-profit-down-about-12-pct-idUSFWN1KT0DK
20170809†5:28PM UTC,BRIEF-Merck & Co says received investigative subpoena from california insurance commissioner‚Äôs fraud liaison bureau - sec filing,http://www.reuters.com/article/brief-merck-co-says-received-investigati/brief-merck-co-says-received-investigative-subpoena-from-california-insurance-commissioners-fraud-liaison-bureau-sec-filing-idUSFWN1KU10J
20170815†7:48PM UTC,UPDATE 8-Merck CEO resigns from Trump council over Charlottesville,http://www.reuters.com/article/virginia-protests-merck/update-8-merck-ceo-resigns-from-trump-council-over-charlottesville-idUSL2N1L00I9
20170815†10:36AM UTC,Trump chides Merck CEO after resignation from presidential council,http://www.reuters.com/article/us-virginia-protests-merck-trump/trump-chides-merck-ceo-after-resignation-from-presidential-council-idUSKCN1AU1GZ
20170815†9:59AM UTC,REFILE-Trump chides Merck CEO after resignation from presidential council,http://www.reuters.com/article/virginia-protests-merck-trump/refile-trump-chides-merck-ceo-after-resignation-from-presidential-council-idUSW1N1J200I
20170815†9:17AM UTC,REFILE-Merck CEO resigns from Trump's manufacturing council,http://www.reuters.com/article/virginia-protests-merck/refile-merck-ceo-resigns-from-trumps-manufacturing-council-idUSL4N1L04LP
20170815†9:13AM UTC,REFILE-UPDATE 1-Merck CEO resigns from Trump council after Charlottesville,http://www.reuters.com/article/virginia-protests-merck/refile-update-1-merck-ceo-resigns-from-trump-council-after-charlottesville-idUSL4N1L04ML
20170815†8:30AM UTC,"BRIEF-Merck CEO Frazier says I am resigning from the president's American Manufacturing Council"" - tweet""",http://www.reuters.com/article/brief-merck-ceo-frazier-says-i-am-resign/brief-merck-ceo-frazier-says-i-am-resigning-from-the-presidents-american-manufacturing-council-tweet-idUSL4N1L04IG
20170815†1:14PM UTC,Merck CEO pulls out of Trump panel,http://www.reuters.com/news/video/videoStory?storyID=131591785
20170816†12:00AM UTC,"Trump on Twitter (Aug 14) - Luther Strange, Merck Pharma, Charlottesville",http://www.reuters.com/article/us-usa-trump-tweet-factbox/trump-on-twitter-luther-strange-merck-pharma-charlottesville-idUSKCN1AU14T
20170818†5:43PM UTC,FDA expands use of AstraZeneca/Merck ovarian cancer drug,http://www.reuters.com/article/us-astrazeneca-lynparza-fda/fda-expands-use-of-astrazeneca-merck-ovarian-cancer-drug-idUSKCN1AX2MY
20170818†5:23PM UTC,UPDATE 1-FDA expands use of AstraZeneca/Merck ovarian cancer drug,http://www.reuters.com/article/astrazeneca-lynparza-fda/update-1-fda-expands-use-of-astrazeneca-merck-ovarian-cancer-drug-idUSL2N1L31YK
20170818†9:43AM UTC,Fitch Affirms Merck at 'A'; Outlook Stable,http://www.reuters.com/article/fitch-affirms-merck-at-a-outlook-stable/fitch-affirms-merck-at-a-outlook-stable-idUSFithDV12
20170826†3:10AM UTC,BRIEF-Merck says European Commission approves cladribine tablets,http://www.reuters.com/article/brief-merck-says-european-commission-app/brief-merck-says-european-commission-approves-cladribine-tablets-idUSFWN1LB06B
20170829†8:59AM UTC,BRIEF-Merck to acquire Natrix Separations,http://www.reuters.com/article/brief-merck-to-acquire-natrix-separation/brief-merck-to-acquire-natrix-separations-idUSFWN1LE0IU
20170830†6:46AM UTC,"Merck cholesterol drug cuts heart risk only 9 percent, future unclear",http://www.reuters.com/article/us-merck-cholesterol/merck-cholesterol-drug-cuts-heart-risk-only-9-percent-future-unclear-idUSKCN1B90J5
20170830†6:08AM UTC,"UPDATE 1-Merck cholesterol drug cuts heart risk only 9 pct, future unclear",http://www.reuters.com/article/merck-cholesterol/update-1-merck-cholesterol-drug-cuts-heart-risk-only-9-pct-future-unclear-idUSL2N1LF0AP
20170830†2:42AM UTC,BRIEF-Merck announces results of REVEAL outcomes study of Anacetrapib,http://www.reuters.com/article/brief-merck-announces-results-of-reveal/brief-merck-announces-results-of-reveal-outcomes-study-of-anacetrapib-idUSFWN1LF03Y
20170830†2:30AM UTC,Merck cholesterol drug cuts heart risk by 9 pct in study,http://www.reuters.com/article/merck-cholesterol/merck-cholesterol-drug-cuts-heart-risk-by-9-pct-in-study-idUSL2N1LF02W
20170906†12:02PM UTC,Germany's Merck considers sale of consumer health business,http://www.reuters.com/article/us-merck-consumer/germanys-merck-considers-sale-of-consumer-health-business-idUSKCN1BG0R0
20170906†11:42AM UTC,UPDATE 3-Germany's Merck considers sale of consumer health business,http://www.reuters.com/article/merck-consumer/update-3-germanys-merck-considers-sale-of-consumer-health-business-idUSL8N1LM18H
20170906†7:03AM UTC,BRIEF-European Commission approves Merck‚ÄôS KEYTRUDA (pembrolizumab),http://www.reuters.com/article/brief-european-commission-approves-merck/brief-european-commission-approves-mercks-keytruda-idUSFWN1LM0GQ
20170906†3:11AM UTC,German Merck eyes sale of consumer health business,http://www.reuters.com/article/merck-consumer/german-merck-eyes-sale-of-consumer-health-business-idUSASM000EI0
20170907†1:02PM UTC,Merck & Co snaps up three year-old German biotech firm for up to $550 million,http://www.reuters.com/article/us-rigontec-m-a-merck-co/merck-co-snaps-up-three-year-old-german-biotech-firm-for-up-to-550-million-idUSKCN1BH2EK
20170907†9:57AM UTC,Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln,http://www.reuters.com/article/rigontec-ma-merck-co/merck-co-snaps-up-3-yr-old-german-biotech-firm-for-up-to-550-mln-idUSASM000EK7
20170908†6:05PM UTC,"Merck's immunotherapy, chemo mix shows extended lung cancer gains",http://www.reuters.com/article/health-cancer-merck-co/mercks-immunotherapy-chemo-mix-shows-extended-lung-cancer-gains-idUSL8N1LN5DV
20170912†9:17AM UTC,BRIEF-Merck announces findings from phase 3 study of KEYTRUDA,http://www.reuters.com/article/brief-merck-announces-findings-from-phas/brief-merck-announces-findings-from-phase-3-study-of-keytruda-idUSFWN1LS0L8
20170912†5:22AM UTC,BRIEF-Merck KGaA to enter into strategic collaboration with Project Data Sphere LLC,http://www.reuters.com/article/brief-merck-kgaa-to-enter-into-strategic/brief-merck-kgaa-to-enter-into-strategic-collaboration-with-project-data-sphere-llc-idUSFWN1LS0C9
20170912†3:27AM UTC,RPT-UPDATE 1-Germany's Merck hires JP Morgan to sell consumer health,http://www.reuters.com/article/merckkgaa-jpmorgan-consumerhealth/rpt-update-1-germanys-merck-hires-jp-morgan-to-sell-consumer-health-idUSL5N1LS1C4
20170913†2:30PM UTC,BRIEF-Merck says Isentress HD now available in Canada,http://www.reuters.com/article/brief-merck-says-isentress-hd-now-availa/brief-merck-says-isentress-hd-now-available-in-canada-idUSFWN1LT0PP
20170922†3:21AM UTC,"Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod",http://www.reuters.com/article/us-merck-bavencio/merck-kgaa-pfizers-cancer-drug-bavencio-gets-eu-nod-idUSKCN1BW0V3
20170922†3:19AM UTC,"Merck KGaA, Pfizer's cancer drug Bavencio gets EU nod",http://www.reuters.com/article/merck-bavencio/merck-kgaa-pfizers-cancer-drug-bavencio-gets-eu-nod-idUSL5N1M213A
20170922†3:17AM UTC,BRIEF-Merck KGaA's Bavencio drug wins EU approval for Merkel cell carcinoma,http://www.reuters.com/article/brief-merck-kgaas-bavencio-drug-wins-eu/brief-merck-kgaas-bavencio-drug-wins-eu-approval-for-merkel-cell-carcinoma-idUSFWN1M208Q
20170923†3:47PM UTC,BRIEF-Merck says FDA approves Keytruda(pembrolizumab) for previously treated patients,http://www.reuters.com/article/brief-merck-says-fda-approves-keytruda-f/brief-merck-says-fda-approves-keytruda-for-previously-treated-patients-idUSASB0BKLS
20170926†7:50AM UTC,"BRIEF-Merck KGAA appoints Paolo Carli head of Middle East, Africa & Turkey for healthcare business‚Äç‚Äã",http://www.reuters.com/article/brief-merck-kgaa-appoints-paolo-carli-he/brief-merck-kgaa-appoints-paolo-carli-head-of-middle-east-africa-turkey-for-healthcare-business-idUSFWN1M60GQ
20170929†6:55AM UTC,Merck KGaA CFO: 2017 profit guidance 'damn challenging',http://www.reuters.com/article/us-merck-outlook/merck-kgaa-cfo-2017-profit-guidance-damn-challenging-idUSKCN1C31CN
20170929†6:53AM UTC,Merck KGaA eyes up to 700 million euro Mavenclad sales in EU,http://www.reuters.com/article/us-merck-mavenclad/merck-kgaa-eyes-up-to-700-million-euro-mavenclad-sales-in-eu-idUSKCN1C312F
20170929†6:39AM UTC,"Merck KGaA CFO: 2017 profit guidance damn challenging""""",http://www.reuters.com/article/merck-outlook/merck-kgaa-cfo-2017-profit-guidance-damn-challenging-idUSL8N1M92WD
20170929†5:23AM UTC,"BRIEF-Merck KGaA says 2017 guidance range achievable, but challenging",http://www.reuters.com/article/brief-merck-kgaa-says-2017-guidance-rang/brief-merck-kgaa-says-2017-guidance-range-achievable-but-challenging-idUSFWN1M9074
20170929†4:37AM UTC,Merck KGaA eyes up to 700 mln eur Mavenclad sales in EU,http://www.reuters.com/article/merck-mavenclad/merck-kgaa-eyes-up-to-700-mln-eur-mavenclad-sales-in-eu-idUSL8N1M91AW
20170930†8:25AM UTC,Merck to stop development of hepatitis C treatments,http://www.reuters.com/article/us-merck-co-hepatitis-c/merck-to-stop-development-of-hepatitis-c-treatments-idUSKCN1C41QD
20170930†8:05AM UTC,Merck to stop development of hepatitis C treatments,http://www.reuters.com/article/merck-co-hepatitis-c/merck-to-stop-development-of-hepatitis-c-treatments-idUSL4N1MA44K
20170930†7:08AM UTC,BRIEF-Merck discontinues MK-3682B and MK-3682C development programs,http://www.reuters.com/article/brief-merck-discontinues-mk-3682b-and-mk/brief-merck-discontinues-mk-3682b-and-mk-3682c-development-programs-idUSFWN1MA0DA
20171003†7:20PM UTC,Judge upholds patent on Merck's antifungal drug Noxafil,http://www.reuters.com/article/ip-noxafil/judge-upholds-patent-on-mercks-antifungal-drug-noxafil-idUSL2N1MD2C5
20171004†10:29AM UTC,Police search Merck KGaA's French plant in thyroid pill inquiry,http://www.reuters.com/article/us-merck-levothyrox/police-search-merck-kgaas-french-plant-in-thyroid-pill-inquiry-idUSKCN1C81KO
20171004†10:24AM UTC,REFILE-Police search Merck KGaA's French plant in thyroid pill inquiry,http://www.reuters.com/article/merck-levothyrox/refile-police-search-merck-kgaas-french-plant-in-thyroid-pill-inquiry-idUSL8N1ME3G5
20171011†8:26AM UTC,BRIEF-Kalvista Pharmaceuticals announces collaboration with Merck,http://www.reuters.com/article/brief-kalvista-pharmaceuticals-announces/brief-kalvista-pharmaceuticals-announces-collaboration-with-merck-idUSFWN1ML0GZ
20171012†5:40PM UTC,Merck says will not seek approval of cholesterol treatment,http://www.reuters.com/article/us-merck-cholesterol/merck-says-will-not-seek-approval-of-cholesterol-treatment-idUSKBN1CG2W1
20171012†5:14PM UTC,Merck says will not seek approval of cholesterol treatment,http://www.reuters.com/article/merck-cholesterol/merck-says-will-not-seek-approval-of-cholesterol-treatment-idUSL4N1MM5JP
20171012†5:07PM UTC,BRIEF-Merck provides update on Anacetrapib development program,http://www.reuters.com/article/brief-merck-provides-update-on-anacetrap/brief-merck-provides-update-on-anacetrapib-development-program-idUSASB0BMS2
20171017†10:46AM UTC,BRIEF-Aeglea Biotherapeutics announces clinical collaboration with Merck,http://www.reuters.com/article/brief-aeglea-biotherapeutics-announces-c/brief-aeglea-biotherapeutics-announces-clinical-collaboration-with-merck-idUSFWN1MR0J0
20171019†7:12AM UTC,BRIEF-Merck announces updated overall survival findings from Phase 3 trial of KEYTRUDA,http://www.reuters.com/article/brief-merck-announces-updated-overall-su/brief-merck-announces-updated-overall-survival-findings-from-phase-3-trial-of-keytruda-idUSFWN1MT09W
20171019†2:53AM UTC,Astra and Merck win speedy review for Lynparza in breast cancer,http://www.reuters.com/article/us-astrazeneca-lynparza/astra-and-merck-win-speedy-review-for-lynparza-in-breast-cancer-idUSKBN1CN0OR
20171019†2:46AM UTC,Astra and Merck win speedy review for Lynparza in breast cancer,http://www.reuters.com/article/astrazeneca-lynparza/astra-and-merck-win-speedy-review-for-lynparza-in-breast-cancer-idUSL8N1MT0YO
20171020†6:26PM UTC,Merck cyber attack may cost insurers $275 million: Verisk's PCS,http://www.reuters.com/article/us-merck-co-cyber-insurance/merck-cyber-attack-may-cost-insurers-275-million-verisks-pcs-idUSKBN1CO2NP
20171020†6:24PM UTC,CORRECTED-Merck cyber attack may cost insurers $275 mln -Verisk's PCS,http://www.reuters.com/article/merck-co-cyber-insurance/corrected-merck-cyber-attack-may-cost-insurers-275-mln-verisks-pcs-idUSL2N1MT26K
20171021†12:45PM UTC,"Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care",http://www.reuters.com/article/us-merck-layoffs/merck-to-cut-1800-u-s-sales-jobs-add-960-in-chronic-care-idUSKBN1CP26S
20171021†12:41PM UTC,"UPDATE 1-Merck to cut 1,800 U.S. sales jobs, add 960 in chronic care",http://www.reuters.com/article/merck-layoffs/update-1-merck-to-cut-1800-u-s-sales-jobs-add-960-in-chronic-care-idUSL2N1MV14Z
20171021†12:10PM UTC,"Merck to cut 1,800 U.S. sales jobs, add 960 jobs in chronic care",http://www.reuters.com/article/merck-layoffs/merck-to-cut-1800-u-s-sales-jobs-add-960-jobs-in-chronic-care-idUSL2N1MV11I
20171024†7:05AM UTC,BRIEF-AstraZeneca and Merck advance LYNPARZA in Japan with a second regulatory submission,http://www.reuters.com/article/brief-astrazeneca-and-merck-advance-lynp/brief-astrazeneca-and-merck-advance-lynparza-in-japan-with-a-second-regulatory-submission-idUSFWN1MY0JZ
20171024†2:28AM UTC,BRIEF-AstraZeneca and Merck submit application for breast cancer drug in Japan,http://www.reuters.com/article/brief-astrazeneca-and-merck-submit-appli/brief-astrazeneca-and-merck-submit-application-for-breast-cancer-drug-in-japan-idUSFWN1MY01L
20171025†8:12AM UTC,BRIEF-Merck KGaA: Canadian patent office to grant patent application for CRISPR technology,http://www.reuters.com/article/brief-merck-kgaa-canadian-patent-office/brief-merck-kgaa-canadian-patent-office-to-grant-patent-application-for-crispr-technology-idUSFWN1MZ0O4
20171026†1:28PM UTC,U.S. committee recommends GSK shingles vaccine over Merck rival,http://www.reuters.com/article/us-gsk-shingles/u-s-committee-recommends-gsk-shingles-vaccine-over-merck-rival-idUSKBN1CU2EE
20171026†1:25PM UTC,UPDATE 1-U.S. committee recommends GSK shingles vaccine over Merck rival,http://www.reuters.com/article/gsk-shingles/update-1-u-s-committee-recommends-gsk-shingles-vaccine-over-merck-rival-idUSL8N1N07EB
20171026†12:02PM UTC,U.S. committee recommends GSK shingles vaccine over Merck rival,http://www.reuters.com/article/gsk-shingles/u-s-committee-recommends-gsk-shingles-vaccine-over-merck-rival-idUSL8N1N02I9
20171026†11:10AM UTC,BRIEF-ACIP votes 8-7 to prefer GSK's shingles vaccine Shingrix over Merck's Zostavax,http://www.reuters.com/article/brief-acip-votes-8-7-to-prefer-gsks-shin/brief-acip-votes-8-7-to-prefer-gsks-shingles-vaccine-shingrix-over-mercks-zostavax-idUSL9N15G04D
20171026†7:47AM UTC,"BRIEF-GSK will look at Pfizer, Merck consumer assets if offered for sale",http://www.reuters.com/article/brief-gsk-will-look-at-pfizer-merck-cons/brief-gsk-will-look-at-pfizer-merck-consumer-assets-if-offered-for-sale-idUSL9N15G04B
20171028†6:04PM UTC,"Merck Keytruda sales soar, but European application pulled",http://www.reuters.com/article/us-merck-co-results/merck-keytruda-sales-soar-but-european-application-pulled-idUSKBN1CW1EF
20171028†5:59PM UTC,"UPDATE 4-Merck Keytruda sales soar, but European application pulled",http://www.reuters.com/article/merck-co-results/update-4-merck-keytruda-sales-soar-but-european-application-pulled-idUSL4N1N24B1
20171028†4:45PM UTC,Merck withdraws marketing application for Keytruda in Europe,http://www.reuters.com/article/us-merck-co-ema/merck-withdraws-marketing-application-for-keytruda-in-europe-idUSKBN1CW2WI
20171028†4:43PM UTC,Merck withdraws marketing application for Keytruda in Europe,http://www.reuters.com/article/merck-co-ema/merck-withdraws-marketing-application-for-keytruda-in-europe-idUSL4N1N264K
20171028†4:32PM UTC,BRIEF-Merck withdraws European application for Keytruda,http://www.reuters.com/article/brief-merck-withdraws-european-applicati/brief-merck-withdraws-european-application-for-keytruda-idUSFWN1N21WE
20171028†9:05AM UTC,BRIEF-Merck says cyber attack to impact fourth quarter results,http://www.reuters.com/article/brief-merck-says-cyber-attack-to-impact/brief-merck-says-cyber-attack-to-impact-fourth-quarter-results-idUSL2N1N20K8
20171028†7:06AM UTC,BRIEF-Merck reports Q3 loss per share of $0.02,http://www.reuters.com/article/brief-merck-reports-q3-loss-per-share-of/brief-merck-reports-q3-loss-per-share-of-0-02-idUSASB0BPCG
20171028†6:54AM UTC,Merck posts quarterly loss vs. year-ago profit,http://www.reuters.com/article/merck-co-results/merck-posts-quarterly-loss-vs-year-ago-profit-idUSL4N1N24AA
20171031†5:35PM UTC,"Wall Street slips as Merck drops, tax talk rattles",http://www.reuters.com/article/us-usa-stocks/wall-street-slips-as-merck-drops-tax-talk-rattles-idUSKBN1CZ181
20171031†4:30PM UTC,"US STOCKS-Wall St slips as Merck drops, tax talk rattles",http://www.reuters.com/article/usa-stocks/us-stocks-wall-st-slips-as-merck-drops-tax-talk-rattles-idUSL2N1N51U8
20171031†4:05PM UTC,"US STOCKS SNAPSHOT-Wall St ends lower; Merck, Trump tax talk weigh",http://www.reuters.com/article/usa-stocks/us-stocks-snapshot-wall-st-ends-lower-merck-trump-tax-talk-weigh-idUSZXN0R5B2I
20171031†2:38PM UTC,"US STOCKS-Wall St slips amid Merck losses, tax talk",http://www.reuters.com/article/usa-stocks/us-stocks-wall-st-slips-amid-merck-losses-tax-talk-idUSL2N1N51IH
20171031†12:10PM UTC,Cancer-drug setback sends Merck shares down again,http://www.reuters.com/article/us-merck-stocks/cancer-drug-setback-sends-merck-shares-down-again-idUSKBN1CZ1WJ
20171031†12:09PM UTC,UPDATE 1-Cancer-drug setback sends Merck shares down again,http://www.reuters.com/article/merck-stocks/update-1-cancer-drug-setback-sends-merck-shares-down-again-idUSL2N1N510Z
20171031†11:08AM UTC,Cancer-drug setback sends Merck shares down again,http://www.reuters.com/article/merck-stocks/cancer-drug-setback-sends-merck-shares-down-again-idUSL2N1N50W6
20171103†2:31PM UTC,"CORRECTED-BRIEF-Merck KGaA, Samsung Biologics sign MoU on strategic alliance",http://www.reuters.com/article/idUSFWN1N61F5
20171106†6:31PM UTC,Top Massachusetts court weighs Merck case over generic drug injury,http://www.reuters.com/article/products-merck/top-massachusetts-court-weighs-merck-case-over-generic-drug-injury-idUSL1N1NC23L
20171106†8:58AM UTC,BRIEF-Merck announces any and all tender offers,http://www.reuters.com/article/brief-merck-announces-any-and-all-tender/brief-merck-announces-any-and-all-tender-offers-idUSFWN1NC0ZV
